



## (51) International Patent Classification:

*C07D 239/16* (2006.01)    *C07D 401/12* (2006.01)  
*C07D 239/14* (2006.01)    *C07D 233/28* (2006.01)  
*C07D 239/02* (2006.01)    *A61K 31/44* (2006.01)

## (21) International Application Number:

PCT/US2016/069511

## (22) International Filing Date:

30 December 2016 (30.12.2016)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/273,246    30 December 2015 (30.12.2015)    US

(71) Applicant: SAINT LOUIS UNIVERSITY [US/US]; 221  
 N. Grand Blvd., St. Louis, MO 63103 (US).

(72) Inventors: RUMINSKI, Peter, G.; 33 Blackwolf Run  
 Court, Wildwood, MO 63040 (US). GRIGGS, David, W.;  
 1237 Oak Borough Drive, Ballwin, MO 63021 (US).

(74) Agent: LONG, S., Reid; Parker Highlander PLLC, 1120  
 S. Capital Of Texas Highway, Building One, Suite 200,  
 Austin, TX 78746 (US).


(81) Designated States (unless otherwise indicated, for every  
 kind of national protection available): AE, AG, AL, AM,  
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,  
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,  
 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,  
 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,  
 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,  
 RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,  
 TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,  
 ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
 kind of regional protection available): ARIPO (BW, GH,  
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,  
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,  
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,  
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
 GW, KM, ML, MR, NE, SN, TD, TG).

## Published:

— with international search report (Art. 21(3))

(54) Title: META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS



(57) Abstract: The present disclosure provides pharmaceutical agents of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.

**META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES  
AS PAN INTEGRIN ANTAGONISTS**

**DESCRIPTION**

5           This application claims benefit of priority to U.S. Serial No. 62/273,246, filed December 30, 2015, the entire contents of which are hereby incorporated by reference.

**BACKGROUND**

**I.       Field of the Invention**

10           The present disclosure relates to the fields of pharmaceuticals, medicine and cell biology. More specifically, it relates to pharmaceutical agents (compounds) which are useful as integrin receptor antagonists, with biological activity as antagonists of one or more integrins that mediate the pathologic processes of angiogenesis and fibrosis. As such, these compounds may be used are useful in pharmaceutical compositions and in methods for treating diseases and disorders, including conditions mediated by one or more of such  
15   integrins.

**II.     Description of Related Art**

          Integrins are a family of integral cytoplasmic membrane proteins that mediate cell interactions with other cells and with the extracellular matrix. Approximately one third of the members of the integrin family directly bind to a specific amino acid motif, arginine-glycine-  
20   aspartate (RGD), that is contained within the sequence of their cognate protein ligands. It has been established in the art that peptides containing the RGD sequence, and synthetic small molecule compounds that mimic the RGD sequence, are capable of binding to these integrin receptors with varying degrees of specificity, and thereby inhibit the binding to normal physiologic ligands (Millard, 2011; Sun *et al.*, 2014). The biological effects of treatment  
25   with such agents is dependent on intrinsic molecular properties, reflected in the structure, that determine to what degree a particular integrin, or combination of integrins, is inhibited in a body tissue over a period of time.

          Many human diseases are characterized by either or both of two common contributing pathological mechanisms: angiogenesis and fibrosis. Different subsets of the RGD-binding  
30   integrins have predominant roles in driving these dual processes, so that simultaneous antagonism of angiogenesis and fibrosis requires agents capable of binding potently to several target integrins. This contrasts with agents designed specifically for binding to a

single integrin which may be less effective in some applications due to their more restricted mechanism of action.

Integrins which have been shown to have a role in promoting angiogenesis include  $\alpha_v\beta_3$ ,  $\alpha_v\beta_5$ , and  $\alpha_5\beta_1$ .  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  were initially described as mediators of bFGF- and VEGF-induced angiogenesis, respectively, in corneal or choriallantoic models. Subsequent data from studies using mice lacking these integrins also support an important functional role for  $\alpha_5\beta_1$ . The integrin  $\alpha_5\beta_1$  (also known as VLA-5) is often referred to as the ‘classic fibronectin receptor’ reflecting its well characterized interaction with this extracellular matrix protein. Cells expressing  $\alpha_5\beta_1$  bind to fibronectin in a region that incorporates the ninth and tenth type III fibronectin repeats, the latter of which contains the RGD motif critical for integrin binding. In addition to fibronectin,  $\alpha_5\beta_1$  has been reported to interact with other RGD-containing extracellular matrix proteins including fibrinogen, denatured collagen, and fibrillin-1 (Bax *et al.*, 2003; Perdih, 2010; Suehiro *et al.*, 2000). These ligands are components of the provisional matrix that is laid down by cells as part of the wound healing response in tissues. Key components of this response are angiogenesis (new blood vessel formation) and fibrosis (scar formation) which are beneficial for healing of acute injuries, but can be deleterious in many disease contexts.

Antagonists of RGD-binding integrins should be useful for treatment of human diseases having angiogenesis or fibrosis as a principal part of their pathology. In particular, the important role of  $\alpha_5\beta_1$  in angiogenesis is supported by numerous studies. For example, mice lacking this integrin exhibit embryonic lethality at day 10-11 with a phenotype that includes defects in both the embryonic and extraembryonic vasculature (Yang *et al.*, 1993). Angiogenic cytokines such as bFGF, IL-8, TGF $\beta$ , and TNF $\alpha$  upregulate  $\alpha_5\beta_1$  expression on endothelial cells *in vitro* and *in vivo*, and immunohistochemistry shows coordinated increases in both  $\alpha_5\beta_1$  and fibronectin staining in blood vessels from various types of human tumor biopsies and xenograft tumors in animals (Collo, 1999; Kim *et al.*, 2000). Monoclonal antibodies that specifically inhibit  $\alpha_5\beta_1$ , and compounds that have been described as  $\alpha_5\beta_1$  inhibitors, significantly reduce angiogenesis in a number of experimental models (Kim *et al.*, 2000; Bhaskar *et al.*, 2007; Livant *et al.*, 2000; Zahn *et al.*, 2009).

Because  $\alpha_5\beta_1$  expression is not confined to the endothelium, it has other functional roles in addition to angiogenesis. It is expressed to varying degrees in many cell types including fibroblasts, hematopoietic and immune cells, smooth muscle cells, epithelial cells, and tumor cells. Expression on tumor cells has been implicated in the progression of tumor

growth and metastasis (Adachi *et al.*, 2000; Blasé *et al.*, 1995; Danen *et al.*, 1994; Edward, 1995). In human fibroblasts,  $\alpha 5\beta 1$  promotes motility and survival (Lobert *et al.*, 2010). In pancreatic stellate cells, it interacts with connective tissue growth factor to stimulate adhesion, migration, and fibrogenesis (Gao and Brigstock, 2006). It has been shown that  
5 pharmacologic antagonism of  $\alpha 5\beta 1$  inhibits the attachment migration, and proliferation of human retinal epithelial cells *in vitro*, and reduces retinal cell proliferation and scarring when administered intravitreally to rabbits with retinal detachment (Li *et al.*, 2009; Zahn *et al.*, 2010).

Besides  $\alpha 5\beta 1$ , another RGD-binding integrin of the beta-1 family that is upregulated  
10 after organ injury is  $\alpha 8\beta 1$ . Studies have shown that this integrin is co-expressed with markers of tissue myofibroblasts, the principal cellular mediators of fibrosis (Levine *et al.*, 2000; Bouzeghrane *et al.*, 2004). Ectopic expression of  $\alpha 8\beta 1$  conferred to cells increased spreading and adhesion on latent TGF $\beta$ , a major pro-fibrotic cytokine, in a manner that was RGD-dependent (Lu *et al.*, 2002).

RGD-binding integrins of the alpha v family have been implicated in promoting the  
15 biological activation of the latent pro-fibrotic cytokine TGF $\beta$ . This is mediated by binding to the latency associated peptide (LAP), particularly by  $\alpha v\beta 6$  and  $\alpha v\beta 8$ , but also by  $\alpha v\beta 1$ ,  $\alpha v\beta 3$ , and  $\alpha v\beta 5$ . Furthermore, the alpha v integrins mediate attachment, migration, proliferation and other functions in diverse cell types associated with the wound repair  
20 process. This functional redundancy, differential cellular expression, and the known fibrosis phenotypes of integrin knockout mice, all suggest that a highly potent antagonist of this entire subset may be particularly useful for therapeutic development. To achieve TGF $\beta$  activation, these integrins are all critically dependent upon the amino acid sequence arg-gly-aspartic (RGD) contained in LAP. Indeed, mice containing a mutation in the RGD sequence of LAP are  
25 incapable of TGF $\beta$  activation and recapitulate the phenotype of TGF $\beta$ -null mice. Genetic ablation of the expression of alpha v integrins specifically from myofibroblasts in mice conferred protection against the development of fibrosis in several models of organ injury, and this efficacy was similarly provided by continuous infusion treatment with a small molecule integrin antagonist of RGD-binding integrins known as CWHM-12 (Henderson *et al.*, 2013). Such studies support the concept that simultaneous inhibition of multiple integrins  
30 may have particular utility to prevent or treat a range of fibrotic conditions.

The multi-integrin receptor antagonist compounds previously described in the art generally lack either demonstrated broad spectrum potency against all of the RGD integrins


described above, or the pharmacokinetic properties suitable for sustained activity with oral dosing, or both. Long plasma half-life at therapeutically significant concentrations following oral administration is a highly desirable property for development of drug formulations for clinical treatments, allowing convenient administration usually without need for medical supervision.

5

## SUMMARY

The present disclosure provides novel integrin receptor antagonists, pharmaceutical compositions thereof, methods of manufacture thereof, and methods for their use.

In some aspects, the present disclosure provides compounds of the formula:



5

wherein:


A is C-H, C-OH, or N;

R' is hydrogen, alkyl<sub>(C≤8)</sub>, substituted alkyl<sub>(C≤8)</sub>, or a substituent convertible *in vivo* to hydrogen; and

10 X and Y are each independently cyano, halo, fluoroalkoxy<sub>(C1-2)</sub>, alkyl<sub>(C1-2)</sub>, or fluoroalkyl<sub>(C1-2)</sub>, with the proviso that X and Y are not both cyano or alkyl<sub>(C1-2)</sub>;

or a pharmaceutically acceptable salt or tautomer of the above formula.

In some embodiments, the compound is further defined as:



15

wherein:

A is C-OH or N;

R' is hydrogen, alkyl<sub>(C≤8)</sub>, substituted alkyl<sub>(C≤8)</sub>, or a substituent convertible *in vivo* to hydrogen; and

X and Y are each independently cyano, halo, fluoroalkoxy<sub>(C1-2)</sub>, alkyl<sub>(C1-2)</sub>, or fluoroalkyl<sub>(C1-2)</sub>, with the proviso that X and Y are not both cyano or alkyl<sub>(C1-2)</sub>;

or a pharmaceutically acceptable salt or tautomer of the above formula.


5 In some embodiments, A is N. In other embodiments, A is C-OH. In some embodiments, R' is hydrogen.


In some embodiments, X is halo such as -F, -Cl, or -Br. In some embodiments, X is -F. In other embodiments, X is -Cl. In other embodiments, X is -Br. In other embodiments, X is fluoroalkoxy<sub>(C1-2)</sub> such as -OCF<sub>3</sub>. In other embodiments, X is fluoroalkyl<sub>(C1-2)</sub>. In some embodiments, X is -CHF<sub>2</sub>. In other embodiments, X is -CF<sub>3</sub>. In other embodiments, X is alkyl<sub>(C1-2)</sub> such as -CH<sub>3</sub>.

In some embodiments, Y is halo such as -F, -Cl, or -Br. In some embodiments, Y is -F. In other embodiments, Y is -Cl. In other embodiments, Y is -Br. In other embodiments, Y is fluoroalkoxy<sub>(C1-2)</sub> such as -OCF<sub>3</sub>. In other embodiments, Y is fluoroalkyl<sub>(C1-2)</sub>. In some embodiments, Y is -CHF<sub>2</sub>. In other embodiments, Y is -CF<sub>3</sub>. In other embodiments, Y is alkyl<sub>(C1-2)</sub> such as -CH<sub>3</sub>.


In some embodiments, X and Y are each independently selected from the groups consisting of -F, -Cl, -Br, -OCF<sub>3</sub>, -CH<sub>3</sub>, -CHF<sub>2</sub>, and -CF<sub>3</sub>, with the proviso that X and Y are not both -CH<sub>3</sub>.

20 In some embodiments, the carbon atom labeled β is in the *S* configuration. In some embodiments, the compounds are further defined as:









or a pharmaceutically acceptable salt or tautomer of any of the above formulas.

5 In some embodiments, the compounds are effective for inhibiting three or more RGD integrins selected from the group consisting of  $\alpha 5\beta 1$ ,  $\alpha \beta 1$ ,  $\alpha 8\beta 1$ ,  $\alpha \beta 3$ ,  $\alpha \beta 5$ ,  $\alpha \beta 6$ , and  $\alpha \beta 8$ , wherein the effectiveness of the compound corresponds to an  $IC_{50}$  value of less than 10 nM for each of the three or more RGD integrins as measured using a solid phase receptor assay (SPRA) for function of the respective integrin.

10 In some embodiments, the compounds possess pharmacokinetic properties that allow therapeutically significant plasma concentrations to be achieved and/or sustained in a patient for two or more hours after oral administration. In some embodiments, the compounds have a sustained plasma half-life of at least two hours as measured in a rat using an i.v. bolus comprising 1 mg of compound per kg of rat.

15 In yet another aspect, the present disclosure provides pharmaceutical compositions comprising:

- a) a compound described herein; and

b) an excipient.

In still yet another aspect, the present disclosure provides methods of treating and/or preventing a disease or a disorder in a patient in need thereof, comprising administering to the patient a compound or composition described herein in an amount sufficient to treat and/or prevent the disease or disorder.

In some embodiments, the disease or disorder is associated with angiogenesis. In other embodiments, the disease or disorder is associated with fibrosis. In some embodiments, the disease or disorder is associated with fibrosis and/or angiogenesis.

In some embodiments, the disease or disorder is pulmonary, liver, renal, cardiac, and pancreatic fibrosis, scleroderma, scarring, retinopathy of prematurity, familial exudative vitreoretinopathy, proliferative vitreoretinopathies, macular degeneration, diabetic retinopathy, cancer, osteoporosis, autoimmune diseases, humoral hypercalcemia of malignancy, Paget's disease, periodontal disease, psoriasis, arthritis, restenosis, and infection. In some embodiments, the disease or disorder is pulmonary fibrosis. In other embodiments, the disease or disorder is liver fibrosis. In other embodiments, the disease or disorder is cardiac fibrosis. In other embodiments, the disease or disorder is renal fibrosis. In other embodiments, the disease or disorder is pancreatic fibrosis.


In other embodiments, the disease or disorder is scleroderma. In other embodiments, the disease or disorder is scarring. In some embodiments, the scarring is dermal scarring. In other embodiments, the scarring is retinal scarring. In other embodiments, the scarring is corneal scarring.

In other embodiments, the disease or disorder is retinopathy of prematurity. In other embodiments, the disease or disorder is familial exudative vitreoretinopathy. In other embodiments, the disease or disorder is proliferative vitreoretinopathies. In other embodiments, the disease or disorder is macular degeneration. In other embodiments, the disease or disorder is diabetic retinopathy.

In other embodiments, the disease or disorder is cancer. In some embodiments, the cancer includes solid tumor growth or neoplasia. In some embodiments, the cancer includes tumor metathesis. In some embodiments, the cancer is of the bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach,

testicle, or thyroid. In some embodiments, the cancer is a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma.

In other embodiments, the disease or disorder is osteoporosis. In other embodiments, the disease or disorder is an autoimmune disease. In some embodiments, the autoimmune disorder is multiple sclerosis. In other embodiments, the disease or disorder is humoral hypercalcemia of malignancy. In other embodiments, the disease or disorder is Paget's disease. In other embodiments, the disease or disorder is periodontal disease. In other embodiments, the disease or disorder is psoriasis. In other embodiments, the disease or disorder is arthritis. In some embodiments, the arthritis is rheumatoid arthritis. In other  
 5  
 10  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55  
 60  
 65  
 70  
 75  
 80  
 85  
 90  
 95  
 100  
 105  
 110  
 115  
 120  
 125  
 130  
 135  
 140  
 145  
 150  
 155  
 160  
 165  
 170  
 175  
 180  
 185  
 190  
 195  
 200  
 205  
 210  
 215  
 220  
 225  
 230  
 235  
 240  
 245  
 250  
 255  
 260  
 265  
 270  
 275  
 280  
 285  
 290  
 295  
 300  
 305  
 310  
 315  
 320  
 325  
 330  
 335  
 340  
 345  
 350  
 355  
 360  
 365  
 370  
 375  
 380  
 385  
 390  
 395  
 400  
 405  
 410  
 415  
 420  
 425  
 430  
 435  
 440  
 445  
 450  
 455  
 460  
 465  
 470  
 475  
 480  
 485  
 490  
 495  
 500  
 505  
 510  
 515  
 520  
 525  
 530  
 535  
 540  
 545  
 550  
 555  
 560  
 565  
 570  
 575  
 580  
 585  
 590  
 595  
 600  
 605  
 610  
 615  
 620  
 625  
 630  
 635  
 640  
 645  
 650  
 655  
 660  
 665  
 670  
 675  
 680  
 685  
 690  
 695  
 700  
 705  
 710  
 715  
 720  
 725  
 730  
 735  
 740  
 745  
 750  
 755  
 760  
 765  
 770  
 775  
 780  
 785  
 790  
 795  
 800  
 805  
 810  
 815  
 820  
 825  
 830  
 835  
 840  
 845  
 850  
 855  
 860  
 865  
 870  
 875  
 880  
 885  
 890  
 895  
 900  
 905  
 910  
 915  
 920  
 925  
 930  
 935  
 940  
 945  
 950  
 955  
 960  
 965  
 970  
 975  
 980  
 985  
 990  
 995  
 1000  
 1005  
 1010  
 1015  
 1020  
 1025  
 1030  
 1035  
 1040  
 1045  
 1050  
 1055  
 1060  
 1065  
 1070  
 1075  
 1080  
 1085  
 1090  
 1095  
 1100  
 1105  
 1110  
 1115  
 1120  
 1125  
 1130  
 1135  
 1140  
 1145  
 1150  
 1155  
 1160  
 1165  
 1170  
 1175  
 1180  
 1185  
 1190  
 1195  
 1200  
 1205  
 1210  
 1215  
 1220  
 1225  
 1230  
 1235  
 1240  
 1245  
 1250  
 1255  
 1260  
 1265  
 1270  
 1275  
 1280  
 1285  
 1290  
 1295  
 1300  
 1305  
 1310  
 1315  
 1320  
 1325  
 1330  
 1335  
 1340  
 1345  
 1350  
 1355  
 1360  
 1365  
 1370  
 1375  
 1380  
 1385  
 1390  
 1395  
 1400  
 1405  
 1410  
 1415  
 1420  
 1425  
 1430  
 1435  
 1440  
 1445  
 1450  
 1455  
 1460  
 1465  
 1470  
 1475  
 1480  
 1485  
 1490  
 1495  
 1500  
 1505  
 1510  
 1515  
 1520  
 1525  
 1530  
 1535  
 1540  
 1545  
 1550  
 1555  
 1560  
 1565  
 1570  
 1575  
 1580  
 1585  
 1590  
 1595  
 1600  
 1605  
 1610  
 1615  
 1620  
 1625  
 1630  
 1635  
 1640  
 1645  
 1650  
 1655  
 1660  
 1665  
 1670  
 1675  
 1680  
 1685  
 1690  
 1695  
 1700  
 1705  
 1710  
 1715  
 1720  
 1725  
 1730  
 1735  
 1740  
 1745  
 1750  
 1755  
 1760  
 1765  
 1770  
 1775  
 1780  
 1785  
 1790  
 1795  
 1800  
 1805  
 1810  
 1815  
 1820  
 1825  
 1830  
 1835  
 1840  
 1845  
 1850  
 1855  
 1860  
 1865  
 1870  
 1875  
 1880  
 1885  
 1890  
 1895  
 1900  
 1905  
 1910  
 1915  
 1920  
 1925  
 1930  
 1935  
 1940  
 1945  
 1950  
 1955  
 1960  
 1965  
 1970  
 1975  
 1980  
 1985  
 1990  
 1995  
 2000  
 2005  
 2010  
 2015  
 2020  
 2025  
 2030  
 2035  
 2040  
 2045  
 2050  
 2055  
 2060  
 2065  
 2070  
 2075  
 2080  
 2085  
 2090  
 2095  
 2100  
 2105  
 2110  
 2115  
 2120  
 2125  
 2130  
 2135  
 2140  
 2145  
 2150  
 2155  
 2160  
 2165  
 2170  
 2175  
 2180  
 2185  
 2190  
 2195  
 2200  
 2205  
 2210  
 2215  
 2220  
 2225  
 2230  
 2235  
 2240  
 2245  
 2250  
 2255  
 2260  
 2265  
 2270  
 2275  
 2280  
 2285  
 2290  
 2295  
 2300  
 2305  
 2310  
 2315  
 2320  
 2325  
 2330  
 2335  
 2340  
 2345  
 2350  
 2355  
 2360  
 2365  
 2370  
 2375  
 2380  
 2385  
 2390  
 2395  
 2400  
 2405  
 2410  
 2415  
 2420  
 2425  
 2430  
 2435  
 2440  
 2445  
 2450  
 2455  
 2460  
 2465  
 2470  
 2475  
 2480  
 2485  
 2490  
 2495  
 2500  
 2505  
 2510  
 2515  
 2520  
 2525  
 2530  
 2535  
 2540  
 2545  
 2550  
 2555  
 2560  
 2565  
 2570  
 2575  
 2580  
 2585  
 2590  
 2595  
 2600  
 2605  
 2610  
 2615  
 2620  
 2625  
 2630  
 2635  
 2640  
 2645  
 2650  
 2655  
 2660  
 2665  
 2670  
 2675  
 2680  
 2685  
 2690  
 2695  
 2700  
 2705  
 2710  
 2715  
 2720  
 2725  
 2730  
 2735  
 2740  
 2745  
 2750  
 2755  
 2760  
 2765  
 2770  
 2775  
 2780  
 2785  
 2790  
 2795  
 2800  
 2805  
 2810  
 2815  
 2820  
 2825  
 2830  
 2835  
 2840  
 2845  
 2850  
 2855  
 2860  
 2865  
 2870  
 2875  
 2880  
 2885  
 2890  
 2895  
 2900  
 2905  
 2910  
 2915  
 2920  
 2925  
 2930  
 2935  
 2940  
 2945  
 2950  
 2955  
 2960  
 2965  
 2970  
 2975  
 2980  
 2985  
 2990  
 2995  
 3000  
 3005  
 3010  
 3015  
 3020  
 3025  
 3030  
 3035  
 3040  
 3045  
 3050  
 3055  
 3060  
 3065  
 3070  
 3075  
 3080  
 3085  
 3090  
 3095  
 3100  
 3105  
 3110  
 3115  
 3120  
 3125  
 3130  
 3135  
 3140  
 3145  
 3150  
 3155  
 3160  
 3165  
 3170  
 3175  
 3180  
 3185  
 3190  
 3195  
 3200  
 3205  
 3210  
 3215  
 3220  
 3225  
 3230  
 3235  
 3240  
 3245  
 3250  
 3255  
 3260  
 3265  
 3270  
 3275  
 3280  
 3285  
 3290  
 3295  
 3300  
 3305  
 3310  
 3315  
 3320  
 3325  
 3330  
 3335  
 3340  
 3345  
 3350  
 3355  
 3360  
 3365  
 3370  
 3375  
 3380  
 3385  
 3390  
 3395  
 3400  
 3405  
 3410  
 3415  
 3420  
 3425  
 3430  
 3435  
 3440  
 3445  
 3450  
 3455  
 3460  
 3465  
 3470  
 3475  
 3480  
 3485  
 3490  
 3495  
 3500  
 3505  
 3510  
 3515  
 3520  
 3525  
 3530  
 3535  
 3540  
 3545  
 3550  
 3555  
 3560  
 3565  
 3570  
 3575  
 3580  
 3585  
 3590  
 3595  
 3600  
 3605  
 3610  
 3615  
 3620  
 3625  
 3630  
 3635  
 3640  
 3645  
 3650  
 3655  
 3660  
 3665  
 3670  
 3675  
 3680  
 3685  
 3690  
 3695  
 3700  
 3705  
 3710  
 3715  
 3720  
 3725  
 3730  
 3735  
 3740  
 3745  
 3750  
 3755  
 3760  
 3765  
 3770  
 3775  
 3780  
 3785  
 3790  
 3795  
 3800  
 3805  
 3810  
 3815  
 3820  
 3825  
 3830  
 3835  
 3840  
 3845  
 3850  
 3855  
 3860  
 3865  
 3870  
 3875  
 3880  
 3885  
 3890  
 3895  
 3900  
 3905  
 3910  
 3915  
 3920  
 3925  
 3930  
 3935  
 3940  
 3945  
 3950  
 3955  
 3960  
 3965  
 3970  
 3975  
 3980  
 3985  
 3990  
 3995  
 4000  
 4005  
 4010  
 4015  
 4020  
 4025  
 4030  
 4035  
 4040  
 4045  
 4050  
 4055  
 4060  
 4065  
 4070  
 4075  
 4080  
 4085  
 4090  
 4095  
 4100  
 4105  
 4110  
 4115  
 4120  
 4125  
 4130  
 4135  
 4140  
 4145  
 4150  
 4155  
 4160  
 4165  
 4170  
 4175  
 4180  
 4185  
 4190  
 4195  
 4200  
 4205  
 4210  
 4215  
 4220  
 4225  
 4230  
 4235  
 4240  
 4245  
 4250  
 4255  
 4260  
 4265  
 4270  
 4275  
 4280  
 4285  
 4290  
 4295  
 4300  
 4305  
 4310  
 4315  
 4320  
 4325  
 4330  
 4335  
 4340  
 4345  
 4350  
 4355  
 4360  
 4365  
 4370  
 4375  
 4380  
 4385  
 4390  
 4395  
 4400  
 4405  
 4410  
 4415  
 4420  
 4425  
 4430  
 4435  
 4440  
 4445  
 4450  
 4455  
 4460  
 4465  
 4470  
 4475  
 4480  
 4485  
 4490  
 4495  
 4500  
 4505  
 4510  
 4515  
 4520  
 4525  
 4530  
 4535  
 4540  
 4545  
 4550  
 4555  
 4560  
 4565  
 4570  
 4575  
 4580  
 4585  
 4590  
 4595  
 4600  
 4605  
 4610  
 4615  
 4620  
 4625  
 4630  
 4635  
 4640  
 4645  
 4650  
 4655  
 4660  
 4665  
 4670  
 4675  
 4680  
 4685  
 4690  
 4695  
 4700  
 4705  
 4710  
 4715  
 4720  
 4725  
 4730  
 4735  
 4740  
 4745  
 4750  
 4755  
 4760  
 4765  
 4770  
 4775  
 4780  
 4785  
 4790  
 4795  
 4800  
 4805  
 4810  
 4815  
 4820  
 4825  
 4830  
 4835  
 4840  
 4845  
 4850  
 4855  
 4860  
 4865  
 4870  
 4875  
 4880  
 4885  
 4890  
 4895  
 4900  
 4905  
 4910  
 4915  
 4920  
 4925  
 4930  
 4935  
 4940  
 4945  
 4950  
 4955  
 4960  
 4965  
 4970  
 4975  
 4980  
 4985  
 4990  
 4995  
 5000  
 5005  
 5010  
 5015  
 5020  
 5025  
 5030  
 5035  
 5040  
 5045  
 5050  
 5055  
 5060  
 5065  
 5070  
 5075  
 5080  
 5085  
 5090  
 5095  
 5100  
 5105  
 5110  
 5115  
 5120  
 5125  
 5130  
 5135  
 5140  
 5145  
 5150  
 5155  
 5160  
 5165  
 5170  
 5175  
 5180  
 5185  
 5190  
 5195  
 5200  
 5205  
 5210  
 5215  
 5220  
 5225  
 5230  
 5235  
 5240  
 5245  
 5250  
 5255  
 5260  
 5265  
 5270  
 5275  
 5280  
 5285  
 5290  
 5295  
 5300  
 5305  
 5310  
 5315  
 5320  
 5325  
 5330  
 5335  
 5340  
 5345  
 5350  
 5355  
 5360  
 5365  
 5370  
 5375  
 5380  
 5385  
 5390  
 5395  
 5400  
 5405  
 5410  
 5415  
 5420  
 5425  
 5430  
 5435  
 5440  
 5445  
 5450  
 5455  
 5460  
 5465  
 5470  
 5475  
 5480  
 5485  
 5490  
 5495  
 5500  
 5505  
 5510  
 5515  
 5520  
 5525  
 5530  
 5535  
 5540  
 5545  
 5550  
 5555  
 5560  
 5565  
 5570  
 5575  
 5580  
 5585  
 5590  
 5595  
 5600  
 5605  
 5610  
 5615  
 5620  
 5625  
 5630  
 5635  
 5640  
 5645  
 5650  
 5655  
 5660  
 5665  
 5670  
 5675  
 5680  
 5685  
 5690  
 5695  
 5700  
 5705  
 5710  
 5715  
 5720  
 5725  
 5730  
 5735  
 5740  
 5745  
 5750  
 5755  
 5760  
 5765  
 5770  
 5775  
 5780  
 5785  
 5790  
 5795  
 5800  
 5805  
 5810  
 5815  
 5820  
 5825  
 5830  
 5835  
 5840  
 5845  
 5850  
 5855  
 5860  
 5865  
 5870  
 5875  
 5880  
 5885  
 5890  
 5895  
 5900  
 5905  
 5910  
 5915  
 5920  
 5925  
 5930  
 5935  
 5940  
 5945  
 5950  
 5955  
 5960  
 5965  
 5970  
 5975  
 5980  
 5985  
 5990  
 5995  
 6000  
 6005  
 6010  
 6015  
 6020  
 6025  
 6030  
 6035  
 6040  
 6045  
 6050  
 6055  
 6060  
 6065  
 6070  
 6075  
 6080  
 6085  
 6090  
 6095  
 6100  
 6105  
 6110  
 6115  
 6120  
 6125  
 6130  
 6135  
 6140  
 6145  
 6150  
 6155  
 6160  
 6165  
 6170  
 6175  
 6180  
 6185  
 6190  
 6195  
 6200  
 6205  
 6210  
 6215  
 6220  
 6225  
 6230  
 6235  
 6240  
 6245  
 6250  
 6255  
 6260  
 6265  
 6270  
 6275  
 6280  
 6285  
 6290  
 6295  
 6300  
 6305  
 6310  
 6315  
 6320  
 6325  
 6330  
 6335  
 6340  
 6345  
 6350  
 6355  
 6360  
 6365  
 6370  
 6375  
 6380  
 6385  
 6390  
 6395  
 6400  
 6405  
 6410  
 6415  
 6420  
 6425  
 6430  
 6435  
 6440  
 6445  
 6450  
 6455  
 6460  
 6465  
 6470  
 6475  
 6480  
 6485  
 6490  
 6495  
 6500  
 6505  
 6510  
 6515  
 6520  
 6525  
 6530  
 6535  
 6540  
 6545  
 6550  
 6555  
 6560  
 6565  
 6570  
 6575  
 6580  
 6585  
 6590  
 6595  
 6600  
 6605  
 6610  
 6615  
 6620  
 6625  
 6630  
 6635  
 6640  
 6645  
 6650  
 6655  
 6660  
 6665  
 6670  
 6675  
 6680  
 6685  
 6690  
 6695  
 6700  
 6705  
 6710  
 6715  
 6720  
 6725  
 6730  
 6735  
 6740  
 6745  
 6750  
 6755  
 6760  
 6765  
 6770  
 6775  
 6780  
 6785  
 6790  
 6795  
 6800  
 6805  
 6810  
 6815  
 6820  
 6825  
 6



given the free rotation of the bond joining the carbon label  $\beta$  in the backbone and the carbon labeled 1 in the aromatic ring.

Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the disclosure, are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description. Note that simply because a particular compound is ascribed to one particular generic formula doesn't mean that it cannot also belong to another generic formula.

### BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed  
5 description of specific embodiments presented herein.

**FIG. 1** – Dot plots comparing potency of comparison compounds (comparators) and Examples shown in Tables 1A & B for each integrin. Horizontal lines indicate group means. Statistical analysis was performed using a two-tailed standard T test for comparison of group means.


## DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

Disclosed herein are new compounds and compositions with integrin receptor antagonists properties, methods for their manufacture, and methods for their use, including for the treatment and/or prevention of disease.

### I. Compounds and Synthetic Methods


The compounds provided by the present disclosure may be made using the methods outlined below and further described in the Examples section. Comparison compounds shown in Table 1 and listed in Tables 3-5 were synthesized as disclosed in the literature. Additionally, these comparison compounds may also be readily synthesized by utilizing the methods and procedures described herein by those skilled in the art. General synthetic sequences for preparing the compounds useful in the present disclosure are outlined in Schemes I-VIII. Both an explanation of, and the actual procedures for, the various aspects of the present disclosure are described where appropriate. The following Schemes and Examples are intended to be merely illustrative of the present disclosure, and not limiting thereof in either scope or spirit. Those with skill in the art will readily understand that known variations of the conditions and processes described in the Schemes and Examples can be used to synthesize the compounds of the present disclosure. Starting materials and equipment employed were either commercially available prepared by methods previously reported and readily duplicated by those skilled in the art.

Scheme I



Scheme I illustrates general methodology which may be used for preparing the cyclic guanidine substituted left hand side aromatic acid portion of Formula I of the present disclosure which can then be coupled to a Gly- $\beta$ -amino acid ester, or to Gly ester first, followed by (after ester hydrolysis) coupling to the appropriate  $\beta$ -amino acid ester. Briefly, in Scheme I, the appropriate amino benzoic (or pyridine) acid is reacted with ammonium thiocyanate in hot dilute hydrochloric to give the resulting 3-thiourea benzoic (or pyridine) acid after normal work-up. The starting amino benzoic (or pyridine) acids are either commercially available or can be converted to such amino benzoic (or pyridine) acids via reduction of the corresponding nitro benzoic (or pyridine) acid, which can be obtained commercially or synthesized by nitration of the appropriate benzoic (or pyridine) acid, followed by reduction to the desired amino benzoic (or pyridine) acid, or by other reported methodologies that are known to those skilled in the art. This thiourea intermediate is converted to the S-methyl derivative by reaction with methyl iodide in ethanol at reflux. The appropriate 1,3-diamino-2-hydroxy propane is reacted with this resulting intermediate in hot DMA (or DMF). Upon cooling, a precipitate forms and the zwitterionic product is isolated by filtration. The HCl salt may be obtained by lyophilizing from dilute hydrochloric acid. Alternatively, the product may be isolated from the original reaction mixture by removing volatiles and concentrating. The resulting product is taken up in water and pH adjusted to about 5-7 where zwitterionic product precipitates and is isolated by filtration. The HCl salt may be obtained as previously stated or by simply dissolving in dilute hydrochloric acid and concentrating to a solid and drying.

## Scheme II




Scheme II illustrates methodology which may be used for preparing the tetrahydropyrimidinobenzoic acid portion of Formula I of the present disclosure which can then be coupled to a Gly- $\beta$ -amino acid ester, or to Gly ester first, followed by (after ester hydrolysis) coupling to the appropriate  $\beta$ -amino acid ester. Briefly, in Scheme II, 3,5-dihydroxybenzoic acid is converted to 3-amino-5-hydroxybenzoic acid using the procedure described in *Austr. J. Chem.* 1981 or Becker *et al.*, 1983. The product is reacted with methyl isothiocyanate in DMF at room temperature (*Organic Process Research & Development*, 2004) to give 3-N'-methyl thiourea-5-hydroxybenzoic acid after normal work-up. This thiourea intermediate is converted to the S-methyl derivative by reaction with methyl iodide neat at below 40 °C. 1,3-diamino-2-hydroxypropane is reacted with this resulting intermediate in hot DMA (or DMF). Upon cooling, a precipitate forms and the zwitterionic product is isolated by filtration. The HCl salt may be obtained by lyophilizing from dilute hydrochloric acid. Alternatively, the product may be isolated from the original reaction mixture by removing volatiles and concentrating. The resulting product is taken up in water and pH adjusted to about 5-7 where zwitterionic product precipitates and is isolated by




filtration. The HCl salt may be obtained as previously stated or by simply dissolving in dilute hydrochloric acid and concentrating to a solid and drying.

**Scheme III**




- 5 Scheme III illustrates a general methodology which may be used for the synthesis of the beta amino acid ester portion of Formula I of the present disclosure, starting from an appropriate benzaldehyde. This beta amino acid ester can then be coupled to Boc-Glycine followed by (after removal of the Boc protecting group) coupling to the appropriate aromatic acid described in Schemes I and II, or to the aromatic acid that has been coupled to Glycine.
- 10 Briefly in Scheme III, to the appropriate benzaldehyde in isopropanol is added ammonium acetate followed by malonic acid. The reaction mixture is stirred at reflux, the resulting precipitate filtered and washed with hot isopropanol and dried to yield the desired racemic beta amino acid. The ethyl ester is synthesized by heating this acid in excess ethanol in the presence of excess HCl gas. These racemic beta amino acid esters can be resolved into the
- 15 (*R*) and the (*S*) enantiomers via chiral chromatographic separation, or via enzymatic resolution as described in Faulconbridge *et al.*, 2000 or Landis *et al.*, 2002, which are incorporated herein by reference. In some embodiments, the (*S*) enantiomer is the preferred enantiomer of the  $\beta$ -amino acid group.

Scheme IV




Scheme IV illustrates a general methodology which may be used for preparing the ethyl-N-Gly-beta amino acid portion of Formula I of the present disclosure, which can be coupled to the aromatic acid portion of Formula I described in Schemes I and II. This method describes coupling a beta amino acid ester to Glycine. Briefly, the desired beta amino acid ester (described in Scheme III above) is treated with activated Boc Glycine. Removal of the Boc protective group (by treatment with ethanol/HCl, for example) affords the Glycine amide of the corresponding beta amino acid ester (the *(S)* enantiomer is afforded by utilizing the *(S)*-beta amino acid ester, described in the above scheme).

Scheme V




Scheme V illustrates a general methodology which may be used for preparing various compounds of the present disclosure. Briefly, the cyclic guanidine substituted left hand side aromatic acid portion of Formula I (described in Schemes I and II) is activated for coupling using known methods. Thus, after dissolving in a suitable solvent such as DMA an equivalent of NMM is added. The reaction mixture is cooled to ice-bath temperatures and IBCF added. To the mixed anhydride intermediate is added the Gly-β-amino acid ester (described in Scheme IV) and NMM. Upon completion of the reaction the product is purified by preparative HPLC and the ester hydrolyzed to the acid by treating with a base, such as LiOH in a suitable solvent (dioxane/water or acetonitrile/water). Alternatively, a suitable acid, such as TFA can be used. The product is isolated by preparative HPLC or by isolating the zwitterion at pH 5-7 and converting to the desired salt by standard procedures. (The (*S*) enantiomer is afforded by utilizing the (*S*) – beta amino acid ester, described in the above schemes).

Scheme VI



Scheme VI illustrates a general methodology that may be used for preparing various compounds of the present disclosure. Briefly, 3-Hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoic acid (described in Scheme II) is activated for coupling using known methods. Thus, after dissolving in a suitable solvent such as DMA an equivalent of NMM is added. The reaction mixture is cooled to ice-bath temperatures and IBCF added. To the mixed anhydride intermediate is added the Gly- $\beta$ -amino acid ester (described in Scheme IV) and NMM. Upon completion of the reaction the product is purified by preparative HPLC and the ester hydrolyzed to the acid by treating with a base, such as LiOH in a suitable solvent (dioxane/water or acetonitrile/water). Alternatively, a suitable acid, such as TFA can be used. The product is isolated by preparative HPLC or by isolating the zwitterion at pH 5-7 and converting to the desired salt by standard procedures. (The (*S*) enantiomer is afforded by utilizing the (*S*) – beta amino acid ester, described in the above schemes).


## Scheme VII



Scheme VII illustrates a general methodology that may be used for preparing various compounds of the present disclosure. Briefly, the cyclic guanidine substituted left hand side aromatic acid portion of Formula I (described for example in Schemes I and II) is activated for coupling using known methods. Thus, after dissolving in a suitable solvent such as DMA an equivalent of NMM is added. The reaction mixture is cooled to ice-bath temperatures and IBCF added. To the mixed anhydride intermediate is added ethyl glycinate HCl and NMM. Upon completion of the reaction the product is purified by preparative HPLC and the ester

hydrolyzed to the acid by treating with a base, such as NaOH in a suitable solvent (water, dioxane/water or acetonitrile/water), followed by acidification. This Gly adduct is then activated for coupling using known methods. Thus, after dissolving in a suitable solvent such as DMA an equivalent of NMM is added. The reaction mixture is cooled to ice-bath  
5 temperatures and IBCF added. To the mixed anhydride intermediate is added the appropriate beta amino acid ester salt (described in Scheme III above) and NMM. Upon completion of the reaction the product is purified by preparative HPLC and the ester hydrolyzed to the acid by treating with a base, such as LiOH in a suitable solvent (dioxane/water or acetonitrile/water). Alternatively, a suitable acid, such as TFA can be used. The product is  
10 isolated by preparative HPLC or by isolating the zwitterion at pH 5-7 and converting to the desired salt by standard procedures (the (*S*) enantiomer is afforded by utilizing the (*S*) – beta amino acid ester, described in the above schemes).

## Scheme VIII



Scheme VIII illustrates a general methodology which may be useful for preparing various compounds of described herein. Briefly, 3-Hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoic acid (described in Scheme II) is activated for coupling using known methods. Thus, after dissolving in a suitable solvent such as DMA, an equivalent of NMM is added. The reaction mixture is cooled to ice-bath temperatures and IBCF added. To the mixed anhydride intermediate is added ethyl glycinate HCl and NMM. Upon completion of the reaction the product is purified by preparative HPLC and the ester






hydrolyzed to the acid by treating with a base, such as NaOH in a suitable solvent (water, dioxane/water or acetonitrile/water), followed by acidification. This Gly adduct is then activated for coupling using known methods. Thus, after dissolving in a suitable solvent such as DMA an equivalent of NMM is added. The reaction mixture is cooled to ice-bath temperatures and IBCF added. To the mixed anhydride intermediate is added the appropriate beta amino acid ester salt (described in Scheme III above) and NMM. Upon completion of the reaction the product is purified by prep hplc and the ester hydrolyzed to the acid by treating with a base, such as LiOH in a suitable solvent (dioxane/water or acetonitrile/water). Alternatively, a suitable acid, such as TFA can be used. The product is isolated by preparative HPLC or by isolating the zwitterion at pH 5-7 and converting to the desired salt by standard procedures (the (*S*) enantiomer is afforded by utilizing the (*S*) – beta amino acid ester, described in the above schemes).






In some embodiments, the compounds of the present disclosure are those described in Table 1A (below), the Examples, and the claims.

**Table 1A: Example Compounds of the Present Disclosure**

Example Number	Compound Structure
1	
2	



Example Number	Compound Structure
3	 <chem>Oc1nc2c(nc(=O)NCC(=O)N[C@H](Cc3cc(Cl)cc(CF)C3)c3cc(O)cc3n2)c3cc(O)cc3n1</chem>
4	 <chem>Oc1nc2c(nc(=O)NCC(=O)N[C@H](Cc3cc(Br)cc(CF)C3)c3cc(O)cc3n2)c3cc(O)cc3n1</chem>
5	 <chem>Oc1nc2c(nc(=O)NCC(=O)N[C@H](Cc3cc(Cl)cc(C(F)(F)F)C3)c3cc(O)cc3n2)c3cc(O)cc3n1</chem>
6	 <chem>Oc1nc2c(nc(=O)NCC(=O)N[C@H](Cc3cc(Cl)cc(Br)C3)c3cc(O)cc3n2)c3cc(O)cc3n1</chem>
7	 <chem>Oc1nc2c(nc(=O)NCC(=O)N[C@H](Cc3cc(Cl)cc(C(F)(F)F)C3)c3cc(O)cc3n2)c3cc(O)cc3n1</chem>

Example Number	Compound Structure
8	 <chem>Oc1ccncc1Nc2ccncc2NC(=O)NCC(=O)N[C@H](Cc3cc(Br)cc(Cl)c3)C(=O)O</chem>
9	 <chem>Oc1ccncc1Nc2ccncc2NC(=O)NCC(=O)N[C@H](Cc3cc(Br)cc(C(F)(F)F)c3)C(=O)O</chem>
10	 <chem>Oc1ccncc1Nc2ccncc2NC(=O)NCC(=O)N[C@H](Cc3cc(F)c(C(F)F)cc3)C(=O)O</chem>
11	 <chem>Oc1ccncc1Nc2ccncc2NC(=O)NCC(=O)N[C@H](Cc3cc(Br)cc(C)c3)C(=O)O</chem>
12	 <chem>Oc1ccncc1Nc2ccncc2NC(=O)NCC(=O)N[C@H](Cc3cc(Cl)cc(C)c3)C(=O)O</chem>


























Example Number	Compound Structure
13	 <chem>Oc1cc(NC2=NC(=O)NC(CO)=N2)ccc1C(=O)NCC(=O)N[C@@H](Cc1cc(Br)cc(F)c1)CC(=O)O</chem>
14	 <chem>Oc1cc(NC2=NC(=O)NC(CO)=N2)nc(C#N)c1C(=O)NCC(=O)N[C@@H](Cc1cc(Br)cc(Br)c1)CC(=O)O</chem>
15	 <chem>Oc1cc(NC2=NC(=O)NC(CO)=N2)ccc1C(=O)NCC(=O)N[C@@H](Cc1cc(Cl)cc(Cl)c1)CC(=O)O</chem>
16	 <chem>Oc1cc(NC2=NC(=O)NC(CO)=N2)ccc1C(=O)NCC(=O)N[C@@H](Cc1cc(Cl)cc(OC(F)(F)F)c1)CC(=O)O</chem>
17	 <chem>Oc1cc(NC2=NC(=O)NC(CO)=N2)ccc1C(=O)NCC(=O)N[C@@H](Cc1cc(Br)cc(OC(F)(F)F)c1)CC(=O)O</chem>





Table 1B: Comparison Compounds

Comparison Number	Compound Structure
C1	
C2	
C3	
C4	
C5	





Comparison Number	Compound Structure
C6	
C7	
C8	
C9	
C10	
C11	



Comparison Number	Compound Structure
C12	 <chem>CC(C)(C)c1cc(Br)ccc1NC(=O)CCNC(=O)c2ccc(NC3=NC(CO)CN3)cc2O</chem>
C13	 <chem>CC(C)(C)c1cc(Br)ccc1NC(=O)CCNC(=O)c2ccc(NC3=NC(CO)CN3)cc2O</chem>
C14	 <chem>CC(C)(C)c1cc(Br)ccc1NC(=O)CCNC(=O)c2ccc(NC3=NC(CO)CN3)cc2O</chem>
C15	 <chem>CC(C)(C)c1cc(Br)ccc1NC(=O)CCNC(=O)c2ccc(NC3=NC(CO)CN3)cc2O</chem>

Comparison Number	Compound Structure
C16	 <chem>CC(C)(O)c1ccc(cc1NC(=O)CCNC(=O)c2ccc(cc2Nc3nc[nH]3)O)Cl</chem>
C17	 <chem>CC(C)(C)c1ccc(cc1NC(=O)CCNC(=O)c2ccccc2Nc3nn[nH]3)Br</chem>
C18	 <chem>CC(C)(C)c1ccc(cc1NC(=O)CCNC(=O)c2ccccc2Nc3nn[nH]3)Br</chem>
C19	 <chem>CC(C)(C)c1ccc(cc1NC(=O)CCNC(=O)c2ccc(cc2Nc3nc[nH]3)O)BrC#N</chem>
C20	 <chem>CC(C)(C)c1ccc(cc1NC(=O)CCNC(=O)c2ccc(cc2Nc3nc[nH]3)O)C#N</chem>

Comparison Number	Compound Structure
C21	 <p>Chemical structure of compound C21: A 4-hydroxyphenylhydrazine derivative linked via an amide bond to a 4-hydroxyphenyl group, which is further linked via another amide bond to a 4-(4-chlorophenyl)-4-hydroxybutanoic acid derivative.</p>
C22	 <p>Chemical structure of compound C22: A 4-hydroxyphenylhydrazine derivative linked via an amide bond to a 4-hydroxyphenyl group, which is further linked via another amide bond to a 4-(4-chlorophenyl)-4-(2-fluoroethoxy)butanoic acid derivative.</p>
C23	 <p>Chemical structure of compound C23: A 4-hydroxyphenylhydrazine derivative linked via an amide bond to a 4-hydroxyphenyl group, which is further linked via another amide bond to a 4-(4-chlorophenyl)-4-(trifluoromethyl)butanoic acid derivative.</p>
C24	 <p>Chemical structure of compound C24: A 4-hydroxyphenylhydrazine derivative linked via an amide bond to a 4-hydroxyphenyl group, which is further linked via another amide bond to a 4-(4-chlorophenyl)-4-(trifluoromethyl)-4-hydroxybutanoic acid derivative.</p>



Comparison Number	Compound Structure
C25	 <p>Chemical structure of compound C25: A 4-hydroxyphenylhydrazine derivative linked via an amide bond to a glycine derivative, which is further linked to a 4-chloro-3-(cyclobutylidene)benzoic acid derivative.</p>
C26	 <p>Chemical structure of compound C26: A 4-hydroxyphenylhydrazine derivative linked via an amide bond to a glycine derivative, which is further linked to a 4-chloro-3-(4-cyano-2-oxa-1,4-dioxane-1-ylidene)benzoic acid derivative.</p>
C27	 <p>Chemical structure of compound C27: A 4-hydroxyphenylhydrazine derivative linked via an amide bond to a glycine derivative, which is further linked to a 4-(trifluoromethyl)-3-(trifluoromethylhydroxymethyl)benzoic acid derivative.</p>
C28	 <p>Chemical structure of compound C28: A 4-hydroxyphenylhydrazine derivative linked via an amide bond to a glycine derivative, which is further linked to a 4-bromo-3-(difluoromethyl)cyclopropylbenzoic acid derivative.</p>

Comparison Number	Compound Structure
C29	
C30	

All these methods described above can be further modified and optimized using the principles and techniques taught in U.S. Patents 6,013,651 and 6,028,223, which are incorporated herein by reference, as well as the principles and techniques of organic chemistry as applied by a person skilled in the art. Such principles and techniques are taught, for example, in *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure* (2007), which is incorporated by reference herein.

Compounds employed in methods of the disclosure may contain one or more asymmetrically-substituted carbon or nitrogen atoms, and may be isolated in optically active or racemic form. Thus, all chiral, diastereomeric, racemic form, epimeric form, and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. In some embodiments, the  $\beta$ -amino acid portion of formula I is in the (*S*) configuration. In some embodiments, the (*S*) enantiomer is the preferred enantiomer of the  $\beta$ -amino acid group. Compounds may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. In some embodiments, a single diastereomer is obtained. The chiral centers of the compounds of the present disclosure can have the *S* or the *R* configuration, as defined by the IUPAC 1974 Recommendations. For example, mixtures of stereoisomers may be separated using the techniques taught in the Examples section below, as well as modifications thereof.

Tautomeric forms are also included as well as pharmaceutically acceptable salts of such isomers and tautomers.

Atoms making up the compounds of the present disclosure are intended to include all isotopic forms of such atoms. Compounds of the present disclosure include those with one or more atoms that have been isotopically modified or enriched, in particular those with pharmaceutically acceptable isotopes or those useful for pharmaceutically research. Isotopes, as used herein, include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium, and isotopes of carbon include  $^{13}\text{C}$  and  $^{14}\text{C}$ . Similarly, it is contemplated that one or more carbon atom(s) of a compound of the present disclosure may be replaced by a silicon atom(s). Furthermore, it is contemplated that one or more oxygen atom(s) of a compound of the present disclosure may be replaced by a sulfur or selenium atom(s).

Compounds of the present disclosure may also exist in prodrug form. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.), the compounds employed in some methods of the disclosure may, if desired, be delivered in prodrug form. Thus, the disclosure contemplates prodrugs of compounds of the present disclosure as well as methods of delivering prodrugs. Prodrugs of the compounds employed in the disclosure may be prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compound. Accordingly, prodrugs include, for example, compounds described herein in which a hydroxy, amino, or carboxy group is bonded to any group that, when the prodrug is administered to a subject, cleaves to form a hydroxy, amino, or carboxylic acid, respectively.

It should be recognized that the particular anion or cation forming a part of any salt of this disclosure is not critical, so long as the salt, as a whole, is pharmacologically acceptable. Additional examples of pharmaceutically acceptable salts and their methods of preparation and use are presented in *Handbook of Pharmaceutical Salts: Properties, and Use* (2002), which is incorporated herein by reference.

It should be further recognized that the compounds of the present disclosure include those that have been further modified to comprise substituents that are convertible to hydrogen *in vivo*. This includes those groups that may be convertible to a hydrogen atom by enzymological or chemical means including, but not limited to, hydrolysis and hydrogenolysis. Examples include hydrolyzable groups, such as acyl groups, groups having

an oxycarbonyl group, amino acid residues, peptide residues, *o*-nitrophenylsulfonyl, trimethylsilyl, tetrahydropyranyl, diphenylphosphinyl, and the like. Examples of acyl groups include formyl, acetyl, trifluoroacetyl, and the like. Examples of groups having an oxycarbonyl group include ethoxycarbonyl, *tert*-butoxycarbonyl ( $-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$ , Boc),  
5 benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, vinyloxycarbonyl,  $\beta$ -(*p*-toluenesulfonyl)ethoxycarbonyl, and the like. Suitable amino acid residues include, but are not limited to, residues of Gly (glycine), Ala (alanine), Arg (arginine), Asn (asparagine), Asp (aspartic acid), Cys (cysteine), Glu (glutamic acid), His (histidine), Ile (isoleucine), Leu (leucine), Lys (lysine), Met (methionine), Phe (phenylalanine), Pro (proline), Ser (serine),  
10 Thr (threonine), Trp (tryptophan), Tyr (tyrosine), Val (valine), Nva (norvaline), Hse (homoserine), 4-Hyp (4-hydroxyproline), 5-Hyl (5-hydroxylysine), Orn (ornithine) and  $\beta$ -Ala. Examples of suitable amino acid residues also include amino acid residues that are protected with a protecting group. Examples of suitable protecting groups include those typically employed in peptide synthesis, including acyl groups (such as formyl and acetyl),  
15 arylmethoxycarbonyl groups (such as benzyloxycarbonyl and *p*-nitrobenzyloxycarbonyl), *tert*-butoxycarbonyl groups ( $-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$ , Boc), and the like. Suitable peptide residues include peptide residues comprising two to five amino acid residues. The residues of these amino acids or peptides can be present in stereochemical configurations of the D-form, the L-form or mixtures thereof. In addition, the amino acid or peptide residue may have an  
20 asymmetric carbon atom. Examples of suitable amino acid residues having an asymmetric carbon atom include residues of Ala, Leu, Phe, Trp, Nva, Val, Met, Ser, Lys, Thr and Tyr. Peptide residues having an asymmetric carbon atom include peptide residues having one or more constituent amino acid residues having an asymmetric carbon atom. Examples of suitable amino acid protecting groups include those typically employed in peptide synthesis,  
25 including acyl groups (such as formyl and acetyl), arylmethoxycarbonyl groups (such as benzyloxycarbonyl and *p*-nitrobenzyloxycarbonyl), *tert*-butoxycarbonyl groups ( $-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$ ), and the like. Other examples of substituents “convertible to hydrogen *in vivo*” include reductively eliminable hydrogenolyzable groups. Examples of suitable reductively eliminable hydrogenolyzable groups include, but are not limited to, arylsulfonyl  
30 groups (such as *o*-toluenesulfonyl); methyl groups substituted with phenyl or benzyloxy (such as benzyl, trityl and benzyloxymethyl); arylmethoxycarbonyl groups (such as benzyloxycarbonyl and *o*-methoxy-benzyloxycarbonyl); and haloethoxycarbonyl groups (such as  $\beta,\beta,\beta$ -trichloroethoxycarbonyl and  $\beta$ -iodoethoxycarbonyl).

Compounds of the disclosure may also have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, and/or have a better pharmacokinetic profile (e.g., higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical properties over, compounds known in the prior art, whether for use in the indications stated herein or otherwise.

## II. Biological Activity

In some embodiments, the compounds of the present disclosure may be used to antagonize multiple RGD-binding integrins. In some of these embodiments, the compounds may be used to treat or prevent diseases in which more than one integrin promotes aberrant angiogenesis. For example, the compounds may be especially useful when a second disease process, which is either co-dependent or independent of angiogenesis, is mediated by RGD integrins that can be simultaneously affected with the anti-angiogenic antagonist. Tumors are known to be dependent on the formation of new blood vessels to sustain growth beyond a few millimeters in diameter. Aberrant angiogenesis in the retina is a characteristic of many blinding disorders such as wet age-related macular degeneration, vitreoretinopathies, retinopathy of prematurity, and diabetic retinopathy. Angiogenesis has been associated with progression of pulmonary and liver fibrosis, and with growth of the synovial pannus in rheumatoid arthritis.

The integrins  $\alpha v \beta 3$  and  $\alpha v \beta 5$  have been implicated in promoting angiogenesis (Avraamides *et al.*, 2008), so that their antagonism in addition to other integrins may be predicted to provide superior blockade of this process. Integrin  $\alpha v \beta 3$  is also known to play a role in tumor cell metastasis, and in the elevated bone resorption associated with osteoporosis and some cancers. The antagonists of the disclosure possess varying activity against at least five integrins that have been reported to bind the latent cytokine TGF $\beta$  complex *in vitro*:  $\alpha v \beta 1$ ,  $\alpha v \beta 3$ ,  $\alpha v \beta 5$ ,  $\alpha v \beta 6$ , and  $\alpha v \beta 8$ . See (Asano *et al.*, 2005; Mu *et al.*, 2002; Munger *et al.*, 1999; Wipff *et al.*, 2007; and Munger *et al.*, 1998), which are incorporated herein by reference. TGF $\beta$  is frequently co-expressed with the angiogenic cytokine VEGF and induces its synthesis (Ferrari *et al.*, 2006). Aside from having vascular regulatory activity, TGF $\beta$  is a powerful inducer of fibrosis in many tissues such as lung, liver, kidney, and skin (Nishimura, 2009). Virtually all TGF $\beta$  is secreted from cells in a complex which contains the latency associated peptide (LAP). The integrins  $\alpha v \beta 3$ ,  $\alpha v \beta 5$ , and  $\alpha v \beta 6$ , interact with the RGD motif

contained within LAP, producing a conformational change in the complex which allows TGF $\beta$  to bind cellular receptors that activate pro-fibrotic pathways. Integrin  $\alpha$ v $\beta$ 8 also activates TGF $\beta$  in an RGD-dependent manner, but utilizes a protease-dependent mechanism distinct from the other integrins.

5        Latent TGF $\beta$  is ubiquitously present in tissues, and is activated by integrins in a spatially and temporally restricted manner. Therefore, upregulation of the epithelial integrin  $\alpha$ v $\beta$ 6 in the lungs or liver may promote localized collagen deposition and scarring, as has been observed in patients with idiopathic pulmonary fibrosis (Horan *et al.*, 2008) or hepatic fibrosis (Popov *et al.*, 2008). Similarly,  $\alpha$ v $\beta$ 5, and to a lesser extent  $\alpha$ v $\beta$ 3, are present on  
10    mesenchymal cells and are able to activate mesenchymal TGF $\beta$  (Wipff *et al.*, 2007; Scotton *et al.*, 2009). Integrin  $\alpha$ v $\beta$ 8 is expressed on subsets of epithelial, neural, immune, and mesenchymal cell types. In the skin, the TGF $\beta$  activation that accompanies the wound healing process mediates matrix deposition and promotes the formation of scars. Compounds of the present disclosure, by virtue of their ability to simultaneously inhibit several TGF $\beta$ -  
15    activating integrins, have the potential for greater efficacy in treatment of fibrosis than previously described compounds having more restricted inhibitory profiles. Furthermore, the compounds provided herein, including, for example, those which have good  $\alpha$ 5 $\beta$ 1 potency, may be used to treat and/or prevent diseases characterized by both aberrant angiogenic and fibrotic pathologies.

20        TGF $\beta$  is an important inducer of the formation of FoxP3<sup>+</sup> regulatory T cells (T<sub>reg</sub>) (Yoshimura, 2011). In some embodiments, compounds of the present disclosure, including those that inhibit the activation of TGF $\beta$  and/or reduce T<sub>reg</sub> activity may be used to relieve immune suppression in disease states such as cancer, when administered alone or in combination with existing therapies. Mitigation of T<sub>reg</sub> activity with such compounds also  
25    has the potential to enhance the activity of vaccines which are intended to prevent or treat cancer and infectious diseases. TGF $\beta$ , in the presence of IL-6, promotes the conversion of naïve T cells to TH17 cells (Yoshimura, 2011). These cells promote a variety of autoimmune diseases. It has been reported that mice lacking all  $\alpha$ v $\beta$ 8 expression on dendritic cells have near complete protection from experimental autoimmune encephalitis, a model of multiple  
30    sclerosis (Melton *et al.*, 2010). Therefore, compounds of the present disclosure, including those that inhibit the activation of TGF $\beta$  and/or reduce Th17 activity, and be used in preventing or treating autoimmune disease when administered alone or in combination with existing therapies.

Antagonism of the integrin  $\alpha\text{IIb}\beta 3$  (also known as the fibrinogen receptor), is known to block platelet aggregation as part of the blood coagulation process. Hence, to avoid increased bleeding when treating conditions or disease states mediated by integrin  $\alpha 5\beta 1$  and other integrins, it would be beneficial to utilize compounds which selectively spare  $\alpha\text{IIb}\beta 3$ .

As discussed above, integrins are a family of integral cytoplasmic membrane proteins that mediate cell interactions with other cells and with the extracellular matrix (ECM). These proteins also play a role in cell signaling and thereby regulate cellular shape, motility, and the cell cycle. Not only do integrins perform “outside-in” signaling typical of receptors, but they also operate an “inside-out” mode. Thus, they transduce information from the ECM to the cell as well as reveal the status of the cell to the outside, allowing rapid and flexible responses to changes in the environment, for example to allow blood coagulation by platelets.

There are many types of integrin, and many cells have multiple types on their surface. Integrins are of vital importance to all animals and have been found in all animals investigated, from sponges to mammals. As such compounds which target integrins have found numerous uses in different animals including companion animals, livestock animals, zoo animals as well as wild animals. Integrins have been extensively studied in humans. Integrins work alongside other proteins such as cadherins, immunoglobulin superfamily cell adhesion molecules, selectins and syndecans to mediate cell–cell and cell–matrix interaction and communication. Integrins bind cell surface and ECM components such as fibronectin, vitronectin, collagen, and laminin.

Each integrin is formed by the non-covalent heterodimerization of alpha and beta glycoprotein subunits, the combination of which conveys distinct biological activities such as cell attachment, migration, proliferation, differentiation, and survival. Currently, 24 integrins have been described in mammals that are formed by pairing of 18  $\alpha$  subunits and 8  $\beta$  subunits, as set out in Table 2.

**Table 2: Integrins**

Gene	Protein	Synonym	Type
ITGA1	CD49a	VLA1	Alpha
ITGA2	CD49b	VLA2	Alpha
ITGA3	CD49c	VLA3	Alpha
ITGA4	CD49d	VLA4	Alpha
ITGA5	CD49e	VLA5	Alpha
ITGA6	CD49f	VLA6	Alpha

Gene	Protein	Synonym	Type
ITGA7	ITGA7	FLJ25220	Alpha
ITGA8	ITGA8		Alpha
ITGA9	ITGA9	RLC	Alpha
ITGA10	ITGA10		Alpha
ITGA11	ITGA11	HsT18964	Alpha
ITGAD	CD11D	FLJ39841	Alpha
ITGAE	CD103	HUMINAE	Alpha
ITGAL	CD11a	LFA1A	Alpha
ITGAM	CD11b	MAC-1	Alpha
ITGAV	CD51	VNRA, MSK8	Alpha
ITGAW	ITGAW		Alpha
ITGAX	CD11c		Alpha
ITGB1	CD29	FNRB, MSK12, MDF2	Beta
ITGB2	CD18	LFA-1, MAC-1, MFI7	Beta
ITGB3	CD61	GP3A, GPIIIa	Beta
ITGB4	CD104		Beta
ITGB5	ITGB5	FLJ26658	Beta
ITGB6	ITGB6		Beta
ITGB7	ITGB7		Beta
ITGB8	ITGB8		Beta

In addition, variants of some of the subunits are formed by differential splicing; for example, four variants of the beta-1 subunit exist. Through different combinations of these  $\alpha$  and  $\beta$  subunits, some 24 unique integrins are generated, although the number varies according to different studies.

### 5 III. Therapeutic Methods

The present disclosure relates to the fields of pharmaceuticals, medicine and cell biology. More specifically, it relates to pharmaceutical agents (compounds) and pharmaceutical compositions thereof which may be used as integrin receptor antagonists, including in some embodiments, multi-integrin receptor antagonists. As such, these  
10 compounds may be used in pharmaceutical compositions and in methods for treating conditions mediated by one or more of such integrins, for example, by inhibiting or antagonizing one or more of these integrins. In several aspects of the present disclosure, the compounds provided herein may be used in a variety of biological, prophylactic or



therapeutic areas, including those one or more the  $\alpha 5\beta 1$ ,  $\alpha 8\beta 1$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 3$ ,  $\alpha v\beta 5$ ,  $\alpha v\beta 6$ , and  $\alpha v\beta 8$  integrins plays a role.

In another aspect, this disclosure provides methods of inhibiting or antagonizing one or more of the  $\alpha 5\beta 1$ ,  $\alpha 8\beta 1$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 3$ ,  $\alpha v\beta 5$ ,  $\alpha v\beta 6$  and  $\alpha v\beta 8$  integrins using one or more of the compounds disclosed herein, as well as pharmaceutical compositions thereof. In some embodiments, these methods inhibit pathological conditions associated therewith, such as angiogenesis, including tumor angiogenesis, fibrosis and fibrotic diseases, such as pulmonary, renal, cardiac, muscle, and liver fibrosis, scarring, such as retinal, corneal and dermal scarring, retinopathy, including diabetic retinopathy and macular degeneration, vitreoretinopathy, including retinopathy of prematurity (ROP) and familial exudative vitreoretinopathy (FEVR), osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid tumor growth (neoplasia), arthritis, including rheumatoid arthritis, periodontal disease, psoriasis, smooth muscle cell migration and restenosis, autoimmune disease, such as multiple sclerosis, and infectious pathogens by administering a therapeutically effective amount of a compound provided herein. In some embodiments, the compound is administered as part of a pharmaceutical composition further comprising a pharmaceutically acceptable carrier. In some embodiments, the compounds and/or pharmaceutical compositions thereof may be administered orally, parenterally, or by inhalation spray, or topically in unit dosage formulations containing conventional pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes, for example, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally. In some embodiments, the compounds of the present disclosure are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds required to prevent or arrest the progress of or to treat a medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the medicinal arts.

Based upon standard laboratory experimental techniques and procedures well known and appreciated by those skilled in the art, as well as comparisons with compounds of known usefulness, the compounds described above can be used in the treatment of patients suffering from the above pathological conditions. One skilled in the art will recognize that selection of the most appropriate compound of the disclosure is within the ability of one with ordinary

skill in the art and will depend on a variety of factors including assessment of results obtained in standard assay and animal models.

In another aspect, the compounds provided herein may be used in a variety of biological, prophylactic or therapeutic areas, including those in wherein one or more the  
5  $\alpha 5\beta 1$ ,  $\alpha 8\beta 1$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 3$ ,  $\alpha v\beta 5$ ,  $\alpha v\beta 6$ , and  $\alpha v\beta 8$  integrins play a role. The disclosure further involves treating or inhibiting pathological conditions associated therewith such as angiogenesis, including tumor angiogenesis, fibrosis and fibrotic diseases such as pulmonary fibrosis, renal, cardiac, muscle, and liver fibrosis, scleroderma, scarring, such as retinal, corneal and dermal scarring, retinopathy, including diabetic retinopathy and macular  
10 degeneration, vitreoretinopathy, including retinopathy of prematurity (ROP) and familial exudative vitreoretinopathy (FEVR), osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid tumor growth (neoplasia), arthritis, including rheumatoid arthritis, periodontal disease, psoriasis, smooth muscle cell migration and restenosis in a mammal in need of such treatment. Additionally, such pharmaceutical agents  
15 are useful as antiviral agents, and antimicrobials. Further, such pharmaceutical agents are useful as immune system modulators via inhibition of TGF- $\beta$  activation resulting from inhibiting or antagonizing the targeted integrins. Such immune modulation affects the immune activity and functions of T regulatory and T effector cells, and as such can be useful in the treatment of immune related pathologies, including autoimmune diseases such as  
20 multiple sclerosis, as well as in the treatment of tumors and infectious pathogens.

#### **IV. Pharmaceutical Formulations and Routes of Administration**

It is another object of the disclosure to provide pharmaceutical compositions comprising one or more of the compounds described herein. Such compositions are useful in inhibiting or antagonizing integrins, including, for examples,  $\alpha 5\beta 1$ ,  $\alpha 8\beta 1$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 3$ ,  
25  $\alpha v\beta 6$ , and  $\alpha v\beta 8$  integrins. In some embodiments, this disclosure provides pharmaceutical compositions comprising a compound that is effective in inhibiting or antagonizing one or more of the  $\alpha 5\beta 1$ ,  $\alpha 8\beta 1$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 3$ ,  $\alpha v\beta 5$ ,  $\alpha v\beta 6$  and  $\alpha v\beta 8$  integrins using one or more of the compounds disclosed herein, as well as pharmaceutical compositions thereof. In some of these embodiments, such pharmaceutical compositions further comprise one or more non-  
30 toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants.

For the purpose of administration to a patient in need of such treatment, pharmaceutical formulations (also referred to as a pharmaceutical preparations,

pharmaceutical compositions, pharmaceutical products, medicinal products, medicines, medications, or medicaments) comprise a therapeutically effective amount of a compound of the present invention formulated with one or more excipients and/or drug carriers appropriate to the indicated route of administration. In some embodiments, the compounds of the present invention are formulated in a manner amenable for the treatment of human and/or veterinary patients. In some embodiments, formulation comprises admixing or combining one or more of the compounds of the present invention with one or more of the following excipients: lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol. In some embodiments, *e.g.*, for oral administration, the pharmaceutical formulation may be tableted or encapsulated. In some embodiments, the compounds may be dissolved or slurried in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Pharmaceutical formulations may be subjected to conventional pharmaceutical operations, such as sterilization and/or may contain drug carriers and/or excipients such as preservatives, stabilizers, wetting agents, emulsifiers, encapsulating agents such as lipids, dendrimers, polymers, proteins such as albumin, or nucleic acids, and buffers, *etc.*

The pharmaceutical compositions useful in the present disclosure may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional pharmaceutical carriers and excipients such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, *etc.*

The compounds of the present disclosure may be administered by a variety of methods, *e.g.*, orally or by injection (*e.g.* subcutaneous, intravenous, intraperitoneal, *etc.*). Depending on the route of administration, the active compounds may be coated in a material to protect the compound from the action of acids and other natural conditions which may inactivate the compound. They may also be administered by continuous perfusion/infusion of a disease or wound site.

To administer the therapeutic compound by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation. For example, the therapeutic compound may be administered to a patient in an appropriate carrier, for example, liposomes, or a diluent. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes.

The therapeutic compound may also be administered parenterally, intraperitoneally, intraspinally, or intracerebrally. Dispersions can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

5        Pharmaceutical compositions may be suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against  
10        the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (such as, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of  
15        dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it may be useful to include isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition. Prolonged absorption of the injectable  
20        compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.

      Sterile injectable solutions can be prepared by incorporating the therapeutic compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally,  
25        dispersions are prepared by incorporating the therapeutic compound into a sterile carrier which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient (*i.e.*, the therapeutic compound) plus any additional desired  
30        ingredient from a previously sterile-filtered solution thereof.

      The therapeutic compound can be orally administered, for example, with an inert diluent or an assimilable edible carrier. The therapeutic compound and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet. For oral therapeutic administration, the

therapeutic compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. The percentage of the therapeutic compound in the compositions and preparations may, of course, be varied. The amount of the therapeutic compound in such therapeutically useful compositions is such that a suitable dosage will be obtained.

In some embodiments, it is advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the disclosure are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such a therapeutic compound for the treatment of a selected condition in a patient.

In some embodiments, the therapeutic compound may also be administered topically to the skin, eye, or mucosa. Alternatively, if local delivery to the lungs is desired, the therapeutic compound may be administered by inhalation in a dry-powder or aerosol formulation.

Active compounds are administered at a therapeutically effective dosage sufficient to treat a condition associated with a condition in a patient. For example, the efficacy of a compound can be evaluated in an animal model system that may be predictive of efficacy in treating the disease in a human or another animal, such as the model systems shown in the examples and drawings.

An effective dose range of a therapeutic can be extrapolated from effective doses determined in animal studies for a variety of different animals. In general a human equivalent dose (HED) in mg/kg can be calculated in accordance with the following formula (see, *e.g.*, Reagan-Shaw *et al.*, 2008, which is incorporated herein by reference):

$$\text{HED (mg/kg)} = \text{Animal dose (mg/kg)} \times (\text{Animal } K_m / \text{Human } K_m)$$

Use of the  $K_m$  factors in conversion results in more accurate HED values, which are based on body surface area (BSA) rather than only on body mass.  $K_m$  values for humans and various animals are well known. For example, the  $K_m$  for an average 60 kg human (with a BSA of 1.6 m<sup>2</sup>) is 37, whereas a 20 kg child (BSA 0.8 m<sup>2</sup>) would have a  $K_m$  of 25.  $K_m$  for some relevant animal models are also well known, including: mice  $K_m$  of 3 (given a weight of 0.02 kg and

BSA of 0.007); hamster  $K_m$  of 5 (given a weight of 0.08 kg and BSA of 0.02); rat  $K_m$  of 6 (given a weight of 0.15 kg and BSA of 0.025) and monkey  $K_m$  of 12 (given a weight of 3 kg and BSA of 0.24).

Precise amounts of the therapeutic composition depend on the judgment of the practitioner and are peculiar to each individual. Nonetheless, a calculated HED dose provides a general guide. Other factors affecting the dose include the physical and clinical state of the patient, the route of administration, the intended goal of treatment and the potency, stability and toxicity of the particular therapeutic formulation.

The actual dosage amount of a compound of the present disclosure or composition comprising a compound of the present disclosure administered to a subject may be determined by physical and physiological factors such as type of animal treated, age, sex, body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the subject and on the route of administration. These factors may be determined by a skilled artisan. The practitioner responsible for administration will typically determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject. The dosage may be adjusted by the individual physician in the event of any complication.

An effective amount typically will vary from about 0.001 mg/kg to about 1000 mg/kg, from about 0.01 mg/kg to about 750 mg/kg, from about 100 mg/kg to about 500 mg/kg, from about 1.0 mg/kg to about 250 mg/kg, from about 10.0 mg/kg to about 150 mg/kg in one or more dose administrations daily, for one or several days (depending of course of the mode of administration and the factors discussed above). Other suitable dose ranges include 1 mg to 10000 mg per day, 100 mg to 10000 mg per day, 500 mg to 10000 mg per day, and 500 mg to 1000 mg per day. In some particular embodiments, the amount is less than 10,000 mg per day with a range of 750 mg to 9000 mg per day.

The effective amount may be less than 1 mg/kg/day, less than 500 mg/kg/day, less than 250 mg/kg/day, less than 100 mg/kg/day, less than 50 mg/kg/day, less than 25 mg/kg/day or less than 10 mg/kg/day. It may alternatively be in the range of 1 mg/kg/day to 200 mg/kg/day. For example, regarding treatment of diabetic patients, the unit dosage may be an amount that reduces blood glucose by at least 40% as compared to an untreated subject. In another embodiment, the unit dosage is an amount that reduces blood glucose to a level that is  $\pm 10\%$  of the blood glucose level of a non-diabetic subject.

In other non-limiting examples, a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body

weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, *etc.*, can be administered, based on the numbers described above.

In certain embodiments, a pharmaceutical composition of the present disclosure may comprise, for example, at least about 0.1% of a compound of the present disclosure. In other embodiments, the compound of the present disclosure may comprise between about 1% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.

Single or multiple doses of the agents are contemplated. Desired time intervals for delivery of multiple doses can be determined by one of ordinary skill in the art employing no more than routine experimentation. As an example, subjects may be administered two doses daily at approximately 12 hour intervals. In some embodiments, the agent is administered once a day.

The agent(s) may be administered on a routine schedule. As used herein a routine schedule refers to a predetermined designated period of time. The routine schedule may encompass periods of time which are identical or which differ in length, as long as the schedule is predetermined. For instance, the routine schedule may involve administration twice a day, every day, every two days, every three days, every four days, every five days, every six days, a weekly basis, a monthly basis or any set number of days or weeks therebetween. Alternatively, the predetermined routine schedule may involve administration on a twice daily basis for the first week, followed by a daily basis for several months, *etc.* In other embodiments, the disclosure provides that the agent(s) may taken orally and that the timing of which is or is not dependent upon food intake. Thus, for example, the agent can be taken every morning and/or every evening, regardless of when the subject has eaten or will eat.

## V. Combination Therapy


In addition to being used as a monotherapy, the compounds of the present disclosure may also find use in combination therapies. Effective combination therapy may be achieved with a single composition or pharmacological formulation that includes both agents, or with two distinct compositions or formulations, administered at the same time, wherein one composition includes a compound of this disclosure, and the other includes the second agent(s). Alternatively, the therapy may precede or follow the other agent treatment by intervals ranging from minutes to months.

Non-limiting examples of such combination therapy include combination of one or more compounds of the disclosure with another agent, for example, an anti-inflammatory agent, a chemotherapeutic agent, radiation therapy, an antidepressant, an antipsychotic agent, an anticonvulsant, a mood stabilizer, an anti-infective agent, an antihypertensive agent, a cholesterol-lowering agent or other modulator of blood lipids, an agent for promoting weight loss, an antithrombotic agent, an agent for treating or preventing cardiovascular events such as myocardial infarction or stroke, an antidiabetic agent, an agent for reducing transplant rejection or graft-versus-host disease, an anti-arthritic agent, an analgesic agent, an anti-asthmatic agent or other treatment for respiratory diseases, or an agent for treatment or prevention of skin disorders. Compounds of the disclosure may be combined with agents designed to improve a patient's immune response to cancer, including (but not limited to) cancer vaccines.

## VI. Definitions

When used in the context of a chemical group: "hydrogen" means  $-H$ ; "hydroxy" means  $-OH$ ; "oxo" means  $=O$ ; "carbonyl" means  $-C(=O)-$ ; "carboxy" means  $-C(=O)OH$  (also written as  $-COOH$  or  $-CO_2H$ ); "halo" means independently  $-F$ ,  $-Cl$ ,  $-Br$  or  $-I$ ; and "amino" means  $-NH_2$ .






In the context of chemical formulas, the symbol  $-$  means a single bond,  $=$  means a double bond, and  $\equiv$  means triple bond. The symbol  $----$  represents an optional bond, which if present is either single or double. The symbol  $\equiv$  represents a single bond or a

double bond. Thus, for example, the formula  includes , , ,  and



. And it is understood that no one such ring atom forms part of more than one double bond. Furthermore, it is noted that the covalent bond symbol  $-$ , when connecting one or



two stereogenic atoms, does not indicate any preferred stereochemistry. Instead, it covers all stereoisomers as well as mixtures thereof. The symbol “”, when drawn perpendicularly across a bond (*e.g.*, -CH<sub>3</sub> for methyl) indicates a point of attachment of the group. It is noted that the point of attachment is typically only identified in this manner for larger groups  
 5 in order to assist the reader in unambiguously identifying a point of attachment. The symbol “” means a single bond where the group attached to the thick end of the wedge is “out of the page.” The symbol “” means a single bond where the group attached to the thick end of the wedge is “into the page”. The symbol “” means a single bond where the geometry around a double bond (*e.g.*, either *E* or *Z*) is undefined. Both options, as well as  
 10 combinations thereof are therefore intended. Any undefined valency on an atom of a structure shown in this application implicitly represents a hydrogen atom bonded to that atom. A bold dot on a carbon atom indicates that the hydrogen attached to that carbon is oriented out of the plane of the paper.

For the chemical groups and compound classes, the number of carbon atoms in the  
 15 group or class is as indicated as follows: “C<sub>n</sub>” defines the exact number (n) of carbon atoms in the group/class. “C<sub>≤n</sub>” defines the maximum number (n) of carbon atoms that can be in the group/class, with the minimum number as small as possible for the group/class in question, *e.g.*, it is understood that the minimum number of carbon atoms in the group “alkenyl<sub>(C<sub>≤8</sub>)</sub>” or the class “alkene<sub>(C<sub>≤8</sub>)</sub>” is two. Compare with “alkoxy<sub>(C<sub>≤10</sub>)</sub>”, which  
 20 designates alkoxy groups having from 1 to 10 carbon atoms. “C<sub>n-n'</sub>” defines both the minimum (n) and maximum number (n') of carbon atoms in the group. Thus, “alkyl<sub>(C<sub>2-10</sub>)</sub>” designates those alkyl groups having from 2 to 10 carbon atoms. These carbon number indicators may precede or follow the chemical groups or class it modifies and it may or may not be enclosed in parenthesis, without signifying any change in meaning. Thus, the terms  
 25 “C<sub>5</sub> olefin”, “C<sub>5</sub>-olefin”, “olefin<sub>(C<sub>5</sub>)</sub>”, and “olefin<sub>C<sub>5</sub></sub>” are all synonymous.

The term “saturated” when used to modify a compound or chemical group means the compound or chemical group has no carbon-carbon double and no carbon-carbon triple bonds, except as noted below. When the term is used to modify an atom, it means that the atom is not part of any double or triple bond. In the case of substituted versions of saturated  
 30 groups, one or more carbon oxygen double bond or a carbon nitrogen double bond may be present. And when such a bond is present, then carbon-carbon double bonds that may occur as part of keto-enol tautomerism or imine/enamine tautomerism are not precluded. When the

term “saturated” is used to modify a solution of a substance, it means that no more of that substance can dissolve in that solution.

The term “aliphatic” when used without the “substituted” modifier signifies that the compound or chemical group so modified is an acyclic or cyclic, but non-aromatic hydrocarbon compound or group. In aliphatic compounds/groups, the carbon atoms can be joined together in straight chains, branched chains, or non-aromatic rings (alicyclic). Aliphatic compounds/groups can be saturated, that is joined by single carbon-carbon bonds (alkanes/alkyl), or unsaturated, with one or more carbon-carbon double bonds (alkenes/alkenyl) or with one or more carbon-carbon triple bonds (alkynes/alkynyl).

The term “aromatic” when used to modify a compound or a chemical group refers to a planar unsaturated ring of atoms with  $4n + 2$  electrons in a fully conjugated cyclic  $\pi$  system.

The term “alkyl” when used without the “substituted” modifier refers to a monovalent saturated aliphatic group with a carbon atom as the point of attachment, a linear or branched acyclic structure, and no atoms other than carbon and hydrogen. The groups  $-\text{CH}_3$  (Me),  $-\text{CH}_2\text{CH}_3$  (Et),  $-\text{CH}_2\text{CH}_2\text{CH}_3$  (*n*-Pr or propyl),  $-\text{CH}(\text{CH}_3)_2$  (*i*-Pr, *i*Pr or isopropyl),  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$  (*n*-Bu),  $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$  (*sec*-butyl),  $-\text{CH}_2\text{CH}(\text{CH}_3)_2$  (isobutyl),  $-\text{C}(\text{CH}_3)_3$  (*tert*-butyl, *t*-butyl, *t*-Bu or *t*Bu), and  $-\text{CH}_2\text{C}(\text{CH}_3)_3$  (*neo*-pentyl) are non-limiting examples of alkyl groups. The term “alkanediyl” when used without the “substituted” modifier refers to a divalent saturated aliphatic group, with one or two saturated carbon atom(s) as the point(s) of attachment, a linear or branched acyclic structure, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen. The groups  $-\text{CH}_2-$  (methylene),  $-\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{C}(\text{CH}_3)_2\text{CH}_2-$ , and  $-\text{CH}_2\text{CH}_2\text{CH}_2-$  are non-limiting examples of alkanediyl groups. The term “alkylidene” when used without the “substituted” modifier refers to the divalent group  $=\text{CRR}'$  in which R and R' are independently hydrogen or alkyl.

Non-limiting examples of alkylidene groups include:  $=\text{CH}_2$ ,  $=\text{CH}(\text{CH}_2\text{CH}_3)$ , and  $=\text{C}(\text{CH}_3)_2$ . An “alkane” refers to the class of compounds having the formula  $\text{H}-\text{R}$ , wherein R is alkyl as this term is defined above. When any of these terms is used with the “substituted” modifier one or more hydrogen atom has been independently replaced by  $-\text{OH}$ ,  $-\text{F}$ ,  $-\text{Cl}$ ,  $-\text{Br}$ ,  $-\text{I}$ ,  $-\text{NH}_2$ ,  $-\text{NO}_2$ ,  $-\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{CH}_3$ ,  $-\text{CN}$ ,  $-\text{SH}$ ,  $-\text{OCH}_3$ ,  $-\text{OCH}_2\text{CH}_3$ ,  $-\text{C}(\text{O})\text{CH}_3$ ,  $-\text{NHCH}_3$ ,  $-\text{NHCH}_2\text{CH}_3$ ,  $-\text{N}(\text{CH}_3)_2$ ,  $-\text{C}(\text{O})\text{NH}_2$ ,  $-\text{C}(\text{O})\text{NHCH}_3$ ,  $-\text{C}(\text{O})\text{N}(\text{CH}_3)_2$ ,  $-\text{OC}(\text{O})\text{CH}_3$ ,  $-\text{NHC}(\text{O})\text{CH}_3$ ,  $-\text{S}(\text{O})_2\text{OH}$ , or  $-\text{S}(\text{O})_2\text{NH}_2$ . The following groups are non-limiting examples of substituted alkyl groups:  $-\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{Cl}$ ,  $-\text{CF}_3$ ,  $-\text{CH}_2\text{CN}$ ,  $-\text{CH}_2\text{C}(\text{O})\text{OH}$ ,  $-\text{CH}_2\text{C}(\text{O})\text{OCH}_3$ ,  $-\text{CH}_2\text{C}(\text{O})\text{NH}_2$ ,  $-\text{CH}_2\text{C}(\text{O})\text{CH}_3$ ,  $-\text{CH}_2\text{OCH}_3$ ,  $-\text{CH}_2\text{OC}(\text{O})\text{CH}_3$ ,  $-\text{CH}_2\text{NH}_2$ ,  $-\text{CH}_2\text{N}(\text{CH}_3)_2$ , and  $-\text{CH}_2\text{CH}_2\text{Cl}$ . The term “haloalkyl” is a subset of substituted alkyl, in

which the hydrogen atom replacement is limited to halo (*i.e.* -F, -Cl, -Br, or -I) such that no other atoms aside from carbon, hydrogen and halogen are present. The group, -CH<sub>2</sub>Cl is a non-limiting example of a haloalkyl. The term “fluoroalkyl” is a subset of substituted alkyl, in which the hydrogen atom replacement is limited to fluoro such that no other atoms aside from carbon, hydrogen and fluorine are present. The groups -CH<sub>2</sub>F, -CF<sub>3</sub>, and -CH<sub>2</sub>CF<sub>3</sub> are non-limiting examples of fluoroalkyl groups.

The term “alkoxy” when used without the “substituted” modifier refers to the group -OR, in which R is an alkyl, as that term is defined above. Non-limiting examples include: -OCH<sub>3</sub> (methoxy), -OCH<sub>2</sub>CH<sub>3</sub> (ethoxy), -OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -OCH(CH<sub>3</sub>)<sub>2</sub> (isopropoxy), -OC(CH<sub>3</sub>)<sub>3</sub> (*tert*-butoxy), -OCH(CH<sub>2</sub>)<sub>2</sub>, -O-cyclopentyl, and -O-cyclohexyl. The term “fluoroalkoxy” when used without the “substituted” modifier, refers to groups, defined as -OR, in which R is fluoroalkyl. The term “alkylthio” and “acylthio” when used without the “substituted” modifier refers to the group -SR, in which R is an alkyl and acyl, respectively. The term “alcohol” corresponds to an alkane, as defined above, wherein at least one of the hydrogen atoms has been replaced with a hydroxy group. The term “ether” corresponds to an alkane, as defined above, wherein at least one of the hydrogen atoms has been replaced with an alkoxy group. When any of these terms is used with the “substituted” modifier one or more hydrogen atom has been independently replaced by -OH, -F, -Cl, -Br, -I, -NH<sub>2</sub>, -NO<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>CH<sub>3</sub>, -CN, -SH, -OCH<sub>3</sub>, -OCH<sub>2</sub>CH<sub>3</sub>, -C(O)CH<sub>3</sub>, -NHCH<sub>3</sub>, -NHCH<sub>2</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, -C(O)NH<sub>2</sub>, -C(O)NHCH<sub>3</sub>, -C(O)N(CH<sub>3</sub>)<sub>2</sub>, -OC(O)CH<sub>3</sub>, -NHC(O)CH<sub>3</sub>, -S(O)<sub>2</sub>OH, or -S(O)<sub>2</sub>NH<sub>2</sub>.

The term “effective,” as that term is used in the specification and/or claims, means adequate to accomplish a desired, expected, or intended result. “Effective amount,” “Therapeutically effective amount” or “pharmaceutically effective amount” when used in the context of treating a patient or subject with a compound means that amount of the compound which, when administered to a subject or patient for treating a disease, is sufficient to effect such treatment for the disease.

As used herein, the term “IC<sub>50</sub>” refers to an inhibitory dose which is 50% of the maximum response obtained. This quantitative measure indicates how much of a particular drug or other substance (inhibitor) is needed to inhibit a given biological, biochemical or chemical process (or component of a process, *i.e.* an enzyme, cell, cell receptor or microorganism) by half.

An “isomer” of a first compound is a separate compound in which each molecule contains the same constituent atoms as the first compound, but where the configuration of those atoms in three dimensions differs.

As used herein, the term “patient” or “subject” refers to a living mammalian  
5 organism, such as a human, monkey, cow, sheep, goat, dog, cat, mouse, rat, guinea pig, or transgenic species thereof. In certain embodiments, the patient or subject is a primate. Non-limiting examples of human subjects are adults, juveniles, infants and fetuses.

As generally used herein “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical  
10 judgment, suitable for use in contact with the tissues, organs, and/or bodily fluids of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.

“Pharmaceutically acceptable salts” means salts of compounds of the present disclosure which are pharmaceutically acceptable, as defined above, and which possess the  
15 desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalenesulfonic acid, 3-phenylpropionic acid, 4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 4-methylbicyclo[2.2.2]oct-2-ene-  
20 1-carboxylic acid, acetic acid, aliphatic mono- and dicarboxylic acids, aliphatic sulfuric acids, aromatic sulfuric acids, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hexanoic acid, hydroxynaphthoic acid, lactic acid, laurylsulfuric acid, maleic acid, malic acid, malonic  
25 acid, mandelic acid, methanesulfonic acid, muconic acid, *o*-(4-hydroxybenzoyl)benzoic acid, oxalic acid, *p*-chlorobenzenesulfonic acid, phenyl-substituted alkanoic acids, propionic acid, *p*-toluenesulfonic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tartaric acid, tertiarybutylacetic acid, trimethylacetic acid, and the like. Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable  
30 of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, *N*-methylglucamine and the like. It should be recognized that the particular anion or cation forming a part of any salt of this disclosure is not critical, so long as the salt,

as a whole, is pharmacologically acceptable. Additional examples of pharmaceutically acceptable salts and their methods of preparation and use are presented in *Handbook of Pharmaceutical Salts: Properties, and Use* (P. H. Stahl & C. G. Wermuth eds., Verlag Helvetica Chimica Acta, 2002).

5       The term “pharmaceutically acceptable carrier,” as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a chemical agent.

10       “Prevention” or “preventing” includes: (1) inhibiting the onset of a disease in a subject or patient which may be at risk and/or predisposed to the disease but does not yet experience or display any or all of the pathology or symptomatology of the disease, and/or (2) slowing the onset of the pathology or symptomatology of a disease in a subject or patient which may be at risk and/or predisposed to the disease but does not yet experience or display any or all of the pathology or symptomatology of the disease.

15       “Prodrug” means a compound that is convertible *in vivo* metabolically into an inhibitor according to the present disclosure. The prodrug itself may or may not also have activity with respect to a given target protein. For example, a compound comprising a hydroxy group may be administered as an ester that is converted by hydrolysis *in vivo* to the hydroxy compound. Suitable esters that may be converted *in vivo* into hydroxy compounds  
20 include acetates, citrates, lactates, phosphates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- $\beta$ -hydroxynaphthoate, gentisates, isethionates, di-*p*-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, *p*-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like. Similarly, a compound comprising an amine group may be administered as an amide that is  
25 converted by hydrolysis *in vivo* to the amine compound.

A “stereoisomer” or “optical isomer” is an isomer of a given compound in which the same atoms are bonded to the same other atoms, but where the configuration of those atoms in three dimensions differs. “Enantiomers” are stereoisomers of a given compound that are mirror images of each other, like left and right hands. “Diastereomers” are stereoisomers of a  
30 given compound that are not enantiomers. Chiral molecules contain a chiral center, also referred to as a stereocenter or stereogenic center, which is any point, though not necessarily an atom, in a molecule bearing groups such that an interchanging of any two groups leads to a stereoisomer. In organic compounds, the chiral center is typically a carbon, phosphorus or

sulfur atom, though it is also possible for other atoms to be stereocenters in organic and inorganic compounds. A molecule can have multiple stereocenters, giving it many stereoisomers. In compounds whose stereoisomerism is due to tetrahedral stereogenic centers (e.g., tetrahedral carbon), the total number of hypothetically possible stereoisomers will not exceed  $2^n$ , where  $n$  is the number of tetrahedral stereocenters. Molecules with symmetry frequently have fewer than the maximum possible number of stereoisomers. A 50:50 mixture of enantiomers is referred to as a racemic mixture. Alternatively, a mixture of enantiomers can be enantiomerically enriched so that one enantiomer is present in an amount greater than 50%. Typically, enantiomers and/or diastereomers can be resolved or separated using techniques known in the art. It is contemplated that for any stereocenter or axis of chirality for which stereochemistry has not been defined, that stereocenter or axis of chirality can be present in its *R* form, *S* form, or as a mixture of the *R* and *S* forms, including racemic and non-racemic mixtures. As used herein, the phrase “substantially free from other stereoisomers” means that the composition contains  $\leq 15\%$ , more preferably  $\leq 10\%$ , even more preferably  $\leq 5\%$ , or most preferably  $\leq 1\%$  of another stereoisomer(s).

“Substituent convertible to hydrogen *in vivo*” means any group that is convertible to a hydrogen atom by enzymological or chemical means including, but not limited to, hydrolysis and hydrogenolysis. Examples include hydrolyzable groups, such as acyl groups, groups having an oxycarbonyl group, amino acid residues, peptide residues, *o*-nitrophenylsulfonyl, trimethylsilyl, tetrahydropyranyl, diphenylphosphinyl, and the like. Examples of acyl groups include formyl, acetyl, trifluoroacetyl, and the like. Examples of groups having an oxycarbonyl group include ethoxycarbonyl, *tert*-butoxycarbonyl ( $-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$ ), benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, vinyloxycarbonyl,  $\beta$ -(*p*-toluenesulfonyl)ethoxycarbonyl, and the like. Suitable amino acid residues include, but are not limited to, residues of Gly (glycine), Ala (alanine), Arg (arginine), Asn (asparagine), Asp (aspartic acid), Cys (cysteine), Glu (glutamic acid), His (histidine), Ile (isoleucine), Leu (leucine), Lys (lysine), Met (methionine), Phe (phenylalanine), Pro (proline), Ser (serine), Thr (threonine), Trp (tryptophan), Tyr (tyrosine), Val (valine), Nva (norvaline), Hse (homoserine), 4-Hyp (4-hydroxyproline), 5-Hyl (5-hydroxylysine), Orn (ornithine) and  $\beta$ -Ala. Examples of suitable amino acid residues also include amino acid residues that are protected with a protecting group. Examples of suitable protecting groups include those typically employed in peptide synthesis, including acyl groups (such as formyl and acetyl), arylmethoxycarbonyl groups (such as benzyloxycarbonyl and *p*-nitrobenzyloxycarbonyl), *tert*-butoxycarbonyl groups ( $-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$ ), and the like. Suitable peptide residues

include peptide residues comprising two to five amino acid residues. The residues of these amino acids or peptides can be present in stereochemical configurations of the D-form, the L-form or mixtures thereof. In addition, the amino acid or peptide residue may have an asymmetric carbon atom. Examples of suitable amino acid residues having an asymmetric carbon atom include residues of Ala, Leu, Phe, Trp, Nva, Val, Met, Ser, Lys, Thr and Tyr. Peptide residues having an asymmetric carbon atom include peptide residues having one or more constituent amino acid residues having an asymmetric carbon atom. Examples of suitable amino acid protecting groups include those typically employed in peptide synthesis, including acyl groups (such as formyl and acetyl), arylmethoxycarbonyl groups (such as benzyloxycarbonyl and *p*-nitrobenzyloxycarbonyl), *tert*-butoxycarbonyl groups (–C(O)OC(CH<sub>3</sub>)<sub>3</sub>), and the like. Other examples of substituents “convertible to hydrogen *in vivo*” include reductively eliminable hydrogenolyzable groups. Examples of suitable reductively eliminable hydrogenolyzable groups include, but are not limited to, arylsulfonyl groups (such as *o*-toluenesulfonyl); methyl groups substituted with phenyl or benzyloxy (such as benzyl, trityl and benzyloxymethyl); arylmethoxycarbonyl groups (such as benzyloxycarbonyl and *o*-methoxy-benzyloxycarbonyl); and haloethoxycarbonyl groups (such as β,β,β-trichloroethoxycarbonyl and β-iodoethoxycarbonyl).

“Treatment” or “treating” includes (1) inhibiting a disease in a subject or patient experiencing or displaying the pathology or symptomatology of the disease (*e.g.*, arresting further development of the pathology and/or symptomatology), (2) ameliorating a disease in a subject or patient that is experiencing or displaying the pathology or symptomatology of the disease (*e.g.*, reversing the pathology and/or symptomatology), and/or (3) effecting any measurable decrease in a disease in a subject or patient that is experiencing or displaying the pathology or symptomatology of the disease.

Other abbreviations used herein are as follows: <sup>1</sup>H NMR is proton nuclear magnetic resonance, AcOH is acetic acid, Ar is argon, ACN or CH<sub>3</sub>CN is acetonitrile, CHN analysis is carbon/hydrogen/nitrogen elemental analysis, CHNCl analysis is carbon/hydrogen/nitrogen/chlorine elemental analysis, CHNS analysis is carbon/hydrogen/nitrogen/sulfur elemental analysis, DI water is deionized water, DIC is diisopropyl carbodiimide, DMA is *N,N*-dimethylacetamide, DMAP is 4-(*N,N*-dimethylamino)pyridine, DMF is *N,N*-dimethylformamide, EDCI is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, EtOAc is ethyl acetate, EtOH is ethanol, FAB MS is fast atom bombardment mass spectroscopy, g is gram(s), HOBt is 1-hydroxybenzotriazole hydrate, HPLC is high performance liquid chromatography, IBCF is

isobutylchloroformate, KSCN is potassium thiocyanate, L is liter, LiOH is lithium hydroxide, MEM is methoxyethoxymethyl, MEMCl is methoxyethoxymethyl chloride, MeOH is methanol, mg is milligram, MgSO<sub>4</sub> is magnesium sulfate, ml is milliliter, mL is milliliter, MS is mass spectroscopy, MTBE is methyl tert-butyl ether, N<sub>2</sub> is nitrogen, NaHCO<sub>3</sub> is sodium bicarbonate, NaOH is sodium hydroxide, Na<sub>2</sub>SO<sub>4</sub> is sodium sulfate, NMM is N-methylmorpholine, NMP is N-methyl pyrrolidinone, NMR is nuclear magnetic resonance, P<sub>2</sub>O<sub>5</sub> is phosphorous pentoxide, PTSA is para-toluenesulfonic acid, RPHPLC is reverse phase high performance liquid chromatography, RT is room temperature, TFA is trifluoroacetic acid, THF is tetrahydrofuran, TMS is trimethylsilyl, and Δ signifies heating the reaction mixture.

The above definitions supersede any conflicting definition in any of the reference that is incorporated by reference herein. The fact that certain terms are defined, however, should not be considered as indicative that any term that is undefined is indefinite. Rather, all terms used are believed to describe the disclosure in terms such that one of ordinary skill can appreciate the scope and practice the present disclosure.

## VII. Examples

The following examples are included to demonstrate preferred embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the disclosure, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.

### A. Instrumentation and General Methods.

Analytical HPLC analyses were performed on an Agilent 1100 system and LC-MS analyses were conducted on Agilent 1100 Series LC/MSD system. Reverse-phase preparative HPLC purifications were performed on a Biotage SP4 HPFC system using a variable dual wavelength UV detector on a Biotage KP-C18-HS 120 g SNAP column using acetonitrile/water gradient containing 0.05% TFA. All final compounds were analyzed by analytical HPLC and peaks were monitored at 210, 254 and 280 nm for purity. <sup>1</sup>H and <sup>19</sup>F NMR spectra were recorded in DMSO-*d*<sub>6</sub> on a Bruker *Avance*-III/400 MHz spectrometer




equipped with a Broad Band NMR probe. The signal of the deuterated solvent was used as an internal reference. The chemical shifts are expressed in ppm ( $\delta$ ) and coupling constants ( $J$ ) are reported in hertz (Hz).  $^{19}\text{F}$  NMR detects a signal for the TFA salt of final products ( $\sim 74$  ppm) stemming from TFA in the prep HPLC solvents during final purification. Reactions were performed under an atmosphere of dry nitrogen unless otherwise stated.

## B. Preparation of Compounds

### Example A


#### Preparation of 3-Hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)aminobenzoic acid



3-Hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)aminobenzoic acid was synthesized according to literature procedures (see *Organic Process Research & Development*, 8:571-575, 2004, which is incorporated herein by reference).


### Example B

#### Preparation of 2-(3-Hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid




2-(3-Hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid was prepared according to the following procedure:

#### Coupling of 3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)aminobenzoic acid with glycine ethyl ester:



To a suspension of 3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)aminobenzoic acid (9.013 g, 35.87 mmol) in a 1:1 mixture of DMF (50.0 mL) and DCM (50.0 mL) was added glycine ethyl ester hydrochloride (5.02 g, 35.95 mmol) and the mixture

was stirred at room temperature under nitrogen atmosphere. Neat *N,N'*-diisopropylcarbodiimide (6.75 mL, 43.60 mmol) was added to above reaction mixture and the mixture was stirred at room temperature overnight to give a colorless suspension. The crude reaction mixture was used as such for the hydrolysis of the above ester.




The above crude reaction mixture was cooled to 10 °C (ice-bath) and a 2.5 N NaOH solution (90.0 mL) was added slowly with stirring, the solution temperature was kept below 20 °C, to give a pale yellow solution/suspension. The reaction mixture was stirred at room temperature for 1.5 h. The reaction mixture was acidified with 5N HCl with stirring to pH 5 to give a colorless precipitate and the mixture was stirred at room temperature for another 15 min and filtered to give a colorless solid. The solid was washed with water (1×25 mL) and then with acetonitrile (1×25 mL). The solid was dried *in-vacuo* to give a colorless powder (9.686 g, yield 88%).

<sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 3.37 (dd, *J* = 12.7 and 3.1 Hz, 2H), 3.50 (dd, *J* = 12.7 and 2.8 Hz, 2H), 4.17 (s, 2H), 4.37 (m, 1H), 6.97 (t, *J* = 2.01 Hz, 1H), 7.17-7.26 (m, 2H). <sup>1</sup>H NMR spectrum of the sample was consistent with the suggested structure of the product.


### Example C

#### Preparation of 5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino) nicotinic acid



5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino) nicotinic acid was prepared according to the following procedure:


#### Step 1



A mixture of **compound 1** (40 g, 0.3 mol) and benzoylisothiocyanate (95 g, 0.58 mol) in CH<sub>3</sub>CN (2.0 L) was stirred at room temperature for 12 h. TLC showed no starting material left. The precipitate was filtered and washed with CH<sub>3</sub>CN, dried to afford **Compound 2** (80 g, 90%) as a light yellow solid.

5


## Step 2



Into a stirred solution of **compound 2** (80 g, 0.27 mol) in anhydrous CH<sub>3</sub>OH (500 ml) was added NaOMe (28.5 g, 0.53 mol) slowly at room temperature. A clear solution resulted in 20 min, and the reaction mixture was stirred for 1 h. The solvent was removed and the residue was triturated with t-BuOMe to leave a light yellow powder. The powder was diluted with H<sub>2</sub>O, acidified to pH=2-3. The yellow solid formed was filtered, dried to afford **Compound 3** (33.7 g, 65%).


10

## Step 3



Into a stirred solution of **compound 3** (33.7 g, 0.17 mol) in DMF (200 mL) was added CH<sub>3</sub>I (24.3 g, 0.17 mol) slowly at room temperature. The reaction mixture was stirred at RT for 1 h. TLC showed no starting material left. The solvent was removed, and **Compound 4** (34.3 g, 95%) was obtained as a yellow oil.


15



A mixture of **compound 4** (15.5 g, 0.074 mol) and the hydroxy diamino propane (20 g, 0.22 mol) in DMF (100 mL) was heated to reflux and stirred for 5 h. The solid formed was filtered and dried. **Example C** (5.2 g, 30%) was obtained as a white solid. LC/MS ( $M+H = 237$ ) is consistent for the desired product.  $^1\text{H}$  NMR: DMSO- $d_6$  400MHz  $\delta$  13.053 (s, 1H), 9.881 (s, 2H), 8.783 (s, 1H), 8.630 (s, 1H), 7.897 (s, 1H), 5.492 (s, 1H), 4.112 (s, 1H), 3.410 (s, 2H), 3.228-3.190 (m, 2H).


#### Example D

#### Preparation of 2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetic acid



2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetic acid was prepared according to the following procedure:


#### Step 1



To a suspension of 5-((5-Hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)nicotinic acid (1.20 g, 5.08 mmol) in a 1:1 mixture of DMF (10.0 mL) and DCM (10.0 mL) was added glycine ethyl ester hydrochloride (0.798 g, 5.717 mmol) and the mixture was stirred at room temperature under nitrogen atmosphere for 10 min. Neat *N,N'*-diisopropylcarbodiimide (1.10 mL, 7.104 mmol) was added to above reaction mixture and the mixture was stirred at room temperature overnight to give a colorless to cream suspension. The solvent was evaporated *in-vacuo* to afford a pale yellow viscous residue. LC-MS analysis of the residue shows the desired product's mass:  $m/z$  322 ( $M+H$ ),  $m/z$  344 ( $M+Na$ ) and  $m/z$  643 ( $2M+H$  Calculated for

C<sub>14</sub>H<sub>19</sub>N<sub>5</sub>O<sub>4</sub>:321.33. The crude product was used as such in the next step for the saponification of the above ester.

#### Step 2



#### Example D

The above crude product was dissolved in a mixture of DMF/DCM (1:1) (10 mL) and the solution was cooled to 10 °C (ice-bath) and a 2.5 N NaOH solution (10.0 mL) was added slowly with stirring, the solution temperature was kept below 20 °C, to give a pale yellow solution. The reaction mixture was stirred at room temperature overnight. The reaction mixture was acidified with 5N HCl with stirring to pH 5 to give a yellow-orange solution. The mixture was diluted with DCM (25 mL) and the organic and the aqueous layers were separated. The aqueous layer was evaporated *in-vacuo* to afford a yellow gummy solid. The crude product was purified by reverse-phase HPLC with a gradient 10-40% CH<sub>3</sub>CN in water containing 0.05% TFA to give the desired product as a colorless to yellow gummy solid. The solid was triturated with acetonitrile to give a colorless to pale yellow crystalline solid which was recrystallized from methanol to afford a cream solid (869.3 mg, yield 59%). LC-MS analysis of the solid shows the desired product's mass: *m/z* 294 (M+H), and *m/z* 316 (M+Na); Calculated for C<sub>12</sub>H<sub>15</sub>N<sub>5</sub>O<sub>4</sub>:293.28. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 3.19 (dd, J = 12.47 and 3.67 Hz, 2H), 3.37 (dd, J = 12.47 and 2.93 Hz, 2H), 3.96 (s, 2H), 4.11 (m, 1H), 8.12 (t, J = 2.20 Hz, 1H), 8.64 (d, J = 2.45 Hz, 1H), 8.90 (d, J = 1.96 Hz, 1H). <sup>1</sup>H NMR spectrum of the compound was consistent with the suggested structure of the product as Example D.

#### Beta amino acids and their corresponding beta amino ester intermediates


Beta amino acids and their corresponding beta amino ester intermediates used as starting materials and reagents in the synthesis of examples 1 – 17 can be synthesized as depicted in Scheme III above. Briefly, such beta amino acids and esters can be synthesized from the appropriate benzaldehyde and under the conditions depicted. Alternatively, the appropriate benzaldehyde can be reacted with mono-ethyl or methyl malonate to yield the racemic beta amino ethyl ester directly. Examples utilizing such an alternative method are described below. Unless otherwise exemplified, all relevant benzaldehydes are readily available commercially or can be readily synthesized from the appropriate phenyl bromide, *n*-BuLi and DMF by methods known to those skilled in the art. As noted in Scheme III, the corresponding racemic beta amino esters can be converted to the desired (*S*) enantiomer

either via supercritical fluid chiral chromatographic separation or via selective enzymatic cleavage of the (*S*) beta amino ester with Amano Lipase PS (Sigma Aldrich) to the readily isolated (*S*) beta amino acid, which can then be converted to the (*S*) ester and used as such for the synthesis of the examples 1-17 disclosed herein.

5 The following are representative methods exemplifying a variety of general procedures used in various steps in the formation of all beta amino ester intermediates utilized in the synthesis of examples 1-17 which follow, and are meant to illustrate the general utility of such methods:

### Example E


#### 10 Preparation of ethyl (3*S*)-3-amino-3-[3-chloro-5-(trifluoromethyl)phenyl]propanoate hydrochloride



NH<sub>4</sub>OAc (1.33 g, 0.12 mol), HOOCCH<sub>2</sub>COOEt (4.5 g, 0.034 mol) and benzaldehyde  
 15 1 (3.6 g, 0.017 mol) in EtOH (30 mL) were stirred at 70 °C for 6 h. The mixture was concentrated and adjusted to pH=7.5 by addition of aq. NaHCO<sub>3</sub>. The mixture was extracted with EtOAc (3×50 mL). The organic layer was washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness to give an oil. The crude product was purified via silica gel chromatography to give racemic compound 2 (1.5 g, 29.4%). The (*S*) enantiomer, Example  
 20 E, was isolated using the enzymatic resolution procedures described for Example F (below).

### Example F


#### Preparation of ethyl (3*S*)-3-amino-3-[3-bromo-5-(trifluoromethyl)phenyl]propanoate hydrochloride



5

#### Step 1

*Preparation of racemic ethyl 3-amino-3-[3-bromo-5-(trifluoromethyl)phenyl]propanoate*




(rac)-Ethyl 3-amino-3-[3-bromo-5-(trifluoromethyl)phenyl]propanoate was prepared according to the method described for the preparation of Example E, substituting 3-bromo-5-trifluoromethyl benzaldehyde for 3-chloro-5-trifluoromethyl benzaldehyde.

10

#### Step 2

*Preparation of (3*S*)-3-amino-3-[3-bromo-5-(trifluoromethyl)phenyl]propanoic acid*



**Enzymatic resolution of the racemic mixture:** A suspension of (rac)-ethyl 3-amino-

15

3-[3-bromo-5-(trifluoromethyl)phenyl]propanoate (570.0 mg, 1.676 mmol) in 50 mM  $\text{KH}_2\text{PO}_4$  solution (30.0 mL) was stirred at room temperature and the pH of the aqueous layer was adjusted to pH 8.32 by the addition of 1.0 N NaOH solution and 50 mM  $\text{KH}_2\text{PO}_4$  solution. Amano Lipase PS (625.0 mg) was added to the above suspension and the reaction mixture was stirred at room temperature for 2 days. The mixture was diluted with MTBE (25 mL) and reaction mixture was stirred at room temperature for 1 h to extract the (*R*)-ester. The MTBE layer containing the (*R*)-ester was discarded after analyzing by LC-MS. Evaporation of the aqueous layer *in-vacuo* afforded a cream solid containing the (*S*)-acid as well as Amano Lipase and Phosphate buffer salt. The above crude product was purified by reverse-phase HPLC with a gradient 10-60%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product as a colorless glassy solid (231.0 mg). LC/MS analysis of the product shows


20

25

the desired product's mass:  $m/z$  312 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  314 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  334 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  336 ( $^{81}\text{BrM}+\text{Na}$ ); Calculated for  $\text{C}_{10}\text{H}_9\text{BrF}_3\text{NO}_2$ : 312.08. The isolated TFA salt of the (*S*)-acid was used as such for the preparation of the (*S*)-ester.

### Step 3

#### 5      *Preparation of ethyl (3*S*)-3-amino-3-[3-bromo-5-(trifluoromethyl)phenyl]propanoate hydrochloride (Example F)*




To a solution of (3*S*)-3-amino-3-[3-bromo-5-(trifluoromethyl)phenyl]propanoic acid TFA salt from step 2 above (231.0 mg, 0.542 mmol) in absolute ethanol (3 mL) was added absolute ethyl alcohol saturated with dry HCl gas (10 mL) and the reaction mixture was stirred at room temperature for 1.5 h. Evaporation of the solvent *in-vacuo* gave a colorless crystalline solid, (Example F) (198.5 mg, 97%). LC-MS analysis of the solid shows the desired product's mass:  $m/z$  340 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  342 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  362 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  364 ( $^{81}\text{BrM}+\text{Na}$ ); Calculated for  $\text{C}_{12}\text{H}_{13}\text{BrF}_3\text{NO}_2$ : 340.14.

15


### Example G

#### **Preparation of ethyl (3*S*)-3-amino-3-[3-chloro-5-(trifluoromethoxy)phenyl]propanoate hydrochloride**



### Step 1

#### 20      *Preparation of racemic ethyl 3-amino-3-[3-chloro-5-(trifluoromethoxy)phenyl]propanoate*



A solution of a mixture of 3-chloro-5-(trifluoromethoxy)benzaldehyde (1.05 g, 4.676 mmol) mono-ethyl malonate (1.54 g, 11.69 mmol) and ammonium acetate (1.985 g, 25.75 mmol) in absolute ethanol (30 mL) was heated at 80 °C overnight to give a colorless solution.


25      The reaction mixture was cooled to room temperature and the solvent was evaporated *in-*



*vacuo* to give a yellow viscous liquid. The residue was partitioned between aqueous saturated NaHCO<sub>3</sub> solution (50 mL) and ethyl acetate (50 mL), the organic layer was removed, dried over anhydrous sodium sulfate, filtered and evaporated *in-vacuo* to give a yellow-brown viscous liquid (1.56 g). LC-MS analysis of the crude product shows the desired product's mass: *m/z* 312 (<sup>35</sup>ClM+H), *m/z* 314 (<sup>37</sup>ClM+H), *m/z* 334 (<sup>35</sup>ClM+Na), and *m/z* 336 (<sup>37</sup>ClM+Na); Calculated for C<sub>12</sub>H<sub>13</sub>ClF<sub>3</sub>NO<sub>3</sub>: 311.68. LC-MS also shows the byproduct: (*E*)-ethyl 3-(3-chloro-5-(trifluoromethoxy) phenyl)acrylate's mass: *m/z* 295 (<sup>35</sup>ClM+H), and *m/z* 297 (<sup>37</sup>ClM+H); Calculated for C<sub>12</sub>H<sub>10</sub>ClF<sub>3</sub>O<sub>3</sub>: 294.65. To a solution of the crude residue in absolute ethanol (2 mL) was added a 2.0 M solution of HCl in diethyl ether (10.0 mL) and the reaction mixture was stirred at room temperature for 1 h to give a yellow solution. The residue after evaporation of the solvents was partitioned between water (25 mL) and dichloromethane (50 mL). The organic and the aqueous layers were separated. The aqueous layer was evaporated *in-vacuo* to afford a colorless gummy residue. The residue was purified by reverse-phase preparative HPLC with a gradient 10-70% CH<sub>3</sub>CN in water containing 0.05% TFA. The pure fractions mixture was evaporated *in-vacuo* to afford the desired product as a colorless crystalline solid (347.2 mg, yield 24%). LC/MS analysis of the product shows the desired product's mass: *m/z* 312 (<sup>35</sup>ClM+H), *m/z* 314 (<sup>37</sup>ClM+H), *m/z* 334 (<sup>35</sup>ClM+Na), and *m/z* 336 (<sup>37</sup>ClM+Na); Calculated for C<sub>12</sub>H<sub>13</sub>ClF<sub>3</sub>NO<sub>3</sub>: 311.68

### Step 2

*Preparation of racemic ethyl 3-amino-3-[3-chloro-5-(trifluoromethoxy)phenyl]propanoate hydrochloride*




To a solution of (rac)-ethyl 3-amino-3-[3-chloro-5-(trifluoromethoxy)phenyl]propanoate TFA salt from above (347.2 mg, 0.816 mmol) in absolute ethanol (2 mL) was added absolute ethyl alcohol saturated with dry HCl gas (5 mL) and the reaction mixture was stirred at room temperature for 30 min. Evaporation of the solvent *in-vacuo* gave a colorless gummy solid. The solid was slurried with hexanes (2×10 mL), the solvent layer was decanted off and the residue was dried *in-vacuo* to afford a colorless crystalline solid (270.7 mg, yield 95%). LC-MS analysis of the solid shows the desired product's mass: *m/z* 312 (<sup>35</sup>ClM+H), *m/z* 314 (<sup>37</sup>ClM+H), *m/z* 334 (<sup>35</sup>ClM+Na), and *m/z* 336 (<sup>37</sup>ClM+Na); Calculated for C<sub>12</sub>H<sub>13</sub>ClF<sub>3</sub>NO<sub>3</sub>: 311.68 <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ

1.08 (t, J = 7.1 Hz, 3H, CH<sub>3</sub>-CH<sub>2</sub>-), 3.06 (dd, J = 16.1 and 8.8 Hz, 1H, CHH-C=O-), 3.20 (dd, J = 16.4 and 10.3 Hz, 1H, -CHH-C=O-), 4.01 (q, J = 7.1 and 2.0 Hz, 2H, CH<sub>3</sub>-CH<sub>2</sub>-), 4.72 (m, 1H, -NH<sub>2</sub>-CH-CH<sub>2</sub>-C=O-), 7.62 (s, 1H, H-2), 7.64 (s, 1H, H-6), 7.80 (s, 1H, H-4), 8.87 (brs, 3H, -NH<sub>2</sub>·HCl). <sup>1</sup>H NMR spectrum of the solid was consistent with the suggested structure of the product.

### Step 3


*Preparation of (3S)-3-amino-3-[3-chloro-5-(trifluoromethoxy)phenyl]propanoic acid*



**Enzymatic resolution of the racemic mixture:** A suspension of (rac)-ethyl 3-amino-3-[3-chloro-5-(trifluoromethoxy)phenyl]propanoate hydrochloride (185.30 mg, 0.532 mmol) in 50 mM KH<sub>2</sub>PO<sub>4</sub> solution (25.0 mL) was stirred at room temperature and the pH of the aqueous layer was adjusted to pH 8.32 by the addition of 1.0 N NaOH solution and 50 mM KH<sub>2</sub>PO<sub>4</sub> solution. Amano Lipase PS (201.0 mg) was added to above suspension and the reaction mixture was stirred at room temperature for 2 days. The mixture was diluted with MTBE (25 mL) and reaction mixture was stirred at room temperature for 1 h to extract the (R)-ester. The MTBE layer containing the (R)-ester was discarded after analyzing by LC-MS. Evaporation of the aqueous layer *in-vacuo* afforded a cream solid containing the (S)-acid as well as Amano Lipase and Phosphate buffer salt. The above crude product was purified by reverse-phase HPLC with a gradient 10-70% CH<sub>3</sub>CN in water containing 0.05% TFA to give the desired product as a colorless glassy solid (83.1 mg). LC/MS analysis of the product shows the desired product's mass: *m/z* 284 (<sup>35</sup>ClM+H), *m/z* 286 (<sup>37</sup>ClM+H), *m/z* 306 (<sup>35</sup>ClM+Na), and *m/z* 308 (<sup>37</sup>ClM+Na); Calculated for C<sub>10</sub>H<sub>9</sub>ClF<sub>3</sub>NO<sub>3</sub>: 283.63. The isolated TFA salt of the (S)-acid was used as such for the preparation of the (S)-ester.

### Step 4


*Preparation of ethyl (3S)-3-amino-3-[3-chloro-5-(trifluoromethoxy)phenyl]propanoate hydrochloride (Example G)*



To a solution of (*S*)-3-amino-3-[3-chloro-5-(trifluoromethoxy)phenyl]propanoic acid TFA salt from Step 3 above (83.0 mg, 0.209 mmol), in absolute ethanol (2.0 mL), was added absolute ethyl alcohol saturated with dry HCl gas (5 mL) and the reaction mixture was stirred at room temperature for 1 h to give a colorless solution. LC-MS analysis of the reaction mixture after 1 h shows the desired product: ethyl (*3S*)-3-amino-3-[3-chloro-5-(trifluoromethoxy)phenyl]propanoate's mass:  $m/z$  312 ( $^{35}\text{ClM}+\text{H}$ ),  $m/z$  314 ( $^{37}\text{ClM}+\text{H}$ ),  $m/z$  334 ( $^{35}\text{ClM}+\text{Na}$ ), and  $m/z$  336 ( $^{37}\text{ClM}+\text{Na}$ ); Calculated for  $\text{C}_{12}\text{H}_{13}\text{ClF}_3\text{NO}_3$ : 311.68. The solvent was evaporated *in-vacuo* to afford the desired HCl salt of the ester (Example G) as a colorless crystalline solid (68.70 mg, yield 94%).


### Example H

#### Preparation of ethyl (*3S*)-3-amino-3-[3-bromo-5-(trifluoromethoxy)phenyl]propanoate hydrochloride



Step 1

#### Preparation of racemic ethyl 3-amino-3-[3-bromo-5-(trifluoromethoxy)phenyl]propanoate




A solution of a mixture of 3-bromo-5-(trifluoromethoxy)benzaldehyde (1.05 g, 3.90 mmol) mono-ethyl malonate (1.31 g, 9.91 mmol) and ammonium acetate (1.68 g, 21.79 mmol) in absolute ethanol (25 mL) was heated at 80 °C for 5 h to give a colorless solution. The reaction mixture was cooled to room temperature and the solvent was evaporated *in-vacuo* to give a colorless viscous liquid. The residue was partitioned between aqueous saturated  $\text{NaHCO}_3$  solution (50 mL) and ethyl acetate (50 mL), the organic layer was removed, dried over anhydrous sodium sulfate, filtered and evaporated *in-vacuo* to give a pale yellow viscous liquid (1.40 g). LC-MS analysis of the crude product shows the desired product's mass:  $m/z$  356 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  358 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  378 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  380 ( $^{81}\text{BrM}+\text{Na}$ ); Calculated for  $\text{C}_{12}\text{H}_{13}\text{BrF}_3\text{NO}_3$ : 356.14. LC-MS also shows the byproduct: (E)-ethyl 3-(3-bromo-5-(trifluoromethoxy)phenyl)acrylate's mass:  $m/z$  339 ( $^{79}\text{BrM}+\text{H}$ ), and  $m/z$

341 ( $^{81}\text{BrM}+\text{H}$ ); Calculated for  $\text{C}_{12}\text{H}_{10}\text{BrF}_3\text{O}_3$ : 339.11. To a solution of the crude residue in absolute ethanol (2 mL) was added a 2.0 M solution of HCl in diethyl ether (15.0 mL) and the reaction mixture was stirred at room temperature for 30 min to give a pale yellow solution. The residue after evaporation of the solvents was partitioned between water (25 mL) and dichloromethane (25 mL). The organic and the aqueous layers were separated. The aqueous layer was evaporated *in-vacuo* to afford a colorless gummy residue. The residue was purified by reverse-phase preparative HPLC with a gradient 10-70%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA. The pure fractions mixture was evaporated *in-vacuo* to afford the desired product as a colorless crystalline solid (442.5 mg, yield 31%). LC/MS analysis of the product shows the desired product's mass:  $m/z$  356 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  358 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  378 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  380 ( $^{81}\text{BrM}+\text{Na}$ ); Calculated for  $\text{C}_{12}\text{H}_{13}\text{BrF}_3\text{NO}_3$ : 356.14.

### Step 2


*Preparation of racemic ethyl 3-amino-3-[3-bromo-5-(trifluoromethoxy)phenyl]propanoate hydrochloride*



To a solution of (rac)-ethyl 3-amino-3-[3-bromo-5-(trifluoromethoxy)phenyl]propanoate TFA salt from above (442.8 mg, 0.942 mmol) in absolute ethanol (2 mL) was added a 2.0 M HCl solution in diethyl ether (10 mL) and the reaction mixture was stirred at room temperature for 1 h. Evaporation of the solvent *in-vacuo* gave a colorless gummy solid. The solid was slurried with hexanes ( $2 \times 10$  mL), the solvent layer was decanted off and the residue was dried *in-vacuo* to afford a colorless crystalline solid (358.0 mg, yield 96%). LC-MS analysis of the solid shows the desired product's mass:  $m/z$  356 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  358 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  378 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  380 ( $^{81}\text{BrM}+\text{Na}$ ); Calculated for  $\text{C}_{12}\text{H}_{13}\text{BrF}_3\text{NO}_3$ : 356.14.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  1.08 (t,  $J = 7.1$  Hz, 3H,  $\text{CH}_3\text{-CH}_2\text{-}$ ), 3.095 (double AB q,  $J = 16.4$  and 8.7 Hz, and  $J = 16.4$  and 10.3 Hz, (each 1H), 2H,  $\text{-CHH-C=O-}$  and  $\text{-CHH-C=O-}$ ; diastereotopic), 4.01 (dq,  $J = 7.1$  and 2.0 Hz, 2H,  $\text{CH}_3\text{-CH}_2\text{-}$ ), 4.72 (dd,  $J = 8.3$  and 6.1 Hz, 1H,  $\text{-NH}_2\text{-CH-CH}_2\text{-C=O-}$ ), 7.65 (appt,  $J = 1.7$  Hz, 1H), 7.73 (appt,  $J = 1.7$  Hz, 1H), 7.90 (appt,  $J = 1.5$  Hz, 1H), 8.74 (brs, 3H,  $\text{-NH}_2\cdot\text{HCl}$ ).  $^1\text{H}$  NMR spectrum of the solid was consistent with the suggested structure of the product.

## Step 3

*Preparation of (3S)-3-amino-3-[3-bromo-5-(trifluoromethoxy)phenyl]propanoic acid*



Enzymatic resolution of the racemic mixture:

5           A           suspension           of           (rac)-ethyl           3-amino-3-[3-bromo-5-(trifluoromethoxy)phenyl]propanoate hydrochloride from step 2 above (345.40 mg, 0.880 mmol) in 50 mM KH<sub>2</sub>PO<sub>4</sub> solution (30.0 mL) was stirred at room temperature and the pH of the aqueous layer was adjusted to pH 8.32 by the addition of 1.0 N NaOH solution and 50 mM KH<sub>2</sub>PO<sub>4</sub> solution. Amano Lipase PS (317.0 mg) was added to above suspension and the


10 reaction mixture was stirred at room temperature overnight. The mixture was diluted with MTBE (25 mL) and reaction mixture was stirred at room temperature for 1 h to extract the (R)-ester. The MTBE layer containing the (R)-ester was discarded after analyzing by LC-MS. Evaporation of the aqueous layer *in-vacuo* afforded a cream solid containing the (S)-acid as well as Amano Lipase and Phosphate buffer salt. The above crude product was purified by

15 reverse-phase HPLC with a gradient 10-70% CH<sub>3</sub>CN in water containing 0.05% TFA to give the desired product as a colorless glassy solid (201.3 mg). LC/MS analysis of the product shows the desired product's mass: *m/z* 328 (<sup>79</sup>BrM+H), *m/z* 330 (<sup>81</sup>BrM+H), *m/z* 350 (<sup>79</sup>BrM+Na), and *m/z* 352 (<sup>81</sup>BrM+Na), Calculated for C<sub>10</sub>H<sub>9</sub>BrF<sub>3</sub>NO<sub>3</sub>: 328.08. The isolated TFA salt of the (S)-acid was used as such for the preparation of the (S)-ester.

20

## Step 4

*Preparation of ethyl (3S)-3-amino-3-[3-bromo-5-(trifluoromethoxy)phenyl]propanoate hydrochloride (Example H)*



25


To a solution of (S)-3-amino-3-[3-bromo-5-(trifluoromethoxy)phenyl]propanoic acid TFA salt from step 3 above (201.30 mg, 0.455 mmol) in absolute ethanol (2.0 mL) was added absolute ethyl alcohol saturated with dry HCl gas (5 mL) and the reaction mixture was stirred at room temperature for 1.5 h to give a colorless solution. LC-MS analysis of the reaction

mixture after 1.5 h shows the desired product: (*S*)-ethyl 3-amino-3-[3-bromo-5-(trifluoromethoxy)phenyl]propanoate's mass:  $m/z$  356 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  358 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  378 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  380 ( $^{81}\text{BrM}+\text{Na}$ ); Calculated for  $\text{C}_{12}\text{H}_{13}\text{BrF}_3\text{NO}_3$ : 356.14 The solvent was evaporated *in-vacuo* to afford the desired HCl salt of the ester (Example H) as a colorless crystalline solid (171.0 mg, yield 95%).

### Example I


#### Preparation of ethyl (3*S*)-3-amino-3-[3,5-dichloro-phenyl]propanoate

##### hydrochloride



Step 1


#### Preparation of (*S*)-3-amino-3-[3,5-dichloro-phenyl]propanoic acid



**Enzymatic resolution of the racemic mixture:** A suspension of (rac)-ethyl 3-amino-3-[3,5-dichlorophenyl]propanoate hydrochloride (synthesized according to procedures described herein starting from 3,5-dichlorophenyl benzaldehyde) (316.0 mg, 1.058 mmol) in 50 mM  $\text{KH}_2\text{PO}_4$  solution (30.0 mL) was stirred at room temperature and the pH of the aqueous layer was adjusted to pH 8.32 by the addition of 1.0 N NaOH solution and 50 mM  $\text{KH}_2\text{PO}_4$  solution. Amano Lipase PS (295.0 mg) was added to above suspension and the reaction mixture was stirred at room temperature for 2 days. The mixture was diluted with MTBE (25 mL) and reaction mixture was stirred at room temperature for 1 h to extract the (*R*)-ester. The MTBE layer containing the (*R*)-ester was discarded after analyzing by LC-MS. Evaporation of the aqueous layer *in-vacuo* afforded a cream solid containing the (*S*)-acid as well as Amano Lipase and Phosphate buffer salt. The above crude product was purified by reverse-phase HPLC with a gradient 10-50%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product as a colorless glassy solid (103.0 mg). LC/MS analysis of the product shows the desired product's mass:  $m/z$  234 ( $^{35}\text{ClM}+\text{H}$ ),  $m/z$  236 ( $^{37}\text{ClM}+\text{H}$ ),  $m/z$  256 ( $^{35}\text{ClM}+\text{Na}$ ), and  $m/z$  258 ( $^{37}\text{ClM}+\text{Na}$ ); Calculated for  $\text{C}_9\text{H}_9\text{Cl}_2\text{NO}_2$ : 234.08. The isolated TFA salt of the (*S*)-acid was used as such for the preparation of the (*S*)-ester.

## Step 2


*Preparation of ethyl (S)-3-amino-3-[3,5-dichloro-phenyl]propanoate hydrochloride*  
(Example I)



- 5 To a suspension of (S)-3-amino-3-[3,5-dichlorophenyl]propanoic acid from step 1 above (103.0 mg, 0.440 mmol) in absolute ethanol (2.0 mL) was added absolute ethyl alcohol saturated with dry HCl gas (5 mL) and the reaction mixture was stirred at room temperature for 1 h to give a colorless solution. LC-MS analysis of the reaction mixture after 1.5 h shows the desired product: (S)-ethyl 3-amino-3-[3,5-dichlorophenyl]propanoate's mass:
- 10 *m/z* 262 ( $^{35}\text{ClM}+\text{H}$ ), *m/z* 264 ( $^{37}\text{ClM}+\text{H}$ ), *m/z* 284 ( $^{35}\text{ClM}+\text{Na}$ ), and *m/z* 286 ( $^{37}\text{ClM}+\text{Na}$ ); Calculated for  $\text{C}_{11}\text{H}_{13}\text{Cl}_2\text{NO}_2$ : 262.13. The solvent was evaporated *in-vacuo* to afford the desired HCl salt of the ester (Example I) as a colorless crystalline solid (131.20 mg, yield 99%).


## Example J

- 15 **Preparation of racemic ethyl 3-amino-3-[3,5-bromophenyl]propanoate hydrochloride**




## Step 1

*Preparation of racemic 3-amino-3-[3,5-bromo-phenyl]propanoic acid*




- 20 A suspension of 3,5-dibromo-benzaldehyde (50 g, 189.39 mmol), malonic acid (39.39 g, 378.78 mmol) and ammonium acetate (29.19 g, 378.78 mmol) in isopropanol (350 mL) was heated at reflux under nitrogen for 14 h to afford a thick colorless solid. The solid was filtered hot, washed with hot isopropanol (2 × 100 mL) and dried *in vacuo* to give the desired racemic product as a colorless solid (32.2 g).

## Step 2


*Preparation of racemic ethyl 3-amino-3-[3,5-bromophenyl]propanoate hydrochloride*

Absolute ethanol (500 mL, saturated with anhydrous HCl gas) was added to 3-amino-3-(3,5-dibromo-phenyl)-propionic acid from step 1 above (32 g, 99.07 mmol) and the reaction mixture was heated to reflux for 1.5 h to give a pale yellow solution. The solvent was removed *in vacuo* to give a colorless solid. The solid was washed with hexane ( $2 \times 100$  mL). After the solvent layer was decanted off, the residue was dried *in vacuo* to give the racemic amino ester hydrochloride salt (Example J) as a white solid (38 g).

## Example K

**Preparation of ethyl (3*S*)-3-amino-3-[3-bromo-5-(di-fluoromethyl)phenyl]propanoate hydrochloride**


## Step 1



3,5-dibromo benzaldehyde **1** (10 g, 37.8 mmol, 1.0 eq), ethane-1,2-diol (7.0 g, 114 mmol, 3.0 eq) and TsOH (0.32g, 1.89 mmol) in toluene (20 mL) was stirred at 110 °C for 4 h. The mixture was cooled to 23 °C and concentrated, extracted with EtOAc. The organic layer was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to dryness to give compound **2** (9.2 g, 83.6 %) as an oil.




## Step 2




Compound **2** (9.2 g, 29.8 mmol, 1.0 eq) in THF (100 mL) was stirred at -78 °C. n-BuLi (12 mL, 1.0 eq) was added dropwise to above mixture at -78 °C. The mixture was stirred at -78 °C for 1 h. DMF (4.56 g, 1.5 eq) was added dropwise to above mixture at -78°C. The mixture was stirred at -78 °C for 3 h then warmed to 25 °C. Water was added to the mixture and then extracted with ethyl acetate. The organic layer was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to dryness to give crude product. The crude product was purified by silica gel chromatograph to give compound **3** (6.6 g, 86.8%) as a white solid.

## Step 3




Compound **3** (6.6 g, 0.026 mol) was added to DCM (50 mL), then DAST (8.3 g, 0.052 mol) was added to the solution and the reaction was stirred for 8h under N<sub>2</sub>. The solution was washed with aq. NaHCO<sub>3</sub>, and the mixture was extracted with DCM. The organic layer was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The crude material was purified by silica gel chromatograph to give compound **4** (4.2 g, 58.3 %).

## Step 4




Compound **4** (4.2 g, 0.026 mol) was added to a solution of THF (40 mL) and 3N HCl (20 mL) and the reaction was stirred for 6h. The mixture was concentrated and the crude product was purified by silica gel chromatography to give compound **5** (3.6 g, 76.9%).

## Step 5




NH<sub>4</sub>OAc (0.54 g, 0.077mol), HOOCCH<sub>2</sub>COOEt (2.9 g, 0.022mol) and compound **5** (3.6 g, 0.011 mol), in EtOH (30 mL) were stirred at 70 °C for 6h. The mixture was concentrated and adjusted to pH=7.5 by addition of aq. NaHCO<sub>3</sub>. The mixture was extracted with EtOAc. The organic layer was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to dryness to give oil. The crude was purified by silica gel chromatography to give compound **6** (0.6 g, 17.1 %). The (*S*) enantiomer, Example K, was isolated using the enzymatic resolution procedures described above.

10

**Example L****Preparation of ethyl (3*S*)-3-amino-3-[3-chloro-5-(di-fluoromethyl)phenyl]propanoate hydrochloride**


Example L was synthesized as described in the procedure for Example K, but substituting 3-bromo-5-chloro benzaldehyde for 3,5-di-bromo benzaldehyde in Step 1.

15

**Example 1****Preparation of (3*S*)-3-(3,5-dibromophenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid**

## Step 1


*Preparation of ethyl (3S) 3-[3,5-dibrom-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoate*



5           A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (513.80 mg, 1.667 mmol), ethyl (3S)-3-amino-3-(3,5-dibromophenyl) propanoate hydrochloride (the (S) ester of Example J formed via the enzymatic lipase cleavage method) (645.80 mg, 1.667 mmol) and 1-hydroxybenzotriazole hydrate (52.0 mg, 0.340 mmol) was dissolved in a mixture of DMF (6 mL) and  
10 dichloromethane (6 mL) and the reaction mixture was stirred under nitrogen atmosphere for 10 min to give a cream suspension. Neat *N,N'*-diisopropylcarbodiimide (360.0  $\mu$ L, 2.325 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a colorless viscous residue of the product: ethyl (3S)-3-[3,5-dibromophenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate. LC-MS  
15 analysis of the crude residue shows the desired product's mass:  $m/z$  640 ( $^{79}\text{Br},^{79}\text{Br}\text{M}+\text{H}$ ),  $m/z$  642 ( $^{79}\text{Br},^{81}\text{Br}\text{M}+\text{H}$ ),  $m/z$  644 ( $^{81}\text{Br},^{81}\text{Br}\text{M}+\text{H}$ ),  $m/z$  662 ( $^{79}\text{Br},^{79}\text{Br}\text{M}+\text{Na}$ ),  $m/z$  664 ( $^{79}\text{Br},^{81}\text{Br}\text{M}+\text{Na}$ ), and  $m/z$  666 ( $^{81}\text{Br},^{81}\text{Br}\text{M}+\text{Na}$ ); Calculated for  $\text{C}_{24}\text{H}_{27}\text{Br}_2\text{N}_5\text{O}_6$ : 641.31. The crude residue was used as such for the saponification reaction in Step 2.

## Step 2


*Preparation of (3S)-3-(3,5-dibromophenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid*



- 5 To a solution of crude ethyl (3S)-3-[3,5-dibromophenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate from step 1 above (1.667 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (10 mL) was added lithium hydroxide monohydrate (350.0 mg, 8.341 mmol) at room temperature and the reaction mixture was stirred at room temperature for 1 h. The mixture was neutralized
- 10 with TFA (1.0 mL in 10.0 mL CH<sub>3</sub>CN) and the mixture was evaporated *in-vacuo* to give a colorless gummy residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-70% CH<sub>3</sub>CN in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 1) (684.2 mg, yield 67%). LC/MS analysis of the product shows the desired product's mass: *m/z* 612 (<sup>79</sup>Br,<sup>79</sup>BrM+H), *m/z* 614
- 15 (<sup>79</sup>Br,<sup>81</sup>BrM+H), and *m/z* 616 (<sup>81</sup>Br,<sup>81</sup>BrM+H); Calculated for C<sub>22</sub>H<sub>23</sub>Br<sub>2</sub>N<sub>5</sub>O<sub>6</sub>: 613.26. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 2.74 (d, J = 7.10 Hz, 2H), 3.16 (d, J = 12.23 Hz, 2H), 3.33 (d, J = 11.25 Hz, 2H), 3.86 (d, J = 5.87 Hz, 2H), 4.08 (brs, 1H), 5.14 (q, J = 7.34 Hz, 1H), 6.74 (appt, J = 2.0 Hz, 1H), 7.11 (appt, 1H), 7.14 (appt, J = 1.7 Hz, 1H), 7.56 (d, J = 1.71 Hz, 2H), 7.71 (t, J = 1.7 Hz, 1H), 8.11 (s, 1H), 8.53 (d, J = 7.8 Hz, 1H), 8.64 (t, J = 6.0 Hz, 1H), 9.61
- 20 (s, 1H), 10.01 (brs, 1H), 12.40 (brs, 1H). <sup>1</sup>H NMR spectrum of the sample was consistent with the proposed structure for Example 1.

## Example 2


### Preparation of (3*S*)-3-(3-bromo-5-(trifluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid



5

#### Step 1

*Preparation of ethyl (3*S*) 3-(3-bromo-5-(trifluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate*




A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (83.0 mg, 0.269 mmol), ethyl (3*S*)-3-amino-3-(3-bromo-5-(trifluoromethyl)phenyl)propanoate hydrochloride (Example F) (102.0 mg, 0.271 mmol) was dissolved in DMF (4 mL) and dichloromethane (4 mL) to give a cream suspension. Solid 1-hydroxybenzotriazole hydrate (8.7 mg, 0.057 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min.

15 *N,N'*-diisopropylcarbodiimide (60.0  $\mu$ L, 0.387 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a colorless gummy residue of the product: ethyl (3*S*)-3-[3-bromo-5-(trifluoromethyl)phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate. LC-MS analysis of

20 the crude residue shows the desired product's mass:  $m/z$  630 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  632 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  652 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  654 ( $^{81}\text{BrM}+\text{Na}$ ); Calculated for  $\text{C}_{25}\text{H}_{27}\text{BrF}_3\text{N}_5\text{O}_6$ : 630.41. The crude residue was used as such for the saponification reaction in step 2.

## Step 2


*Preparation of (3S)-3-(3-bromo-5-(trifluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid*



- 5 To a solution of crude ethyl (3S)-3-[3-bromo-5-(trifluoromethyl)phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate from step 1 above (0.344 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (4 mL) was added lithium hydroxide monohydrate (77.0 mg, 1.83 mmol) at room temperature and the reaction mixture was stirred
- 10 at room temperature for 1.5 h. The mixture was neutralized with TFA (1.0 mL in 10.0 mL CH<sub>3</sub>CN) and the mixture was evaporated *in-vacuo* to give a colorless gummy residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-60% CH<sub>3</sub>CN in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 2) (124.0 mg, yield 60%). LC/MS analysis of the product shows
- 15 the desired product's mass: *m/z* 602 (<sup>79</sup>BrM+H), and *m/z* 604 (<sup>81</sup>BrM+H); Calculated for C<sub>23</sub>H<sub>23</sub>BrF<sub>3</sub>N<sub>5</sub>O<sub>6</sub>: 602.36. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 2.78 (d, J = 7.3 Hz, 2H), 3.16 (d, J = 12.2 Hz, 2H), 3.33 (d, J = 12.2 Hz, 2H), 3.87 (d, J = 5.8 Hz, 2H), 4.08 (appt, J = 3.07 Hz, 1H), 5.23 (q, J = 7.3 Hz, 1H), 6.74 (t, J = 2.1 Hz, 1H), 7.11 (t, J = 1.8 Hz, 1H), 7.14 (t, J = 1.8 Hz, 1H), 7.72 (s, 1H), 7.85 (s, 1H), 7.87 (s, 1H), 8.10 (brs, 2H), 8.61 (d, J = 7.9 Hz, 1H),
- 20 8.64 (t, J = 5.9 Hz, 1H), 9.60 (s, 1H), 10.02 (brs, 1H), 12.41 (brs, 1H, -COOH). <sup>1</sup>H NMR spectrum of the product was consistent with the proposed structure for Example 2. <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>): δ -61.09 (s), and -73.82 (s).

### Example 3


#### Preparation of (3*S*)-3-[3-chloro-5-(difluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoic acid



5

#### Step 1

*Preparation of (3S)-ethyl 3-[3-chloro-5-(difluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoate*




A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (27.0 mg; 0.088 mmol), (*S*)-ethyl 3-amino-3-(3-chloro-5-(1-(difluoromethyl)phenyl)propanoate hydrochloride (Example L) (27.51 mg, 0.088 mmol) was dissolved in DMF (1 mL) and dichloromethane (1 mL) to give a colorless suspension. Solid 1-hydroxybenzotriazole hydrate (3.0 mg, 0.020 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min.

15 *N,N'*-diisopropylcarbodiimide (20.0  $\mu$ L, 0.129 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a pale yellow viscous residue of the product: (3*S*)-ethyl 3-(3-chloro-5-(difluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  568 ( $^{35}\text{ClM}+\text{H}$ ),  $m/z$  570 ( $^{37}\text{ClM}+\text{H}$ ),  $m/z$  590 ( $^{35}\text{ClM}+\text{Na}$ ), and  $m/z$  592 ( $^{37}\text{ClM}+\text{Na}$ ); Calculated for  $\text{C}_{25}\text{H}_{28}\text{ClF}_2\text{N}_5\text{O}_6$ : 567.97. The crude residue was used as such for the saponification reaction in Step 2.

20

## Step 2

Preparation of (3S)-3-[3-chloro-5-(difluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoic acid




- 5 To a suspension of crude (3S)-ethyl 3-(3-chloro-5-(difluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate from step 1 above (0.088 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (4 mL) was added lithium hydroxide monohydrate (20.0 mg, 0.477 mmol) at room temperature and the reaction mixture was stirred at room temperature
- 10 overnight. The mixture was neutralized with TFA (1 mL in 10.0 mL CH<sub>3</sub>CN) and the mixture was evaporated *in-vacuo* to give a yellow gummy residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-60% CH<sub>3</sub>CN in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 3) (41.2 mg, yield 87%). LC/MS analysis of the product shows the desired
- 15 product's mass: *m/z* 540 (<sup>35</sup>ClM+H) and *m/z* 542 (<sup>37</sup>ClM+H), Calculated for C<sub>23</sub>H<sub>24</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>6</sub>: 539.92. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 2.76 (d, J = 7.34 Hz, 2H, -CH<sub>2</sub>-COOH), 3.16 (d, J = 12.23 Hz, 2H), 3.33 (d, J = 10.76 Hz, 2H), 3.87 (dd/m, 3H), 4.08 (t, J = 3.18 Hz, 1H), 5.21 (q, J = 7.34 Hz, 1H, -NH-CH-CH<sub>2</sub>-COOH), 6.74 (t, J = 2.08 Hz, 1H), 7.03 (s, 1H), 7.11 (t, J = 1.71 Hz, 1H), 7.13 (apt, 1H), 7.53 (brs, 1H), 7.59 (s, 1H), 8.14 (brs, 2H), 8.63 (t, J = 5.87
- 20 Hz, 1H), 9.67 (brs, 1H), 10.02 (brs, 1H), 12.44 (brs, 1H, -COOH). <sup>1</sup>H NMR spectrum of the product was consistent with the proposed structure for Example 3. <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>): δ -74.12 (s), and -110.28 (d, J = 56.0 Hz).



### Example 4


#### Preparation of (3*S*)-3-[3-bromo-5-(difluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid



5

#### Step 1

*Preparation of (3S)-ethyl 3-[3-bromo-5-(difluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate*




A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (25.0 mg; 0.081 mmol), ethyl (3*S*)-3-amino-3-(3-bromo-5-(1-(difluoromethyl)phenyl)propanoate hydrochloride (Example K) (29.08 mg, 0.081 mmol) was dissolved in DMF (1 mL) and dichloromethane (1 mL) to give a colorless suspension. Solid 1-hydroxybenzotriazole hydrate (3.0 mg, 0.020 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min.

15 *N,N'*-diisopropylcarbodiimide (20.0  $\mu$ L, 0.129 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a yellow orange viscous residue of the product: (3*S*)-ethyl 3-(3-bromo-5-(difluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate. LC-MS analysis of the

20 crude residue shows the desired product's mass:  $m/z$  612 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  614 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  634 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  636 ( $^{81}\text{BrM}+\text{Na}$ ); Calculated for  $\text{C}_{25}\text{H}_{28}\text{BrF}_2\text{N}_5\text{O}_6$ : 612.42. The crude residue will be used as such for the saponification reaction in Step 2.

## Step 2


Preparation of (3S)-3-[3-bromo-5-(difluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoic acid



- 5 To a suspension of crude ethyl (3S)-3-(3-bromo-5-(difluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate from step 1 above (0.080 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (4 mL) was added lithium hydroxide monohydrate (18.0 mg, 0.429 mmol) at room temperature and the reaction mixture was stirred at room temperature
- 10 overnight. The mixture was neutralized with TFA (500  $\mu$ L in 5.0 mL  $\text{CH}_3\text{CN}$ ) and the mixture was evaporated *in-vacuo* to give a yellow gummy residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-60%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 4) (33.4 mg, yield 71%). LC/MS analysis of the product shows the desired
- 15 product's mass:  $m/z$  584 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  586 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  606 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  608 ( $^{81}\text{BrM}+\text{Na}$ ); Calculated for  $\text{C}_{23}\text{H}_{24}\text{BrF}_2\text{N}_5\text{O}_6$ : 584.37.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  2.76 (d,  $J$  = 7.34 Hz, 2H,  $-\text{CH}_2-\text{COOH}$ ), 3.16 (d,  $J$  = 12.47 Hz, 2H), 3.33 (d,  $J$  = 10.76 Hz, 2H), 3.87 (dd/m, 3H), 4.08 (t,  $J$  = 2.90 Hz, 1H), 5.21 (q,  $J$  = 7.34 Hz, 1H,  $-\text{NH}-\text{CH}-\text{CH}_2-\text{COOH}$ ), 6.74 (t,  $J$  = 2.08 Hz, 1H), 7.02 (appt, 1H), 7.14 (appt, 1H), 7.56 (s, 1H), 7.66 (s, 1H), 7.72 (s, 1H), 8.13 (brs, 1H), 8.58 (s, 1H), 8.62 (t,  $J$  = 5.99 Hz, 1H), 9.65 (brs, 1H), 10.02 (brs, 1H), 12.40 (brs, 1H,  $-\text{COOH}$ ).  $^1\text{H}$  NMR spectrum of the product was consistent with the proposed
- 20 structure for Example 4.  $^{19}\text{F}$  NMR (376 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  -73.81 (s), and -110.23 (d,  $J$  = 56.0 Hz).

### Example 5


#### Preparation of (3*S*)-3-[3-chloro-5-(trifluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoic acid



5

#### Step 1


*Preparation of (3S)-ethyl 3-[3-chloro-5-(trifluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoate*



A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (43.0 mg; 0.139 mmol), ethyl (3*S*)-3-amino-3-(3-chloro-5-(1-(trifluoromethyl)phenyl)propanoate hydrochloride (Example E) (46.33 mg, 0.139 mmol) was dissolved in DMF (1 mL) and dichloromethane (1 mL) to give a colorless suspension. Solid 1-hydroxybenzotriazole hydrate (4.40 mg, 0.029 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min. *N,N'*-diisopropylcarbodiimide (32.0  $\mu$ L, 0.207 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a colorless gummy residue of the product: (3*S*)-ethyl 3-(3-chloro-5-(trifluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  586 ( $^{35}\text{ClM}+\text{H}$ ),  $m/z$  588 ( $^{37}\text{ClM}+\text{H}$ ),  $m/z$  608 ( $^{35}\text{ClM}+\text{Na}$ ), and  $m/z$  610 ( $^{37}\text{ClM}+\text{Na}$ ); Calculated for  $\text{C}_{25}\text{H}_{27}\text{ClF}_3\text{N}_5\text{O}_6$ : 585.96. The crude residue was used as such for the saponification reaction in step 2.


## Step 2

Preparation of (3S)-3-[3-chloro-5-(trifluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoic acid




To a suspension of crude ethyl (3S)-3-(3-chloro-5-(trifluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate from step 1 above (0.139 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (4 mL) was added lithium hydroxide monohydrate (30.0 mg, 0.715 mmol) at room temperature and the reaction mixture was stirred at room temperature overnight. The mixture was neutralized with TFA (1 mL in 10.0 mL CH<sub>3</sub>CN) and the mixture was evaporated *in-vacuo* to give a cream gummy residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-60% CH<sub>3</sub>CN in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 5) (63.2 mg, yield 81%). LC/MS analysis of the product shows the desired product's mass: *m/z* 558 (<sup>35</sup>ClM+H) and *m/z* 560 (<sup>37</sup>ClM+H), Calculated for C<sub>23</sub>H<sub>23</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>6</sub>: 557.91. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 2.79 (d, J = 7.09 Hz, 2H, -CH<sub>2</sub>-COOH), 3.16 (d, J = 11.98 Hz, 2H), 3.33 (d, J = 11.00 Hz, 2H), 3.87 (d, J = 5.87 Hz, 2H), 4.08 (t, J = 3.18 Hz, 1H), 5.24 (q, J = 7.09 Hz, 1H, -NH-CH-CH<sub>2</sub>-COOH), 6.75 (s, 1H), 7.11 (s, 1H), 7.13 (t, J = 2.00 Hz, 1H), 7.69 (s, 1H), 7.74 (s, 1H), 8.12 (brs, 1H), 8.61 (d, J = 8.07 Hz, 1H), 8.65 (t, J = 5.75 Hz, 1H), 9.66 (brs, 1H), 10.02 (brs, 1H), 12.43 (brs, 1H, -COOH). <sup>1</sup>H NMR spectrum of the product was consistent with the proposed structure for Example 5. <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>): δ -61.11 (s), and -73.94 (s).

## Example 6

**Preparation of (3S)-3-[3-bromo-5-chloro-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoic acid**

5

## Step 1


*Preparation of (3S)-ethyl 3-[3-bromo-5-chloro-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoate*

A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (82.0 mg; 0.266 mmol), ethyl (3S)-3-amino-3-(3-bromo-5-chloro-phenyl)propanoate hydrochloride (synthesized as in the methods described above starting from 3-bromo-5-chloro benzaldehyde) (91.40 mg, 0.266 mmol) was dissolved in DMF (1.5 mL) and dichloromethane (1.5 mL) to give a cream-orange suspension. Solid 1-hydroxybenzotriazole hydrate (9.0 mg, 0.059 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min. *N,N'*-diisopropylcarbodiimide (60.0  $\mu$ L, 0.387 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a dirty yellow-orange gummy residue of the product: (3S)-ethyl 3-(3-bromo-5-chloro-phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  596 ( $^{35}\text{Cl}, ^{79}\text{BrM}+\text{H}$ ),  $m/z$  598 ( $^{35}\text{Cl}, ^{81}\text{Br}, ^{37}\text{Cl}, ^{79}\text{BrM}+\text{H}$ ),  $m/z$  600 ( $^{37}\text{Cl}, ^{81}\text{BrM}+\text{H}$ ),  $m/z$  618 ( $^{35}\text{Cl}, ^{79}\text{BrM}+\text{Na}$ ),  $m/z$  620 ( $^{35}\text{Cl}, ^{81}\text{Br}, ^{37}\text{Cl}, ^{79}\text{BrM}+\text{Na}$ ) and  $m/z$  622

( $^{37}\text{Cl}, ^{81}\text{Br}\text{M}+\text{Na}$ ); Calculated for  $\text{C}_{24}\text{H}_{27}\text{BrClN}_5\text{O}_6$ : 596.86. The crude residue was used as such for the saponification reaction in Step 2.

## Step 2


*Preparation of (3S)-3-[3-bromo-5-chloro-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid*



To a suspension of crude ethyl (3S)-3-(3-bromo-5-chloro-phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate from step 1 above (0.266 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (4 mL) was added lithium hydroxide monohydrate (56.0 mg, 0.1334 mmol) at room temperature and the reaction mixture was stirred at room temperature for 4 h to give an orange-yellow solution. The mixture was neutralized with TFA (1 mL in 10.0 mL  $\text{CH}_3\text{CN}$ ) and the mixture was evaporated *in-vacuo* to give a colorless gummy residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-60%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 6) (88.7 mg, yield 59%). LC/MS analysis of the product shows the desired product's mass:  $m/z$  568 ( $^{35}\text{Cl}, ^{79}\text{Br}\text{M}+\text{H}$ ),  $m/z$  570 ( $^{35}\text{Cl}, ^{81}\text{Br}, ^{37}\text{Cl}, ^{79}\text{Br}\text{M}+\text{H}$ ), and  $m/z$  572 ( $^{37}\text{Cl}, ^{81}\text{Br}\text{M}+\text{H}$ ); Calculated for  $\text{C}_{22}\text{H}_{23}\text{BrClN}_5\text{O}_6$ : 568.80.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  2.74 (d,  $J = 7.34$  Hz, 2H,  $-\text{CH}_2-\text{COOH}$ ), 3.16 (d,  $J = 12.23$  Hz, 2H), 3.34 (d,  $J = 11.74$  Hz, 2H), 3.87 (d,  $J = 5.87$  Hz, 2H), 4.08 (appt, 1H), 5.15 (q,  $J = 7.42$  Hz, 1H,  $-\text{NH}-\text{CH}-\text{CH}_2-\text{COOH}$ ), 6.75 (t,  $J = 1.96$  Hz, 1H), 7.11 (s, 1H), 7.14 (s, 1H), 7.43 (s, 1H), 7.52 (s, 1H), 7.60 (s, 1H), 8.13 (brs, 1H), 8.84 (d,  $J = 8.07$  Hz, 1H), 8.64 (t,  $J = 5.87$  Hz, 1H), 9.65 (brs, 1H), 10.03 (brs, 1H), 12.45 (brs, 1H,  $-\text{COOH}$ ).  $^1\text{H}$  NMR spectrum of the product was consistent with the proposed structure for Example 6.

## Example 7


**Preparation of (3*S*)-3-[3-chloro-5-(trifluoromethyl)phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoic acid**



5

## Step 1

*Preparation of ethyl (3*S*)-3-[3-chloro-5-(trifluoromethyl)phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate*



10


A mixture of 2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetic acid (Example D) (56.0 mg, 0.115 mmol), ethyl (3*S*)-3-amino-3-[3-chloro-5-(trifluoromethyl)phenyl]propanoate hydrochloride (Example E) (38.05 mg, 0.115 mmol) and 1-hydroxybenzotriazole hydrate (3.5 mg, 0.023 mmol) was dissolved in DMF (3 mL) and dichloromethane (3 mL) and stirred at room temperature under nitrogen atmosphere for 10 min to give a cream suspension. *N,N'*-diisopropylcarbodiimide (25  $\mu$ L, 0.161 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a colorless gummy solid of the intermediate product: ethyl (3*S*)-3-[3-chloro-5-(trifluoromethyl)phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  571 ( $^{35}\text{ClM}+\text{H}$ ),  $m/z$  573 ( $^{37}\text{ClM}+\text{H}$ );  $m/z$  593 ( $^{35}\text{ClM}+\text{Na}$ ), and  $m/z$

20

595 ( $^{37}\text{ClM}+\text{Na}$ ); Calculated for  $\text{C}_{24}\text{H}_{26}\text{ClF}_3\text{N}_6\text{O}_5$ : 570.95. The crude residue was used as such for the saponification reaction in Step 2.

### Step 2

Preparation of (3*S*)-3-[3-chloro-5-(trifluoromethyl)phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoic acid




To a suspension of ethyl (3*S*)-3-[3-chloro-5-(trifluoromethyl)phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate from step 1 above (0.115 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (4 mL) was added lithium hydroxide monohydrate (25.0 mg, 0.596 mmol) and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was neutralized with TFA (250  $\mu\text{L}$  in 5 mL  $\text{CH}_3\text{CN}$ ) and the mixture was evaporated *in-vacuo* to give a colorless residue. The crude product was purified by reverse-phase HPLC with a gradient 10-70%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 7) (46.4 mg, yield 74%). LC/MS analysis of the product shows the desired product's mass:  $m/z$  558 ( $^{35}\text{ClM}+\text{H}$ ), and  $m/z$  560 ( $^{37}\text{ClM}+\text{H}$ ); Calculated for  $\text{C}_{22}\text{H}_{22}\text{ClF}_3\text{N}_6\text{O}_5$ : 542.90.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  2.79 (d,  $J$  = 7.34 Hz, 2H,  $-\text{CH}_2-\text{COOH}$ ), 3.17 (d,  $J$  = 11.98 Hz, 2H), 3.36 (d,  $J$  = 11.98 Hz, 2H), 3.94 (d,  $J$  = 5.87 Hz, 2H), 4.11 (brt, 1H), 5.25 (q,  $J$  = 7.09 Hz, 1H,  $-\text{NH}-\text{CH}-\text{CH}_2-\text{COOH}$ ), 7.70 (s, 1H), 7.75 (s, 2H), 8.02 (s, 1H), 8.43 (brs, 2H), 8.59 (brs, 1H), 8.66 (d,  $J$  = 8.07 Hz, 1H), 8.90 (brs, 1H), 9.04 (t,  $J$  = 5.75 Hz, 1H), 9.92 (s, 1H), 12.41 (brs, 1H,  $-\text{COOH}$ ).  $^1\text{H}$  NMR spectrum of the product was consistent with the proposed structure for Example 7.  $^{19}\text{F}$  NMR (376 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  -61.12 (s), and -74.31 (s).




## Example 8

**Preparation of (3*S*)-3-(3-bromo-5-chloro-phenyl)-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoic acid**



## Step 1

*Preparation of ethyl (3*S*)-3-(3-bromo-5-chloro-phenyl)-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate*




A mixture of 2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetic acid (Example D) (80.0 mg, 0.164 mmol), ethyl (3*S*)-3-amino-3-[3-bromo-5-chlorophenyl]propanoate hydrochloride (synthesized as in the methods described above starting from 3-bromo-5-chloro benzaldehyde) (56.15 mg, 0.164 mmol) and 1-hydroxybenzotriazole hydrate (6.0 mg, 0.039 mmol) was dissolved in DMF (3 mL) and dichloromethane (3 mL) and stirred at room temperature under nitrogen atmosphere for 10 min to give a cream suspension. *N,N'*-diisopropylcarbodiimide (35.0  $\mu$ L, 0.226 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a colorless solid of the intermediate product: ethyl (3*S*)-3-[3-bromo-5-chloro-phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl] amino]propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  581 ( $^{35}\text{Cl}, ^{79}\text{Br}\text{M}+\text{H}$ ),  $m/z$  583 ( $^{35}\text{Cl}, ^{81}\text{Br}, ^{37}\text{Cl}, ^{79}\text{Br}\text{M}+\text{H}$ ),  $m/z$  585 ( $^{37}\text{Cl}, ^{81}\text{Br}\text{M}+\text{H}$ ),  $m/z$  603 ( $^{35}\text{Cl}, ^{79}\text{Br}\text{M}+\text{Na}$ ),  $m/z$  605

( $^{35}\text{Cl},^{81}\text{Br},^{37}\text{Cl},^{79}\text{Br}\text{M}+\text{Na}$ ) and  $m/z$  607 ( $^{37}\text{Cl},^{81}\text{Br}\text{M}+\text{Na}$ ); Calculated for  $\text{C}_{23}\text{H}_{26}\text{BrClN}_6\text{O}_5$ : 581.85.

The crude residue was used as such for the saponification reaction in Step 2.

### Step 2


Preparation of (3*S*)-3-(3-bromo-5-chloro-phenyl)-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoic acid



To a suspension of ethyl (3*S*)-3-[3-bromo-5-chloro-phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate from step 1 above (0.164 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (6 mL) was added lithium hydroxide monohydrate (35.0 mg, 0.834 mmol) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was neutralized with TFA (250  $\mu\text{L}$  in 5 mL  $\text{CH}_3\text{CN}$ ) and the mixture was evaporated *in-vacuo* to give a colorless crystalline solid. The crude product was purified by reverse-phase HPLC with a gradient 10-50%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 8) (55.0 mg, yield 61%). LC/MS analysis of the product shows the desired product's mass:  $m/z$  553 ( $^{35}\text{Cl},^{79}\text{Br}\text{M}+\text{H}$ ),  $m/z$  555 ( $^{35}\text{Cl},^{81}\text{Br},^{37}\text{Cl},^{79}\text{Br}\text{M}+\text{H}$ ), and  $m/z$  557 ( $^{37}\text{Cl},^{81}\text{Br}\text{M}+\text{H}$ ); Calculated for  $\text{C}_{21}\text{H}_{22}\text{BrClN}_6\text{O}_5$ : 553.79.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  2.75 (d,  $J$  = 7.34 Hz, 2H,  $-\text{CH}_2-\text{COOH}$ ), 3.17 (d,  $J$  = 12.23 Hz, 2H), 3.36 (d,  $J$  = 11.00 Hz, 2H), 3.94 (d,  $J$  = 5.62 Hz, 2H), 4.11 (t,  $J$  = 3.20 Hz, 1H), 5.16 (q,  $J$  = 7.42 Hz, 1H,  $-\text{NH}-\text{CH}-\text{CH}_2-\text{COOH}$ ), 7.44 (t,  $J$  = 1.47 Hz, 1H), 7.53 (apt, 1H), 7.60 (t,  $J$  = 1.83 Hz, 1H), 8.03 (t,  $J$  = 2.08 Hz, 1H), 8.42 (brs, 2H), 8.59 (d,  $J$  = 7.82 Hz, 1H), 8.90 (brs, 1H), 9.03 (t,  $J$  = 5.87 Hz, 1H), 9.90 (s, 1H), 12.42 (brs, 1H,  $-\text{COOH}$ ).  $^1\text{H}$  NMR spectrum of the product was consistent with the proposed structure for Example 8.

## Example 9


**Preparation of (3*S*)-3-[3-bromo-5-(trifluoromethyl)phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoic acid**



5

## Step 1

*Preparation of ethyl (3*S*)-3-[3-bromo-5-(trifluoromethyl)phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate*



10


A mixture of 2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetic acid (Example D) (64.0 mg, 0.131 mmol), ethyl (3*S*)-3-amino-3-(3-bromo-5-(trifluoromethyl)phenyl)propanoate hydrochloride (Example F) (49.31 mg, 0.131 mmol) and 1-hydroxybenzotriazole hydrate (5.0 mg, 0.033 mmol) was dissolved in DMF (3 mL) and dichloromethane (3 mL) and stirred at room temperature under nitrogen atmosphere for 10 min to give a cream suspension. *N,N'*-diisopropylcarbodiimide (30.0  $\mu$ L, 0.194 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a colorless gummy solid of the intermediate product: ethyl (3*S*)-3-[3-bromo-5-(trifluoromethyl)phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  615 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  617 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  637 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  639 ( $^{81}\text{BrM}+\text{Na}$ );

20

Calculated for  $C_{24}H_{26}BrF_3N_6O_5$ : 615.40. The crude residue was used as such for the saponification reaction in Step 2.

### Step 2


Preparation of (3S)-3-[3-bromo-5-(trifluoromethyl)phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoic acid



To a suspension of ethyl (3S)-3-[3-bromo-5-(trifluoromethyl)phenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate from step 1 above (0.131 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (6 mL) was added lithium hydroxide monohydrate (30.0 mg, 0.715 mmol) and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was neutralized with TFA (250  $\mu$ L in 5 mL  $CH_3CN$ ) and the mixture was evaporated *in-vacuo* to give a colorless crystalline solid. The crude product was purified by reverse-phase HPLC with a gradient 10-60%  $CH_3CN$  in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 9) (69.6 mg, yield 90%). LC/MS analysis of the product shows the desired product's mass:  $m/z$  587 ( $^{79}BrM+H$ ),  $m/z$  589 ( $^{81}BrM+H$ ),  $m/z$  609 ( $^{79}BrM+Na$ ), and  $m/z$  611 ( $^{81}BrM+Na$ ); Calculated for  $C_{22}H_{22}BrF_3N_6O_5$ : 587.35.  $^1H$  NMR (400 MHz,  $DMSO-d_6$ ):  $\delta$  2.79 (d,  $J$  = 7.34 Hz, 2H,  $-CH_2-COOH$ ), 3.17 (d,  $J$  = 12.47 Hz, 2H), 3.36 (d,  $J$  = 11.74 Hz, 2H), 3.94 (d,  $J$  = 5.87 Hz, 2H), 4.11 (brt, 1H), 5.24 (q,  $J$  = 7.25 Hz, 1H,  $-NH-CH-CH_2-COOH$ ), 7.73 (s, 1H), 7.85 (s, 1H), 8.02 (t,  $J$  = 2.08 Hz, 1H), 8.43 (brs, 2H), 8.59 (d,  $J$  = 1.96 Hz, 1H), 8.66 (d,  $J$  = 8.07 Hz, 1H), 8.90 (s, 1H), 9.05 (t,  $J$  = 5.75 Hz, 1H), 9.92 (s, 1H), 12.43 (brs, 1H,  $-COOH$ ).  $^1H$  NMR spectrum of the product was consistent with the proposed structure for Example 9.  $^{19}F$  NMR (376 MHz,  $DMSO-d_6$ ):  $\delta$  -61.10 (s), and -74.47 (s).

### Example 10


#### Preparation of (3*S*)-3-[3,5-bis(trifluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid



5

#### Step 1


#### Preparation of ethyl (3*S*)-3-[3,5-bis(trifluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate



A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (65.50 mg; 0.212 mmol), ethyl (3*S*)-3-amino-3-(3,5-bis(1-(trifluoromethyl)phenyl)propanoate hydrochloride (synthesized as in the methods described above starting from 3,5-bis trifluoromethyl benzaldehyde) (77.70 mg, 0.212 mmol) was dissolved in DMF (2 mL) and dichloromethane (2 mL) to give a colorless suspension. Solid 1-hydroxybenzotriazole hydrate (7.0 mg, 0.046 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min. *N,N'*-diisopropylcarbodiimide (45.0  $\mu$ L, 0.291 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a colorless gummy residue of the product: ethyl (3*S*)-3-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  620 ( $M+H$ ), and  $m/z$  642 ( $M+Na$ ); Calculated for  $C_{26}H_{27}F_6N_5O_6$ : 619.51. The crude residue was used as such for the saponification reaction in Step 2.


Step 2

*Preparation of (3S)-3-[3,5-bis(trifluoromethyl)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoic acid*




To a suspension of crude ethyl (3S)-3-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate from step 1 above (0.212 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (6 mL) was added lithium hydroxide monohydrate (45.0 mg, 1.072 mmol) at room temperature and the reaction mixture was stirred at room temperature for 1 h. The mixture was neutralized with TFA (250  $\mu$ L in 5.0 mL CH<sub>3</sub>CN) and the mixture was evaporated *in-vacuo* to give a colorless gummy residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-60% CH<sub>3</sub>CN in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 10) (69.2 mg, yield 55%). LC/MS analysis of the product shows the desired product's mass: *m/z* 592 (M+H) and *m/z* 614 (M+Na), Calculated for C<sub>24</sub>H<sub>23</sub>F<sub>6</sub>N<sub>5</sub>O<sub>6</sub>: 591.46. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  2.83 (d, J = 7.34 Hz, 2H, -CH<sub>2</sub>-COOH), 3.15 (d, J = 12.23 Hz, 2H), 3.33 (brd, J = 10.67 Hz, 2H), 3.87 (d, J = 5.62 Hz, 2H), 4.08 (d, J = 3.18 Hz, 1H), 5.33 (q, J = 7.09 Hz, 1H, -NH-CH-CH<sub>2</sub>-COOH), 6.74 (t, J = 2.08 Hz, 1H), 7.10 (appt, 1H), 7.13 (appt, 1H), 7.85-8.22 (m, 4H), 8.48-8.93 (m, 2H), 9.64 (s, 1H), 10.02 (brs, 1H), 12.45 (brs, 1H, -COOH). <sup>1</sup>H NMR spectrum of the product was consistent with the proposed structure for Example 10. <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  -61.14 (s), and -73.73 (s).

## Example 11

Preparation of (3*S*)-3-[3-bromo-5-methyl-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid

## Step 1

Preparation of methyl (3*S*)-3-[3-bromo-5-methyl-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate




10 A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (94.70 mg, 0.307 mmol), methyl (3*S*)-3-amino-3-(3-bromo-5-methyl-phenyl)propanoate hydrochloride (synthesized as in the methods described above starting from 3-bromo-5-methyl benzaldehyde) (94.80 mg, 0.307 mmol) was dissolved in DMF (2 mL) and dichloromethane (2 mL) to give a cream suspension. Solid 1-hydroxybenzotriazole hydrate (10.20 mg, 0.067 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min. *N,N'*-diisopropylcarbodiimide (70  $\mu$ L, 0.452 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in vacuo* to give a colorless gummy residue of the product: methyl (3*S*)-3-[3-bromo-5-methyl-phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  562 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  564 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  584

( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  586 ( $^{81}\text{BrM}+\text{Na}$ ), Calculated for  $\text{C}_{24}\text{H}_{28}\text{BrN}_5\text{O}_6$ : 562.41. The crude residue was used as such for the saponification reaction in Step 2.

### Step 2

*Preparation of (3S)-3-[3-bromo-5-methyl-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid*




To a solution of crude methyl (3S)-3-[3-bromo-5-methyl-phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate from step 1 above (0.307 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (6 mL) was added lithium hydroxide monohydrate (65 mg, 1.55 mmol) at room temperature and the reaction mixture was stirred at room temperature for 1 h. The mixture was neutralized with TFA (500  $\mu\text{L}$  in 5.0 mL  $\text{CH}_3\text{CN}$ ) and the mixture was evaporated *in-vacuo* to give a colorless gummy residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-50%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 11) (105.3 mg, yield 62%). LC/MS analysis of the product shows the desired product's mass:  $m/z$  548 ( $^{79}\text{BrM}+\text{H}$ ), and  $m/z$  550 ( $^{81}\text{BrM}+\text{H}$ ); Calculated for  $\text{C}_{23}\text{H}_{26}\text{BrN}_5\text{O}_6$ : 548.39.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  2.28 (s, 3H,  $\text{CH}_3$ -), 2.70 (d, J = 7.34 Hz, 2H,  $-\text{CH}_2-\text{COOH}$ ), 3.16 (d, J = 12.23 Hz, 2H), 3.34 (d, J = 11.98 Hz, 2H), 3.86 (d, J = 5.87 Hz, 2H), 4.09 (t, J = 2.90 Hz, 1H), 5.13 (q, J = 7.50 Hz, 1H,  $-\text{NH}-\text{CH}-\text{CH}_2-\text{COOH}$ ), 6.74 (t, J = 1.96 Hz, 1H), 7.11 (s, 1H), 7.14 (appt, 1H), 7.28 (apt, 1H), 7.31 (apt, 1H), 8.13 (brs, 1H), 8.48 (d, J = 8.31 Hz, 1H), 8.61 (t, J = 5.87 Hz, 1H), 9.64 (s, 1H), 10.02 (brs, 1H), 12.37 (brs, 1H,  $-\text{COOH}$ ).  $^1\text{H}$  NMR spectrum of the product was consistent with the proposed structure for Example 11.



### Example 12


#### Preparation of (3*S*)-3-[3-chloro-5-methyl-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid



5

#### Step 1

*Preparation of ethyl (3*S*)-3-(3-chloro-5-methyl-phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate*




A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (81.80 mg, 0.265 mmol), (*S*)-ethyl 3-amino-3-(3-chloro-5-methyl-phenyl)propanoate hydrochloride (synthesized as in the methods described above starting from 3-chloro-5-methyl benzaldehyde) (73.81 mg, 0.265 mmol) was dissolved in DMF (2 mL) and dichloromethane (2 mL) to give a cream suspension. Solid 1-hydroxybenzotriazole hydrate (8.4 mg, 0.055 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min. *N,N'*-diisopropylcarbodiimide (60  $\mu$ L, 0.390 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in vacuo* to give a colorless gummy residue of the product: ethyl (3*S*)-3-[3-chloro-5-methyl-phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  532 ( $^{35}\text{ClM}+\text{H}$ ),  $m/z$  534 ( $^{37}\text{ClM}+\text{H}$ ),  $m/z$  554

( $^{35}\text{ClM}+\text{Na}$ ), and  $m/z$  556 ( $^{37}\text{ClM}+\text{Na}$ ), Calculated for  $\text{C}_{25}\text{H}_{30}\text{ClN}_5\text{O}_6$ : 531.99. The crude residue was used as such for the saponification reaction in Step 2.


### Step 2

*Preparation of (3S)-3-[3-chloro-5-methyl-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid*



To a solution of crude ethyl (3S)-3-[3-chloro-5-methyl-phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate from step 1 above (0.265 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (6 mL) was added lithium hydroxide monohydrate (56 mg, 1.334 mmol) at room temperature and the reaction mixture was stirred at room temperature for 1 h. The mixture was neutralized with TFA (500  $\mu\text{L}$  in 5.0 mL  $\text{CH}_3\text{CN}$ ) and the mixture was evaporated *in-vacuo* to give a colorless viscous residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-50%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 12) (89.4 mg, yield 67%). LC/MS analysis of the product shows the desired product's mass:  $m/z$  504 ( $^{35}\text{ClM}+\text{H}$ ),  $m/z$  506 ( $^{37}\text{ClM}+\text{H}$ ),  $m/z$  526 ( $^{35}\text{ClM}+\text{Na}$ ), and  $m/z$  528 ( $^{37}\text{ClM}+\text{H}$ ); Calculated for  $\text{C}_{23}\text{H}_{26}\text{ClN}_5\text{O}_6$ : 503.94.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  2.29 (s, 3H,  $\text{CH}_3$ -), 2.70 (d,  $J = 7.34$  Hz, 2H,  $-\text{CH}_2-\text{COOH}$ ), 3.16 (d,  $J = 11.98$  Hz, 2H), 3.34 (d,  $J = 11.00$  Hz, 2H), 3.86 (d,  $J = 5.87$  Hz, 2H), 4.09 (appt/m, 1H), 5.14 (q,  $J = 7.25$  Hz, 1H,  $-\text{NH}-\text{CH}-\text{CH}_2-\text{COOH}$ ), 6.74 (t,  $J = 1.96$  Hz, 1H), 7.11 (d,  $J = 1.47$  Hz, 2H), 7.14 (appt, 2H), 7.18 (s, 1H), 8.14 (br s, 2H), 8.48 (d,  $J = 8.31$  Hz, 1H), 8.61 (t,  $J = 5.99$  Hz, 1H), 9.67 (s, 1H), 10.03 (brs, 1H), 12.32 (brs, 1H,  $-\text{COOH}$ ).  $^1\text{H}$  NMR spectrum of the product was consistent with the proposed structure for Example 12.


## Example 13

**Preparation of (3*S*)-3-[3-bromo-5-fluoro-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid**

5

Step 1

*Preparation of ethyl (3*S*) 3-[3-bromo-5-fluoro-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido]propanoate*




A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (79.50 mg, 0.258 mmol), ethyl (3*S*)-3-amino-3-(3-bromo-5-fluoro-phenyl)propanoate hydrochloride (synthesized as in the methods described above starting from 3-bromo-5-fluoro benzaldehyde) (84.22 mg, 0.258 mmol) was dissolved in DMF (2 mL) and dichloromethane (2 mL) to give a cream suspension. Solid 1-hydroxybenzotriazole hydrate (8.0 mg, 0.052 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min. *N,N'*-diisopropylcarbodiimide (60  $\mu$ L, 0.387 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in vacuo* to give a colorless gummy residue of the product: ethyl (3*S*)-3-[3-bromo-5-fluoro-phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  580 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  582 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  602

( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  604 ( $^{81}\text{BrM}+\text{Na}$ ), Calculated for  $\text{C}_{24}\text{H}_{27}\text{BrFN}_5\text{O}_6$ : 580.40. The crude residue was used as such for the saponification reaction in Step 2.

### Step 2


*Preparation of (3S)-3-[3-bromo-5-fluoro-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid*



To a solution of crude ethyl (3S)-3-[3-bromo-5-fluoro-phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate from step 1 above (0.258 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (6 mL) was added lithium hydroxide monohydrate (55 mg, 1.32 mmol) at room temperature and the reaction mixture was stirred at room temperature overnight. The mixture was neutralized with TFA (250  $\mu\text{L}$  in 5.0 mL  $\text{CH}_3\text{CN}$ ) and the mixture was evaporated *in-vacuo* to give a colorless gummy residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-50%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 13) (110.3 mg, yield 77%). LC/MS analysis of the product shows the desired product's mass:  $m/z$  552 ( $^{79}\text{BrM}+\text{H}$ ), and  $m/z$  554 ( $^{81}\text{BrM}+\text{H}$ ); Calculated for  $\text{C}_{22}\text{H}_{23}\text{BrFN}_5\text{O}_6$ : 552.35.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  2.74 (d,  $J$  = 7.58 Hz, 2H,  $-\text{CH}_2-\text{COOH}$ ), 3.16 (d,  $J$  = 12.23 Hz, 2H), 3.34 (d,  $J$  = 10.80 Hz, 2H), 3.87 (d,  $J$  = 5.87 Hz, 2H), 4.08 (t,  $J$  = 3.18 Hz, 1H), 5.17 (q,  $J$  = 7.34 Hz, 1H,  $-\text{NH}-\text{CH}-\text{CH}_2-\text{COOH}$ ), 6.75 (t,  $J$  = 1.96 Hz, 1H), 7.11 (t,  $J$  = 1.47 Hz, 1H), 7.14 (appt, 1H), 7.21 (t,  $J$  = 1.71 Hz, 1H), 7.24 (appt, 1H), 7.41 (m, 2H), 8.13 (brs, 1H), 8.53 (d,  $J$  = 8.07 Hz, 1H), 8.64 (t,  $J$  = 5.75 Hz, 1H), 9.66 (brs, 1H), 10.03 (brs, 1H), 12.40 (brs, 1H,  $-\text{COOH}$ ).  $^1\text{H}$  NMR spectrum of the product was consistent with the proposed structure for Example 13.  $^{19}\text{F}$  NMR (376 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  -74.07(s), and -110.57 (t,  $J$  = 8.85 Hz).

## Example 14


**Preparation of (3*S*)-3-(3,5-dibromophenyl)-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoic acid**



5

## Step 1

*Preparation of ethyl (3*S*)-3-(3,5-dibromophenyl)-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate*



10 A mixture of 2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetic acid (Example D) (78.0 mg, 0.266 mmol), ethyl (3*S*)-3-amino-3-(3,5-dibromophenyl)propanoate hydrochloride (the (*S*) ester of Example J formed via the enzymatic lipase cleavage method) (103.06 mg, 0.266 mmol) and 1-hydroxybenzotriazole hydrate (8.15 mg, 0.053 mmol) was dissolved in DMF (2 mL) and dichloromethane (2 mL)


15 and stirred at room temperature under nitrogen atmosphere for 10 min to give a cream suspension. *N,N'*-diisopropylcarbodiimide (60.0  $\mu$ L, 0.387 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a colorless crystalline solid of the intermediate product:

20 ethyl (3*S*)-3-[3,5-dibromophenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  625 ( $^{79}\text{Br}, ^{79}\text{Br}\text{M}+\text{H}$ ),  $m/z$  627 ( $^{79}\text{Br}, ^{81}\text{Br}\text{M}+\text{H}$ ),  $m/z$  629 ( $^{81}\text{Br}, ^{81}\text{Br}\text{M}+\text{H}$ ),  $m/z$  647 ( $^{79}\text{Br}, ^{79}\text{Br}\text{M}+\text{Na}$ ),  $m/z$  649 ( $^{79}\text{Br}, ^{81}\text{Br}\text{M}+\text{Na}$ ), and  $m/z$  651

( $^{81}\text{Br}, ^{81}\text{Br}\text{M}+\text{Na}$ ); Calculated for  $\text{C}_{23}\text{H}_{26}\text{Br}_2\text{N}_6\text{O}_5$ : 626.30. The crude residue was used as such for the saponification reaction in Step 2.


### Step 2

Preparation of (3S)-3-(3,5-dibromophenyl)-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoic acid



To a suspension of ethyl (3S)-3-[3,5-dibromophenyl]-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoate from step 1 above (0.266 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (6 mL) was added lithium hydroxide monohydrate (56.0 mg, 0.1334 mmol) and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was neutralized with TFA (250  $\mu\text{L}$  in 5 mL  $\text{CH}_3\text{CN}$ ) and the mixture was evaporated *in-vacuo* to give a colorless crystalline/gummy solid. The crude product was purified by reverse-phase HPLC with a gradient 10-50%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 14) (82.5mg, yield 52%). LC/MS analysis of the product shows the desired product's mass:  $m/z$  597 ( $^{79}\text{Br}, ^{79}\text{Br}\text{M}+\text{H}$ ),  $m/z$  599 ( $^{79}\text{Br}, ^{81}\text{Br}\text{M}+\text{H}$ ), and  $m/z$  601 ( $^{81}\text{Br}, ^{81}\text{Br}\text{M}+\text{H}$ ); Calculated for  $\text{C}_{21}\text{H}_{22}\text{Br}_2\text{N}_6\text{O}_5$ : 598.24.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  2.74 (d,  $J = 7.34$  Hz, 2H,  $-\text{CH}_2-\text{COOH}$ ), 3.17 (d,  $J = 12.23$  Hz, 2H), 3.36 (d,  $J = 11.0$  Hz, 2H), 3.93 (d,  $J = 5.62$  Hz, 2H), 4.11 (t,  $J = 3.06$  Hz, 1H), 5.15 (q,  $J = 7.42$  Hz, 1H,  $-\text{NH}-\text{CH}-\text{CH}_2-\text{COOH}$ ), 7.57 (d,  $J = 1.71$  Hz, 1H), 7.72 (s, 1H), 8.03 (t,  $J = 2.20$  Hz, 1H), 8.42 (brs, 1H), 8.59 (m, 2H), 8.90 (d,  $J = 1.71$  Hz, 1H), 9.03 (t,  $J = 5.75$  Hz, 1H), 9.88 (s, 1H), 12.42 (brs, 1H,  $-\text{COOH}$ ).  $^1\text{H}$  NMR spectrum of the product was consistent with the proposed structure for Example 14.


## Example 15

Preparation of (3*S*)-3-[3,5-dichloro-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid

5

Step 1


Preparation of ethyl (3*S*) 3-(3,5-dichlorophenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate



A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (87.0 mg, 0.282 mmol), ethyl (3*S*)-3-amino-3-(3,5-dichlorophenyl)propanoate hydrochloride (Example I) (84.26 mg, 0.282 mmol) was dissolved in DMF (2 mL) and dichloromethane (2 mL) to give a cream suspension. Solid 1-hydroxybenzotriazole hydrate (9.0 mg, 0.059 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min. *N,N'*-diisopropylcarbodiimide (65  $\mu$ L, 0.420 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in vacuo* to give a colorless gummy residue of the product: ethyl (3*S*)-3-[3,5-dichlorophenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate. LC-MS analysis of the crude residue shows the desired product's mass:  $m/z$  552 ( $^{35}\text{ClM}+\text{H}$ ),  $m/z$  554 ( $^{37}\text{ClM}+\text{H}$ ),  $m/z$  574 ( $^{35}\text{ClM}+\text{Na}$ ), and  $m/z$  576 ( $^{37}\text{ClM}+\text{Na}$ ). Calculated for  $\text{C}_{24}\text{H}_{27}\text{Cl}_2\text{N}_5\text{O}_6$ : 552.41 The crude residue was used as such for the saponification reaction in Step 2.

## Step 2

*Preparation of (3S)-3-[3,5-dichloro-phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid*




- 5 To a solution of crude ethyl (3S)-3-[3,5-chlorophenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate from step 1 above (0.282 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (6 mL) was added lithium hydroxide monohydrate (60 mg, 1.43 mmol) at room temperature and the reaction mixture was stirred at room temperature for 2 h. The mixture was neutralized with
- 10 TFA (100  $\mu$ L in 5.0 mL  $\text{CH}_3\text{CN}$ ) and the mixture was evaporated *in-vacuo* to give a colorless viscous residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-50%  $\text{CH}_3\text{CN}$  in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 15) (101.2 mg, yield 68%). LC/MS analysis of the product shows the desired product's mass:  $m/z$  524 ( $^{35}\text{ClM}+\text{H}$ ), and  $m/z$  526
- 15 ( $^{37}\text{ClM}+\text{H}$ ); Calculated for  $\text{C}_{22}\text{H}_{23}\text{Cl}_2\text{N}_5\text{O}_6$ : 524.35.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  2.75 (d,  $J = 7.34$  Hz, 2H,  $-\text{CH}_2-\text{COOH}$ ), 3.16 (brd,  $J = 11.98$  Hz, 2H), 3.33 (brd,  $J = 12.23$  Hz, 2H), 3.87 (d,  $J = 5.87$  Hz, 2H), 4.08 (brs, 1H), 5.15 (q,  $J = 7.17$  Hz, 1H,  $-\text{NH}-\text{CH}-\text{CH}_2-\text{COOH}$ ), 6.75 (t,  $J = 2.08$  Hz, 1H), 7.11 (appt, 1H), 7.14 (appt, 1H), 7.40 (d,  $J = 1.96$  Hz, 1H), 7.49 (appt, 1H), 8.12 (s, 2H), 8.54 (d,  $J = 8.07$  Hz, 1H), 8.64 (t,  $J = 5.87$  Hz, 1H), 9.64 (s, 1H),
- 20 10.02 (brs, 1H), 12.40 (brs, 1H,  $-\text{COOH}$ ).  $^1\text{H}$  NMR spectrum of the product was consistent with the proposed structure for Example 15.



### Example 16


#### Preparation of (3*S*)-3-[3-chloro-5-(trifluoromethoxy)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid



5

#### Step 1

*Preparation of ethyl (3*S*)-3-(3-chloro-5-(trifluoromethoxy)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate*




A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (61.0 mg, 0.198 mmol), ethyl (3*S*)-3-amino-3-(3-chloro-5-(trifluoromethoxy)phenyl)propanoate hydrochloride (Example G) (68.89 mg, 0.198 mmol) was dissolved in DMF (2 mL) and dichloromethane (2 mL) to give a cream suspension. Solid 1-hydroxybenzotriazole hydrate (6.1 mg, 0.040 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min.

15 *N,N'*-diisopropylcarbodiimide (46  $\mu$ L, 0.297 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a cream gummy residue of the product: ethyl (3*S*)-3-[3-chloro-5-(trifluoromethoxy)phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate. LC-MS analysis of the crude residue

20 shows the desired product's mass:  $m/z$  602 ( $^{35}\text{ClM}+\text{H}$ ),  $m/z$  604 ( $^{37}\text{ClM}+\text{H}$ ),  $m/z$  624 ( $^{35}\text{ClM}+\text{Na}$ ), and  $m/z$  626 ( $^{37}\text{ClM}+\text{Na}$ ). Calculated for  $\text{C}_{25}\text{H}_{27}\text{ClF}_3\text{N}_5\text{O}_7$ : 601.96. The crude residue was used as such for the saponification reaction in Step 2.

## Step 2


Preparation of (3*S*)-3-[3-chloro-5-(trifluoromethoxy)phenyl]-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid



5 To a solution of crude ethyl (3*S*)-3-[3-chloro-5-(trifluoromethoxy)phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate from step 1 above (0.198 mmol) in a mixture of a 1:1 mixture of acetonitrile/water (6 mL) was added lithium hydroxide monohydrate (42 mg, 1.10 mmol) at room temperature and the reaction mixture was stirred at  
10 room temperature for 1 h. The mixture was neutralized with TFA (100  $\mu$ L in 5.0 mL CH<sub>3</sub>CN) and the mixture was evaporated *in-vacuo* to give a colorless viscous residue. The above crude product was purified by reverse-phase HPLC with a gradient 10-70% CH<sub>3</sub>CN in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 16) (69.50 mg, yield 61%). LC/MS analysis of the product shows  
15 the desired product's mass: *m/z* 574 (<sup>35</sup>ClM+H), *m/z* 576 (<sup>37</sup>ClM+H), *m/z* 596 (<sup>35</sup>ClM+Na), and *m/z* 598 (<sup>37</sup>ClM+Na), Calculated for C<sub>23</sub>H<sub>23</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>7</sub>: 573.91. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  2.76 (d, *J* = 7.34 Hz, 2H, -CH<sub>2</sub>-COOH), 3.17 (d, *J* = 12.47 Hz, 2H), 3.34 (d, *J* = 12.72 Hz, 2H), 3.88 (d, *J* = 5.87 Hz, 2H), 4.09 (t, *J* = 3.20 Hz, 1H), 5.21 (q, *J* = 7.17 Hz, 1H, -NH-CH-CH<sub>2</sub>-COOH), 6.76 (t, *J* = 2.08 Hz, 1H), 7.12 (t, *J* = 1.59 Hz, 1H), 7.14 (t, *J* = 1.00 Hz,  
20 1H), 7.35 (s, 1H), 7.45 (d, *J* = 0.73 Hz, 1H), 7.49 (t, *J* = 1.47 Hz, 1H), 8.13 (brs, 1H), 8.58 (d, *J* = 7.82 Hz, 1H), 8.65 (t, *J* = 5.87 Hz, 1H), 9.64 (s, 1H), 10.03 (brs, 1H), 12.44 (brs, 1H, -COOH). <sup>1</sup>H NMR spectrum of the product was consistent with the proposed structure for Example 16. <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  -56.83 (s), and -73.70 (s).

### Example 17


#### Preparation of (3*S*)-3-(3-bromo-5-(trifluoromethoxy)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid



5

Step 1

*Preparation of ethyl (3*S*) 3-(3-bromo-5-(trifluoromethoxy)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate*




A mixture of 2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetic acid (Example B) (65.0 mg, 0.211 mmol), (*S*)-ethyl 3-amino-3-(3-bromo-5-(trifluoromethoxy)phenyl)propanoate hydrochloride (Example H) (82.75 mg, 0.211 mmol) was dissolved in DMF (2 mL) and dichloromethane (2 mL) to give a colorless suspension. Solid 1-hydroxybenzotriazole hydrate (7.0 mg, 0.046 mmol) was added to above reaction mixture and the reaction mixture was stirred under nitrogen atmosphere for 10 min.

15 *N,N'*-diisopropylcarbodiimide (50  $\mu$ L, 0.323 mmol) was added and the reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. The solvent was evaporated *in-vacuo* to give a cream gummy residue of the product: ethyl (3*S*)-3-[3-bromo-5-(trifluoromethoxy)phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoate. LC-MS analysis of the crude residue

20 shows the desired product's mass:  $m/z$  646 ( $^{79}\text{BrM}+\text{H}$ ),  $m/z$  648 ( $^{81}\text{BrM}+\text{H}$ ),  $m/z$  668 ( $^{79}\text{BrM}+\text{Na}$ ), and  $m/z$  670 ( $^{81}\text{BrM}+\text{Na}$ ). Calculated for  $\text{C}_{25}\text{H}_{27}\text{BrF}_3\text{N}_5\text{O}_7$ : 646.41. The crude residue was used as such for the saponification reaction in Step 2.

## Step 2

*Preparation of (3S)-3-(3-bromo-5-(trifluoromethoxy)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid*



5 To a solution of the crude product (0.211 mmol) from step 1 above in a mixture of a 1:1 mixture of acetonitrile/water (6 mL) was added lithium hydroxide monohydrate (48 mg, 1.144 mmol) at room temperature and the reaction mixture was stirred at room temperature for 1 h. The mixture was neutralized with TFA (0.1 mL in 5.0 mL CH<sub>3</sub>CN) and the mixture was evaporated *in-vacuo* to give a colorless viscous residue. The above crude product was

10 purified by reverse-phase HPLC with a gradient 10-70% CH<sub>3</sub>CN in water containing 0.05% TFA to give the desired product, after lyophilization, as a colorless lyophilized solid (Example 17) (83.2 mg, yield 64%). LC/MS analysis of the product shows the desired product's mass: *m/z* 618 (<sup>79</sup>BrM+H), *m/z* 620 (<sup>81</sup>BrM+H), *m/z* 640 (<sup>79</sup>BrM+Na), and *m/z* 642 (<sup>81</sup>BrM+Na). Calculated for C<sub>23</sub>H<sub>23</sub>BrF<sub>3</sub>N<sub>5</sub>O<sub>7</sub>: 618.36. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ

15 2.75 (d, J = 7.09 Hz, 2H, -CH<sub>2</sub>-COOH), 3.16 (d, J = 12.23 Hz, 2H), 3.33 (d, J = 11.25 Hz, 2H), 3.87 (d, J = 5.87 Hz, 2H), 4.08 (t, J = 3.20 Hz, 1H), 5.19 (q, J = 7.42 Hz, 1H, -NH-CH-CH<sub>2</sub>-COOH), 6.75 (t, J = 1.96 Hz, 1H), 7.11 (appt, 1H), 7.14 (t, J = 1.70 Hz, 1H), 7.38 (s, 1H), 7.55 (s, 1H), 7.61 (s, 1H), 8.12 (brs, 1H), 8.58 (d, J = 7.82 Hz, 1H), 8.64 (t, J = 5.87 Hz, 1H), 9.63 (brs, 1H), 10.02 (brs, 1H), 12.42 (brs, 1H, -COOH). <sup>1</sup>H NMR spectrum of the

20 product was consistent with the proposed structure for Example 17. <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>): δ -56.81 (s), and -73.81 (s).

### C. Biological Assay Results

The activities of the compounds of the present disclosure and comparison compounds were tested in the following assays and experimental studies. The results are presented in

25 Tables 2, 3, and 4, and FIG. 1.

### 1. Solid Phase Receptor Assay (SPRA) for $\alpha 5 \beta 1$ Function

Purified human fibronectin (R&D Systems, 1918-FN) diluted to 2  $\mu\text{g/mL}$  in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 1 mM  $\text{MnCl}_2$ ) was added to wells (50  $\mu\text{L}$ /well) of a 96-well half-well transparent microtiter plate (Greiner 675061) and incubated overnight at 4  $^{\circ}\text{C}$ . Wells were washed 3 times with 150  $\mu\text{L}$  TBS+ and 150  $\mu\text{L}$  of blocking buffer (TBS+ with 1% bovine serum albumin, Sigma A7906) were added. The plate was incubated for 1 hr at 37  $^{\circ}\text{C}$  and then washed 3 $\times$  with TBS+ buffer. Recombinant human integrin  $\alpha 5 \beta 1$  (R&D Systems, 3230-A5) was diluted to 0.1  $\mu\text{g/mL}$  in TBS+/0.1% bovine serum albumin. Compounds were diluted 1:100 into the integrin solution and then 50  $\mu\text{L}$  added to empty wells of the washed fibronectin-coated plate according to a standard template with each sample repeated in triplicate. After incubation for two hours at room temperature, the plate was washed 3 $\times$  with 150  $\mu\text{L}$  of TBS+ buffer. To each well, 50  $\mu\text{L}$  of biotinylated anti- $\alpha 5$  antibody (R&D Systems, BAF1864) at 0.5  $\mu\text{g/mL}$  in TBS+/0.1% BSA were added and the plate covered and incubated for 1 hr at room temperature. After washing the plate 3 $\times$  with 150  $\mu\text{L}$  of TBS+ buffer, 50  $\mu\text{L}$  of streptavidin-conjugated horseradish peroxidase (R&D Systems, DY998) diluted in TBS+ blocking buffer were added to the wells and the plate incubated for 20 min at room temperature. The plate was washed 3 $\times$  with TBS+ buffer followed by 50  $\mu\text{L}$  of room temperature TMB substrate (Sigma, T444) added to each well and the plate incubated for 20 min at room temperature. Plates were read by colorimetric detection at 650 nm wavelength using a Tecan Safire II plate reader. Concentration-response curves were constructed by non-linear regression (best fit) analysis, and  $\text{IC}_{50}$  values were calculated for each compound.

### 2. Solid Phase Receptor Assay (SPRA) for $\alpha v \beta 1$ Function

Purified human fibronectin (R&D Systems, 1918-FN) diluted to 5  $\mu\text{g/mL}$  in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 1 mM  $\text{MnCl}_2$ ) was added to wells (50  $\mu\text{L}$ /well) of a 96-well half-well transparent microtiter plate (Greiner 675061) and incubated overnight at 4  $^{\circ}\text{C}$ . Wells were washed 3 times with 150  $\mu\text{L}$  TBS+ and 150  $\mu\text{L}$  of blocking buffer (TBS+ with 1% bovine serum albumin, Sigma A7906) were added. The plate was incubated for 1 hr at 37  $^{\circ}\text{C}$  and then washed 3 $\times$  with TBS+ buffer. Recombinant human integrin  $\alpha v \beta 1$  (R&D Systems, 6579-AV) was diluted to 2.0  $\mu\text{g/mL}$  in TBS+/0.1% bovine serum albumin. Compounds were diluted 1:100 into the integrin solution and 50  $\mu\text{L}$  added to empty wells of the washed fibronectin-coated plate according to a standard template with each sample repeated in triplicate. After incubation for

two hours at room temperature, the plate was washed 3× with 150 µL of TBS+ buffer. To each well, 50 µL of biotinylated anti- $\alpha_v$  antibody (R&D Systems, BAF1219) at 1 µg/mL in TBS+/0.1% BSA were added and the plate covered and incubated for 1 hr at room temperature. After washing the plate 3× with 150 µL of TBS+ buffer, 50 µL of streptavidin-conjugated horseradish peroxidase (R&D Systems, DY998) diluted in TBS+ blocking buffer were added to the wells and the plate incubated for 20 min at room temperature. The plate was washed 3× with TBS+ buffer followed by 50 µL of TMB substrate (Sigma, T4444) added to each well and the plate incubated for 20 min at room temperature. Plates were read by colorimetric detection at 650 nm wavelength using a Tecan Safire II plate reader. Concentration-response curves were constructed by non-linear regression (best fit) analysis, and IC<sub>50</sub> values were calculated for each compound.

### 3. Solid Phase Receptor Assay (SPRA) for $\alpha_v\beta_3$ Function

Recombinant human vitronectin (R& D Systems, 2308-VN) diluted to 1 µg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 1 mM MnCl<sub>2</sub>) was added to wells (50 µL/well) of a 96-well half-well transparent microtiter plate (Greiner 675061) and incubated overnight at 4 °C. Wells were washed 3 times with 150 µL TBS+ and 150 µL of blocking buffer (TBS+ with 1% bovine serum albumin, Sigma A7906) were added. The plate was incubated for 1 hr at 37 °C and then washed 3× with TBS+ buffer. Recombinant human integrin  $\alpha_v\beta_3$  (R&D Systems, 3050-AV) was diluted to 1 µg/mL in TBS+/0.1% bovine serum albumin. Compounds were diluted 1:100 into the integrin solution and then 50 µL added to empty wells of the washed vitronectin-coated plate according to a standard template with each sample repeated in triplicate. After incubation for two hours at room temperature, the plate was washed 3× with 150 µL of TBS+ buffer. To each well, 50 µL of biotinylated anti- $\alpha_v$  antibody (R&D Systems, BAF1219) at 0.5 µg/mL in TBS+/0.1% BSA were added and the plate covered and incubated for 1 hr at room temperature. After washing the plate 3× with 150 µL of TBS+ buffer, 50 µL of streptavidin-conjugated horseradish peroxidase (R&D Systems, DY998) diluted in TBS+ blocking buffer were added to the wells and the plate incubated for 20 min at room temperature. The plate was washed 3× with TBS+ buffer followed by 50 µL of TMB substrate (Sigma, T4444) added to each well and the plate was incubated for 20 min at room temperature. Plates were read by colorimetric detection at 650 nm wavelength using a Tecan Safire II plate reader. Concentration-response curves were constructed by non-linear regression (best fit) analysis, and IC<sub>50</sub> values were calculated for each compound.

#### 4. Solid Phase Receptor Assay (SPRA) for $\alpha\text{v}\beta 5$ Function

Recombinant human vitronectin (R& D Systems, 2308-VN) at 0.25  $\mu\text{g/mL}$  in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 1 mM  $\text{MnCl}_2$ ) was added to wells (50  $\mu\text{L}$ /well) of a 96-well half-well transparent microtiter plate (Greiner 675061) and incubated overnight at 4  $^{\circ}\text{C}$ . Wells were washed 3 times with 150  $\mu\text{L}$  TBS+ and 150  $\mu\text{L}$  of blocking buffer (TBS+ with 1% bovine serum albumin, Sigma A7906) were added. The plate was incubated for 1 hr at 37  $^{\circ}\text{C}$  and then washed 3 $\times$  with TBS+ buffer. Recombinant human integrin  $\alpha\text{v}\beta 5$  (R&D Systems, 2528-AV) was diluted to 0.1  $\mu\text{g/mL}$  in TBS+/0.1% bovine serum albumin. Compounds were diluted 1:100 into the integrin solution and then 50  $\mu\text{L}$  added to empty wells of the washed vitronectin-coated plate according to a standard template with each sample repeated in triplicate. After incubation for two hours at room temperature, the plate was washed 3 $\times$  with 150  $\mu\text{L}$  of TBS+ buffer. To each well, 50  $\mu\text{L}$  of biotinylated anti- $\alpha\text{v}$  antibody (R&D Systems, BAF1219) at 0.5  $\mu\text{g/mL}$  in TBS+/0.1% BSA at 0.5  $\mu\text{g/mL}$  were added and the plate covered and incubated for 1 hr at room temperature. After washing the plate 3 $\times$  with 150  $\mu\text{L}$  of TBS+ buffer, 50  $\mu\text{L}$  of streptavidin-conjugated horseradish peroxidase (R&D Systemsm DY998) diluted in TBS+ blocking buffer were added to the wells and the plate incubated for 20 min at room temperature. The plate was washed 3 $\times$  with TBS+ buffer followed by 50  $\mu\text{L}$  of TMB substrate (Sigma T4444) added to each well and the plate incubated for 20 min at room temperature. Plates were read by colorimetric detection at 650 nm wavelength using a Tecan Safire II plate reader. Concentration-response curves were constructed by non-linear regression (best fit) analysis, and  $\text{IC}_{50}$  values were calculated for each compound.

#### 5. Solid Phase Receptor Assay (SPRA) for $\alpha\text{v}\beta 6$ Function

Recombinant human LAP (R&D Systems, 246-LP) diluted to 0.25  $\mu\text{g/mL}$  in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 1 mM  $\text{MnCl}_2$ ) was added to wells (50  $\mu\text{L}$ /well) of a 96-well half-well transparent microtiter plate (Greiner 675061) and incubated overnight at 4  $^{\circ}\text{C}$ . Wells were washed 3 times with 150  $\mu\text{L}$  TBS+, and 150  $\mu\text{L}$  of blocking buffer (TBS+ with 1% bovine serum albumin, Sigma A7906) were added. The plate was incubated for 1 hr at 37  $^{\circ}\text{C}$ , and then washed 3 $\times$  with TBS+ buffer. Recombinant human integrin  $\alpha\text{v}\beta 6$  (R&D Systems, 3817-AV) was diluted to 0.1  $\mu\text{g/mL}$  in TBS+/0.1% bovine serum albumin. Compounds were diluted 1:100 into the integrin solution and then 50  $\mu\text{L}$  added to empty wells of the washed LAP-coated plate according to a standard template with each sample repeated in triplicate. After incubation for

two hours at room temperature, the plate was washed 3× with 150 µL of TBS+ buffer. To each well, 50 µL of biotinylated anti- $\alpha_v$  antibody (R&D Systems, BAF1219) at 0.5 µg/mL in TBS+/0.1% BSA were added and the plate was covered and incubated for 1 hr at room temperature. After washing the plate 3× with 150 µL of TBS+ buffer, 50 µL of streptavidin-conjugated horseradish peroxidase (R&D Systems, DY998) diluted in TBS+ blocking buffer were added to the wells and the plate incubated for 20 min at room temperature. The plate was washed 3× with TBS+ buffer followed by 50 µL of TMB substrate (Sigma T4444) added to each well and the plate incubated for 20 min at room temperature. Plates were read by colorimetric detection at 650 nm wavelength using a Tecan Safire II plate reader. Concentration-response curves were constructed by non-linear regression (best fit) analysis, and IC<sub>50</sub> values were calculated for each compound.

#### 6. Solid Phase Receptor Assay (SPRA) for $\alpha_v\beta_8$ Function

Recombinant human LAP protein (R&D Systems, Inc, 246-LP) diluted to 0.5 µg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 1 mM MnCl<sub>2</sub>) was added to wells (50 µl/well) of a 96-well half-well transparent microtiter plate (Greiner 675061), and incubated overnight at 4 °C. Wells were washed 3 times with 150 µL TBS+ and 150 µL of blocking buffer (TBS+ with 1% bovine serum albumin, Sigma A7906) were added. The plate was incubated for 1 hr at 37 °C and then washed 3× with TBS+. Recombinant human integrin  $\alpha_v\beta_8$  (R&D Systems, 4135-AV) was diluted to 0.1 µg/mL in TBS+/0.1% bovine serum albumin. Compounds were diluted 1:100 into the integrin solution and 50 µL added to empty wells of the washed LAP-coated plate according to a standard template with each sample repeated in triplicate. After incubation for two hours at room temperature, the plate was washed 3× with 150 µL of TBS+. To each well, 50 µL of biotinylated anti- $\alpha_v$  antibody (R&D Systems, BAF1219) at 1 µg/mL in TBS+/0.1% BSA were added and the plate was covered and incubated for 1 hr at room temperature. After washing the plate 3× with 150 µL of TBS+ buffer, 50 µL of streptavidin-conjugated horseradish peroxidase (R&D Systems, DY998) diluted in TBS+ blocking buffer were added to the wells and the plate incubated for 20 min at room temperature. The plate was washed 3× with TBS+ followed by 50 µL of TMB substrate (Sigma T4444) added to each well and the plate incubated for 20 min at room temperature. Plates were read by colorimetric detection at 650 nm wavelength using a Tecan Safire II plate reader. Concentration-response curves were constructed by non-linear regression (best fit) analysis, and IC<sub>50</sub> values were calculated for each compound.



## 7. Solid Phase Receptor Assay (SPRA) for $\alpha 8\beta 1$ Function

Recombinant mouse nephronectin protein (R&D Systems, Inc, 4298-NP) diluted to 1  $\mu\text{g/mL}$  in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 1 mM  $\text{MnCl}_2$ ) was added to wells (50  $\mu\text{L}$ /well) of a 96-well half-well transparent microtiter plate (Greiner 675061), and incubated overnight at 4  $^{\circ}\text{C}$ . Wells were washed 3 times with 150  $\mu\text{L}$  TBS+ and 150  $\mu\text{L}$  of blocking buffer (TBS+ with 1% bovine serum albumin, Sigma A7906) were added. The plate was incubated for 1 hr at 37  $^{\circ}\text{C}$  and then washed 3 $\times$  with TBS+. Recombinant human integrin  $\alpha 8\beta 1$  (R&D Systems, pre-launch) was diluted to 0.25  $\mu\text{g/mL}$  in TBS+/0.1% bovine serum albumin. Compounds were diluted 1:100 into the integrin solution and 50  $\mu\text{L}$  added to empty wells of the washed nephronectin-coated plate according to a standard template with each sample repeated in triplicate. After incubation for two hours at room temperature, the plate was washed 3 $\times$  with 150  $\mu\text{L}$  of TBS+. To each well, 50  $\mu\text{L}$  of biotinylated anti- $\beta 1$  antibody (R&D Systems, BAF1778) at 0.5  $\mu\text{g/mL}$  in TBS+/0.1% BSA were added and the plate was covered and incubated for 1 hr at room temperature. After washing the plate 3 $\times$  with 150  $\mu\text{L}$  of TBS+ buffer, 50  $\mu\text{L}$  of streptavidin-conjugated horseradish peroxidase (R&D Systems, DY998) diluted in TBS+ blocking buffer were added to the wells and the plate incubated for 20 min at room temperature. The plate was washed 3 $\times$  with TBS+ followed by 50  $\mu\text{L}$  of TMB substrate (Sigma T4444) added to each well and the plate incubated for 20 min at room temperature. Plates were read by colorimetric detection at 650 nm wavelength using a Tecan Safire II plate reader. Concentration-response curves were constructed by non-linear regression (best fit) analysis, and  $\text{IC}_{50}$  values were calculated for each compound.

## D. Pharmacokinetic Analysis

### 1. Materials

A minimally sufficient volume of dimethylsulfoxide (DMSO) was added to each test compound to achieve solubilization. For intravenous (IV) delivery, compounds were then formulated as solutions in glycerol formal: saline (either 20:80 or 40:60 v/v) (Sigma Chemicals, St. Louis). For oral (PO) administration, compounds were formulated with 0.5% methylcellulose. Five to six compound solutions were combined into a singled mixed solution for IV and PO cassette administration with final DMSO concentrations  $< 0.6\%$  or  $< 1.2\%$ , for the IV and PO cassettes, respectively. Analytes were detected in test samples using an LC/MS/MS (liquid chromatography/mass spectrometry) system consisting of an LC-

20AD pump (Shimadzu, Kyoto, Japan), an HTC PAL autosampler (Leap technologies, Carrboro, N.C.), and a Sciex API-4000 mass spectrometer in ESI mode (AB Sciex, Foster City, CA.). An Amour C<sub>18</sub> reverse phase column (Analytical Sales and Services, Pompton Plains, N.J.) was used for chromatographic separation.

## 5                    2. Experimental Protocols

Pharmacokinetic (PK) studies conducted at Saint Louis University used male Sprague-Dawley rats with an initial body weight of 200 to 220 g. IV PK studies were performed with the following compounds: Examples 1-3 and 5-17 and comparison compounds C12-C18, C29, and C30. Animals were allowed free access to food and water.

10 Rats were individually housed and connected to jugular vein catheters. Each cassette formulation was administered intravenously to two rats (1 mL/kg body weight). Each cassette formulation contained 5-6 compounds at 1 mg/kg in either 20:80 or 40/60 glycerol formal/saline (v/v). Blood was collected manually via the catheter into lithium-heparin tubes at 0.017, 0.083, 0.5, 1, 2, 4, 6 and 24 hours post-dose. Animals were euthanized with CO<sub>2</sub> at  
15 the end of the experiment.

Oral PK studies were conducted with the following compounds: Examples 1-3 and 5-17 and comparison compounds C12, C14-16 and C29-30. The PO cassette formulations were administered via oral gavage to two rats (10 mL/kg body weight) containing 5-6 compounds per cassette. The oral dose was administered at 2 mg/kg/compound in 0.5% methylcellulose.  
20 Blood collection time points were 0.25, 0.5, 1, 2, 4, 6 and 24 hours post-dose into lithium-heparin tubes. Animals were euthanized with CO<sub>2</sub> at the end of the experiment.

Internal standard was added to all samples at 200 ng/mL (final), as well as 150 µL of acetonitrile. Plasma samples (50 µL total volume) were diluted with control naïve rat plasma as appropriate to bring the sample measurement into the linear dynamic range of the standard  
25 curve. The samples were capped and mixed on a multi-plate vortexer for 5 minutes and centrifuged for 5 minutes at 3200 rpm. The supernant was transferred to 96-well sample plate and capped for LC/MS/MS analysis. Compounds were optimized and monitored for their respective MRM transitions. The mobile phases consisted of 0.1% formic acid (aqueous) and 100% acetonitrile (organic) with an Amour C<sub>18</sub> reverse phase column (2.1 × 30  
30 mm, 5 micron) at a flow rate of 0.35 mL/min. The starting phase was 10% acetonitrile for the 0.9 minutes then increased to 90% acetonitrile over 0.4 minutes, and was maintained for an additional 0.2 minutes before returning to 10% acetonitrile over 0.4 minutes. The 10%

acetonitrile was held for an additional 1.6 minutes. Peak areas were integrated using Analyst 1.5.1 (AB Sciex, Foster City, CA.).

Similar rat PK studies were conducted by PRESCOS, LLC (San Diego, CA) for comparison compounds C19-C28. Female Sprague-Dawley rats with an initial body weight of 195 to 220 g were used. Cassette formulations with 1 mg/kg/compound in 40/60 glycerol formal/saline were administered intravenously to three rats. The dosing volume for each animal was 5 mL/kg body weight. Blood samples were collected via a jugular vein catheter at 0.017, 0.25, 0.5, 1, 2, 4 and 8 hours post-dose into K2EDTA tubes. Animals were euthanized with CO<sub>2</sub> at the end of the experiment. Sample processing and compound measurement by LC/MS/MS was performed by HT Laboratories (San Diego, CA).

**Table 3A - Integrin Assay Results for Comparison Compounds**

	$\alpha 5\beta 1$ SPRA IC <sub>50</sub> (nM)	$\alpha 8\beta 1$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 1$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 3$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 5$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 6$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 8$ SPRA IC <sub>50</sub> (nM)
Comparison Compounds							
C1	16 ± 9	8 ± 2	17 ± 2	5 ± 2	3 ± 1	2 ± 1	3 ± 2
C2	8	3 ± 0	5	3	0.4	>1000	5
C3	40	14	7	2	2	1	2
C4	7	63	10	4	2	2	6
C5	24	383	17 ± 5	4	1	17 ± 2	66
C6	7 ± 4	17	8 ± 6	6	1	1	9 ± 6
C7	59	26	101	11	25	12	7
C8	38	594	13	5	5	2	18
C9	8 ± 3	40	5 ± 2	4 ± 1	0.4	1	6 ± 3
C10	18	10	14 ± 8	6	2	3	5
C11	33	17	16 ± 4	9	2	4	11

**Table 3B - Integrin Assay Results for Examples**

	$\alpha 5\beta 1$ SPRA IC <sub>50</sub> (nM)	$\alpha 8\beta 1$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 1$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 3$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 5$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 6$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 8$ SPRA IC <sub>50</sub> (nM)
Examples							
1	1 ± 0.5	1.3	2 ± 2	2.3 ± 0.1	0.2	0.4	0.3 ± 0.1
2	0.8	1.5	2	2.7 ± 0.4	0.4	0.3	0.5 ± 0.0
3	0.5	0.9	2	1	0.2	0.4	0.3

	$\alpha 5\beta 1$ SPRA IC <sub>50</sub> (nM)	$\alpha 8\beta 1$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 1$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 3$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 5$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 6$ SPRA IC <sub>50</sub> (nM)	$\alpha v\beta 8$ SPRA IC <sub>50</sub> (nM)
<b>Examples</b>							
4	0.7	0.6	2	3	0.4	0.4	0.4
5	0.8	0.9	2	3	0.5	0.5	0.6
6	0.6	0.5	3	1	0.2	0.4	0.5
7	0.7	0.6	1	3	0.2 ± 0.0	0.3	0.4
8	0.6	0.6	1	4	0.1	0.4	0.4
9	0.3	0.5	1	3	0.3	0.3	0.3
10	1 ± 0.4	1.1	2 ± 1	4	1	0.3 ± 0.1	0.3 ± 0.1
11	0.5	0.7	0.4	2	0.3	0.5	0.6
12	2	0.8	4 ± 2	4	0.4	0.6	0.7 ± 0.1
13	0.6	0.6	1	1.7 ± 0.0	0.1	0.4	1.0 ± 0.3
14	0.6	0.4	0.7	0.3	0.1	0.2	0.2
15	1 ± 0.3	1.2	4 ± 1	4	0.3	0.6	1.1 ± 0.3
16	1 ± 0.4	0.5	3 ± 2	3 ± 0.3	0.6	0.5	0.3 ± 0.1
17	1 ± 0.1	0.7	4 ± 2	2.8 ± 1.1	0.6	0.7	0.3 ± 0.1

**Table 4A – Plasma Half Life of Examples**

<b>Examples</b>	<b>plasma t<sub>1/2</sub> after 1 mg/kg IV bolus dose in rat</b>
1	20.2 hrs
2	9.1 hrs
3	6.1 hrs
4	Not Tested
5	6.6 hrs
6	16.7 hrs
7	4.6 hrs
8	23.9 hrs
9	5.6 hrs
10	3.9 hrs
11	24.0 hrs
12	13.7 hrs
13	11.0 hrs
14	34.2 hrs
15	23.8 hrs

<b>Examples</b>	<b>plasma t <math>\frac{1}{2}</math> after 1 mg/kg IV bolus dose in rat</b>
16	3.2 hrs
17	4.1 hrs

**Table 4B – Plasma Half Life of Comparison Compounds**

<b>Comparison Compounds</b>	<b>plasma t <math>\frac{1}{2}</math> after 1 mg/kg iv bolus dose in rat</b>
C12	0.5 hrs
C13	1.1 hrs
C14	1.0 hr
C15	0.6 hrs
C16	1.6 hrs
C17	0.8 hrs
C18	1.2 hrs
C19	0.43 hrs
C20	0.38 hrs
C21	1.5 hrs
C22	0.30 hrs
C23	0.21 hrs
C24	0.28 hrs
C25	0.23 hrs
C26	0.25 hrs
C27	0.21 hrs
C28	0.3 hrs
C29	< .08 hrs
C30	1.6 hrs

**Table 5A – AUC Plasma Exposure of Compounds**

<b>Example</b>	<b>AUC (0-inf) (ng×hr/mL) after a 2 mg/kg PO dose in rat</b>
1	25048
2	19257
3	4870
4	Not Tested
5	11402

<b>Example</b>	<b>AUC (0-inf) (ng×hr/mL) after a 2 mg/kg PO dose in rat</b>
6	34386
7	3887
8	4468
9	4121
10	12969
11	9136
12	9107
13	13929
14	6502
15	15610
16	6808
17	13128

**Table 5B – AUC Plasma Exposure of Comparison Compounds**

<b>Comparison Compound</b>	<b>AUC (0-inf) (ng×hr/mL) after a 2 mg/kg PO dose in rat</b>
C12	205
C14	224
C15	87
C16	62
C29	< 1
C30	<1

The AUC of the examples described herein and select comparison compounds was determined after a single 2 mg/kg oral (PO) dose in rat, demonstrating improved plasma exposure of the examples of the present disclosure.

\*\*\*\*\*

All of the compounds, compositions, and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compounds, compositions, and methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods, and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both

chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.

## REFERENCES

The following references to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

U.S. Patent No. 6,013,651

U.S. Patent No. 6,028,223

Adachi *et al.*, *Clin. Cancer Res.*, 6(1):96-101, 2000.

Asano *et al.*, *J. Immunol.*, 175(11):7708-7718, 2005.

Avraamides *et al.*, *Nat. Rev. Cancer*, 8(8):604-617, 2008.

Bax *et al.*, *J. Biol. Chem.*, 278(36):34605-34616, 2003.

Becker *et al.*, *Tetrahedron*, 39:4189-4192, 1983.

Bhaskar *et al.*, *J. Transl. Med.*, 5:61, 2007.

Blase *et al.*, *Int. J. Cancer*, 60(6):860-866, 1995.

Bouzeghrane, *et al.*, *J. Mol. Cell. Cardiology*, 36:343-353, 2004.

Clark, *et al.*, *Organic Process Research & Development*, 8:51-61, 2004.

Clark, *et al.*, *Organic Process Research & Development*, 8:571-575, 2004.

Collo, *J. Cell Sci.*, 112(Pt 4):569-578, 1999.

Danen *et al.*, *Histopathology*, 24(3):249-256, 1994.

Edward, *Curr. Opin. Oncol.*, 7(2):185-191, 1995.

Engleman *et al.*, *J. Clin. Invest.*, 99(9):2284-2292, 1997.

Faulconbridge *et al.*, *Tetrahedron Lett.*, 41:2679-2681, 2000.

Ferrari *et al.*, *Proc. Natl. Acad. Sci. USA*, 103(46):17260-17265, 2006.

Gao and Brigstock, *Gut*, 55:856-862, 2006.

Girsch *et al.*, *J. Med. Chem.*, 50:1658-1667, 2007.

Girsch *et al.*, *J. Med. Chem.*, 51:6752-6760, 2008.

Greene & Wuts, *Protective Groups in Organic Synthesis*, 3<sup>rd</sup> Ed., John Wiley, 1999.

*Handbook of Pharmaceutical Salts: Properties, and Use*, Stahl and Wermuth (Eds.), Verlag Helvetica Chimica Acta, 2002.

Henderson, *et al.*, *Nat. Med.*, 19:1617-1624, 2013.

Herlt, *et al.*, *Austr. J. Chem.*, 34(6):1319-1324, 1981.

Horan *et al.*, *Am. J. Respir. Crit. Care Med.*, 177(1):56-65, 2008.


Jorgensen, *et al.*, *J. Am. Chem. Soc.*, 124(42):12557-12565, 2002.



- Kim *et al.*, *Am. J. Pathol.*, 156(4):1345-1362, 2000.
- Landis *et al.*, *Organic Process Research & Development*, 6:539-546, 2002.
- Levine, *et al.*, *Am. J. Pathol.*, 156:1927-1935, 2000.
- Li *et al.*, *Invest. Ophthalmol. Vis. Sci.*, 50(12):5988-5996, 2009.
- Livant *et al.*, *J. Clin. Invest.*, 105(11):1537-1545, 2000.
- Lobert *et al.*, *Dev. Cell*, 19(1):148-159, 2010.
- Lu, *et al.*, *J. Cell Sci.*, 115:4641-4648, 2002.
- March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, 2007.
- Melton *et al.*, *J. Clin. Invest.*, 120(12):4436-4444, 2010.
- Millard *et al.*, *Theranostics*, 1:154-88, 2011.
- Mu *et al.*, *Cell Biol.*, 157(3):493-507, 2002.
- Munger *et al.*, *Cell.*, 96(3):319-328, 1999.
- Munger *et al.*, *Mol. Biol. Cell*, 9:2627-2638, 1998.
- Nishimura, *Am. J. Pathol.*, 175(4):1362-1370, 2009.
- Perdih, *Curr. Med. Chem.*, 17(22):2371-2392, 2010.
- Popov *et al.*, *J. Hepatol.*, 48(3):453-464, 2008.
- Reagan-Shaw *et al.*, *FASEB J.*, 22(3):659-661, 2008.
- Scotton *et al.*, *J. Clin. Invest.*, 119(9):2550-2563, 2009.
- Suehiro *et al.*, *J. Biochem.*, 128(4):705-710, 2000.
- Sun, *et al.*, *Am. J. Therapeutics*, 2014.
- Wipff *et al.*, *J. Cell Biol.*, 179(6):1311-1323, 2007.
- Yang *et al.*, *Development*, 119(4):1093-1105, 1993.
- Yoshimura, *Curr. Top. Microbiol. Immunol.*, 350:127-147, 2011.
- Zahn *et al.*, *Arch. Ophthalmol.*, 127(10):1329-1335, 2009.
- Zahn *et al.*, *Invest. Ophthalmol. Vis. Sci.*, 51(2):1028-1035, 2010

**WHAT IS CLAIMED IS:**

1. A compound of the formula:



wherein:


A is C-H, C-OH, or N;

R' is hydrogen, alkyl<sub>(C≤8)</sub>, substituted alkyl<sub>(C≤8)</sub>, or a substituent convertible *in vivo* to hydrogen; and

X and Y are each independently cyano, halo, fluoroalkoxy<sub>(C1-2)</sub>, alkyl<sub>(C1-2)</sub>, or fluoroalkyl<sub>(C1-2)</sub>, with the proviso that X and Y are not both cyano or alkyl<sub>(C1-2)</sub>;

or a pharmaceutically acceptable salt or tautomer of the above formula.

2. The compound of claim 1 further defined as:



wherein:


A is C-OH or N;

R' is hydrogen, alkyl<sub>(C≤8)</sub>, substituted alkyl<sub>(C≤8)</sub>, or a substituent convertible *in vivo* to hydrogen; and


X and Y are each independently cyano, halo, fluoroalkoxy<sub>(C1-2)</sub>, alkyl<sub>(C1-2)</sub>, or fluoroalkyl<sub>(C1-2)</sub>, with the proviso that X and Y are not both cyano or alkyl<sub>(C1-2)</sub>;  
or a pharmaceutically acceptable salt or tautomer of the above formula.

3. The compound of either claim 1 or claim 2, wherein A is N.
4. The compound of either claim 1 or claim 2, wherein A is C—OH.
5. The compound according to any one of claims 1-4, wherein R' is hydrogen.
6. The compound according to any one of claims 1-5, wherein X is halo.
7. The compound of claim 6, wherein X is —F, —Cl, or —Br.
8. The compound of claim 7, wherein X is —F.
9. The compound of claim 7, wherein X is —Cl.
10. The compound of claim 7, wherein X is —Br.
11. The compound according to any one of claims 1-5, wherein X is fluoroalkoxy<sub>(C1-2)</sub>.
12. The compound of claim 11, wherein X is —OCF<sub>3</sub>.
13. The compound according to any one of claims 1-5, wherein X is fluoroalkyl<sub>(C1-2)</sub>.
14. The compound of claim 13, wherein X is —CHF<sub>2</sub>.
15. The compound of claim 13, wherein X is —CF<sub>3</sub>.
16. The compound according to any one of claims 1-5, wherein X is alkyl<sub>(C1-2)</sub>.
17. The compound of claim 16, wherein X is —CH<sub>3</sub>.
18. The compound according to any one of claims 1-17, wherein Y is halo.
19. The compound of claim 18, wherein Y is —F, —Cl, or —Br.
20. The compound of claim 18, wherein Y is —F.
21. The compound of claim 18, wherein Y is —Cl.

22. The compound of claim 18, wherein Y is  $-\text{Br}$ .
23. The compound according to any one of claims 1-17, wherein Y is fluoroalkoxy<sub>(C1-2)</sub>.
24. The compound of claim 23, wherein Y is  $-\text{OCF}_3$ .
25. The compound according to any one of claims 1-17, wherein Y is fluoroalkyl<sub>(C1-2)</sub>.
26. The compound of claim 25, wherein Y is  $-\text{CHF}_2$ .
27. The compound of claim 25, wherein Y is  $-\text{CF}_3$ .
28. The compound according to any one of claims 1-15, wherein Y is alkyl<sub>(C1-2)</sub>.
29. The compound of claim 28, wherein Y is  $-\text{CH}_3$ .
30. The compound according to any one of claims 1-5, wherein X and Y are each independently selected from the groups consisting of  $-\text{F}$ ,  $-\text{Cl}$ ,  $-\text{Br}$ ,  $-\text{OCF}_3$ ,  $-\text{CH}_3$ ,  $-\text{CHF}_2$ , and  $-\text{CF}_3$ , with the proviso that X and Y are not both  $-\text{CH}_3$ .
31. The compound according to any one of claims 1-30, wherein the carbon atom labeled  $\beta$  is in the *S* configuration.
32. The compound of claim 1, further defined as:







or a pharmaceutically acceptable salt or tautomer of any of the above formulas.

33. The compound according to any one of claims 1-32, wherein the compound is effective for inhibiting three or more RGD integrins selected from the group consisting of  $\alpha 5\beta 1$ ,  $\alpha v\beta 1$ ,  $\alpha 8\beta 1$ ,  $\alpha v\beta 3$ ,  $\alpha v\beta 5$ ,  $\alpha v\beta 6$ , and  $\alpha v\beta 8$ , wherein the effectiveness of the compound corresponds to an  $IC_{50}$  value of less than 10 nM for each of the three or more RGD integrins as measured using a solid phase receptor assay (SPRA) for function of the respective integrin.
34. The compound according to any one of claims 1-32, wherein the compound has a sustained plasma half life of at least 2 hours as measured in a rat using an iv bolus comprising 1 mg of compound per kg of rat.
35. A pharmaceutical composition comprising:
  - a) the compound according to any one of claims 1-34; and
  - b) an excipient.
36. A method of treating and/or preventing a disease or a disorder in a patient in need thereof, comprising administering to the patient a compound according to any one of claims 1-34 in an amount sufficient to treat and/or prevent the disease or disorder.
37. The method of claim 36, wherein the disease or disorder is associated with angiogenesis.

38. The method of claim 36, wherein the disease or disorder is associated with fibrosis.
39. The method of claim 36, wherein the disease or disorder is associated with fibrosis and/or angiogenesis.
40. The method according to any one of claims 36-39, wherein the disease or disorder is pulmonary, liver, renal, cardiac, and pancreatic fibrosis, scleroderma, scarring, retinopathy of prematurity, familial exudative vitreoretinopathy, proliferative vitreoretinopathies, macular degeneration, diabetic retinopathy, cancer, osteoporosis, autoimmune diseases, humoral hypercalcemia of malignancy, Paget's disease, periodontal disease, psoriasis, arthritis, restenosis, and infection.
41. The method of claim 40, wherein the disease or disorder is pulmonary fibrosis.
42. The method of claim 40, wherein the disease or disorder is liver fibrosis.
43. The method of claim 40, wherein the disease or disorder is cardiac fibrosis.
44. The method of claim 40, wherein the disease or disorder is renal fibrosis.
45. The method of claim 40, wherein the disease or disorder is pancreatic fibrosis.
46. The method of claim 40, wherein the disease or disorder is scleroderma.
47. The method of claim 40, wherein the disease or disorder is scarring.
48. The method of claim 47, wherein the scarring is dermal scarring.
49. The method of claim 47, wherein the scarring is retinal scarring.
50. The method of claim 47, wherein the scarring is corneal scarring.
51. The method of claim 40, wherein the disease or disorder is retinopathy of prematurity.
52. The method of claim 40, wherein the disease or disorder is familial exudative vitreoretinopathy.
53. The method of claim 40, wherein the disease or disorder is proliferative vitreoretinopathies.

54. The method of claim 40, wherein the disease or disorder is macular degeneration.
55. The method of claim 40, wherein the disease or disorder is diabetic retinopathy.
56. The method of claim 40, wherein the disease or disorder is cancer.
57. The method of claim 56, wherein the cancer includes solid tumor growth or neoplasia.
58. The method of claim 56, wherein the cancer includes tumor metathesis.
59. The method of claim 56, wherein the cancer is of the bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach, testicle, or thyroid.
60. The method of claim 56, wherein the cancer is a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma.
61. The method of claim 40, wherein the disease or disorder is osteoporosis.
62. The method of claim 40, wherein the disease or disorder is an autoimmune disease.
63. The method of claim 62, wherein the autoimmune disorder is multiple sclerosis.
64. The method of claim 40, wherein the disease or disorder is humoral hypercalcemia of malignancy.
65. The method of claim 40, wherein the disease or disorder is Paget's disease.
66. The method of claim 40, wherein the disease or disorder is periodontal disease.
67. The method of claim 40, wherein the disease or disorder is psoriasis.
68. The method of claim 40, wherein the disease or disorder is arthritis.
69. The method of claim 68, wherein the arthritis is rheumatoid arthritis.
70. The method of claim 40, wherein the disease or disorder is restenosis.
71. The method of claim 40, wherein the disease or disorder is an infection.



72. The method of claim 36-71, wherein the patient is a human, monkey, cow, horse, sheep, goat, dog, cat, mouse, rat, guinea pig, or transgenic species thereof.
73. The method of claim 72, wherein the patient is a monkey, cow, horse, sheep, goat, dog, cat, mouse, rat, or guinea pig.
74. The method of claim 72, wherein the patient is a human.




FIG. 1